CHRONIC
MYELOGENOUS LEUKEMIA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Chronic Myelogenous Leukemia: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-497-00251-5 1. Chronic Myelogenous Leukemia-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on chronic myelogenous leukemia. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON CHRONIC MYELOGENOUS LEUKEMIA ..................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Chronic Myelogenous Leukemia ................................................... 4 E-Journals: PubMed Central ....................................................................................................... 59 The National Library of Medicine: PubMed ................................................................................ 62 CHAPTER 2. NUTRITION AND CHRONIC MYELOGENOUS LEUKEMIA.......................................... 111 Overview.................................................................................................................................... 111 Finding Nutrition Studies on Chronic Myelogenous Leukemia................................................ 111 Federal Resources on Nutrition ................................................................................................. 114 Additional Web Resources ......................................................................................................... 114 CHAPTER 3. ALTERNATIVE MEDICINE AND CHRONIC MYELOGENOUS LEUKEMIA ................... 117 Overview.................................................................................................................................... 117 National Center for Complementary and Alternative Medicine................................................ 117 Additional Web Resources ......................................................................................................... 128 General References ..................................................................................................................... 130 CHAPTER 4. DISSERTATIONS ON CHRONIC MYELOGENOUS LEUKEMIA ..................................... 131 Overview.................................................................................................................................... 131 Dissertations on Chronic Myelogenous Leukemia..................................................................... 131 Keeping Current ........................................................................................................................ 131 CHAPTER 5. PATENTS ON CHRONIC MYELOGENOUS LEUKEMIA ................................................ 133 Overview.................................................................................................................................... 133 Patents on Chronic Myelogenous Leukemia .............................................................................. 133 Patent Applications on Chronic Myelogenous Leukemia .......................................................... 141 Keeping Current ........................................................................................................................ 154 CHAPTER 6. PERIODICALS AND NEWS ON CHRONIC MYELOGENOUS LEUKEMIA ...................... 157 Overview.................................................................................................................................... 157 News Services and Press Releases.............................................................................................. 157 Academic Periodicals covering Chronic Myelogenous Leukemia .............................................. 159 CHAPTER 7. RESEARCHING MEDICATIONS .................................................................................. 161 Overview.................................................................................................................................... 161 U.S. Pharmacopeia..................................................................................................................... 161 Commercial Databases ............................................................................................................... 162 Researching Orphan Drugs ....................................................................................................... 163 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 167 Overview.................................................................................................................................... 167 NIH Guidelines.......................................................................................................................... 167 NIH Databases........................................................................................................................... 169 Other Commercial Databases..................................................................................................... 171 APPENDIX B. PATIENT RESOURCES ............................................................................................... 173 Overview.................................................................................................................................... 173 Patient Guideline Sources.......................................................................................................... 173 Finding Associations.................................................................................................................. 174 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 177 Overview.................................................................................................................................... 177 Preparation................................................................................................................................. 177 Finding a Local Medical Library................................................................................................ 177 Medical Libraries in the U.S. and Canada ................................................................................. 177 ONLINE GLOSSARIES................................................................................................................ 183
viii Contents
Online Dictionary Directories ................................................................................................... 185 CHRONIC MYELOGENOUS LEUKEMIA DICTIONARY................................................... 187 INDEX .............................................................................................................................................. 243
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with chronic myelogenous leukemia is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about chronic myelogenous leukemia, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to chronic myelogenous leukemia, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on chronic myelogenous leukemia. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to chronic myelogenous leukemia, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on chronic myelogenous leukemia. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON CHRONIC MYELOGENOUS LEUKEMIA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on chronic myelogenous leukemia.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and chronic myelogenous leukemia, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “chronic myelogenous leukemia” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Low-energy Laser Therapy in Oral Mucositis Source: Journal of Oral Laser Applications. 1(2): 97-101. Autumn 2001. Contact: Available from Quintessence Publishing Co., Inc. 551 Kimberly Drive, Carol Stream, Ill. 60188. (630) 682-3223. Website: www.quintessenz.de. Email:
[email protected]. Summary: The use of high dose chemotherapy as part of the preparative regimen for stem cell transplantation is associated with mucosal damage. Laser irradiation of the oral mucosa may help to decrease the severity of mucositis. This article reports on a pilot trial that was conducted to evaluate the usefulness of low energy laser therapy in
4
Chronic Myelogenous Leukemia
the control of pain associated with oral mucositis after stem cell transplantation or high dose chemotherapy. Eleven patients with the diagnosis of chronic myelogenous leukemia (n = 4), non-Hodgkin's lymphoma (n = 3), acute myelocytic leukemia (n = 1), and other malignancies (n = 3) were submitted to high dose chemotherapy for myeloablation. Seven patients received autologous stem cell transplantation, two patients received stem cells from allogeneic sources, and two were given high dose chemotherapy only. The oral cavity of all patients was examined by an oral medicine specialist during the pretransplant and prechemotherapy work up. The patients received irradiation with the mucolaser daily until posttransplant day 5. Mucositis was clinically evaluated according the WHO (World Health Organization) scale, and pain was measured by a visual analog scale (VAS). The laser treatment was well tolerated by the patients. Two patients had mucositis grade I or II, 8 patients had grade III to IV, and 1 patient had none. None of the patients had the maximal pain score. Six patients had grade 0 to 3, and 5 patients had grade 5 to 8 by VAS. The majority of patients associated the daily application of laser with prompt pain relief. The authors conclude that the use of low energy laser therapy may play a role in the control of pain associated with oral mucositis. 3 figures. 2 tables. 23 references.
Federally Funded Research on Chronic Myelogenous Leukemia The U.S. Government supports a variety of research studies relating to chronic myelogenous leukemia. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to chronic myelogenous leukemia. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore chronic myelogenous leukemia. The following is typical of the type of information found when searching the CRISP database for chronic myelogenous leukemia: •
Project Title: A NOVEL AUTOTRANSPLANT PROTOCOL FOR CML Principal Investigator & Institution: De Lima, Marcos; Medicine; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2004; Project Start 08-JUN-2004; Project End 31-MAY-2006 Summary: (provided by applicant): Imatinib mesylate has shown remarkable promise in the treatment of chronic myeloid leukemia (CML); however, in some patients it is clearly insufficient as a single agent to produce long-term disease-free or overall survival. AIIogeneic hematopoietic cell transplant-based therapies remain an established curative approach, but complications such as graft-versus-host disease and the need for
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
a suitable donor limit its application. The use of autografts to support high-dose chemotherapy was being explored extensively prior to the introduction of imatinib and promising results with both in vitro and in vivo-purged autologous cells were reported. In the interim, our understanding of the abnormal biology of CML stem cells has advanced significantly and methods for quantitating different types of transplantable normal and leukemic stem cells and for expanding normal cells with rapid, short-term reconstituting potential have been devised. These advances provide an attractive basis for designing an improved strategy for purging CML stem cells from patients' autografts for use with myeloablative chemotherapy in patients without other therapeutic options. Here we will evaluate three purging methods to selectively eliminate CML stem cells: ex vivo pharmacologic treatment with Gleevec and mafosfamide; a novel culture-purging method that exploits the known intrinsically determined, highly defective self-renewal property of CML stem cells under conditions that are predicted to simultaneously amplify residual normal short-term repopulating cells typically present in many CML patients; and a combination of these. We plan to proceed as rapidly as possible to a clinical test of these approaches, in which we will compare the results obtained when patients are randomly assigned to one of the three purging methods. Key to the success of this project is the commitment of two leading groups with complementary expertise in the biology of normal and CML stem cells and the development and clinical evaluation of cultured autografts. The proposed work will thus build on an exciting history in these areas in an attempt to address an emerging need for innovative and broadly applicable approaches to the treatment of CML prompted by a growing recognition of the limitations of imatinib mesylate as a single therapeutic agent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ABNORMALITIES/SIGNAL TRANSDUCTION/HEMATOPOIETIC DISEASE Principal Investigator & Institution: D'andrea, Alan D.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 23-AUG-1996; Project End 31-JUL-2007 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ACTION OF INTERFERON IN CHRONIC MYELOGENOUS LEUKEMIA Principal Investigator & Institution: Platanias, Leonidas C.; Professor of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University Office of Sponsored Research Chicago, Il 60611 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant): Interferon alpha (IFNa) has significant clinical activity in the treatment of chronic myelogenous leukemia (CML), but the mechanisms by which it exhibits its antileukemic effects remain unknown. We have identified a novel signaling cascade activated by the Type I IFN receptor, involving the small GTPase Rac1 and the p38 Map kinase. This pathway acts independently of the Statpathway, but in cooperation with it, to regulate transcriptional regulation of IFNasensitive genes. Our data demonstrate that this signaling cascade is activated in primary granulocytes from CML patients and that pharmacological blockade of its activation reverses the growth inhibitory effects of IFNa on primary leukemia bone marrow
6
Chronic Myelogenous Leukemia
progenitors. This proposal is a systematic approach to identify the signaling mechanisms by which IFNa exhibits its antileukemic effects. Specific aim A is to determine the mechanisms of regulation of activation of the p38 pathway by the Type I IFN receptor in BCR-ABL expressing cells and to identify downstream effector mechanisms. Studies will be performed to determine the roles of Jak kinases and the vav proto-oncogene product on the activation of the Rac1/p38 pathway in BCR-ABL expressing cells and to define the role of p38-dependent nuclear histone serine phosphorylation in the induction of IFNa-responses in CML cells. Specific aim B is to determine the biological consequences of activation of p38 in CML. It will involve studies to determine whether Rac1 and p38 are essential for the generation of the growth inhibitory effects of IFNa on primary leukemic progenitors and whether defective activation of this pathway correlates with IFNa-resistance. It will also examine the hypothesis that IFNa downregulates BCR-ABL protein expression via a p38dependent mechanism. Specific aim C includes studies to identify the mechanisms by which the BCR-ABL-tyrosine kinase antagonizes IFNa-dependent gene transcription and determine whether the BCR-ABL specific inhibitor, STI571, augments the growth inhibitory effects of IFNa via regulatory effects on the Rac1/p38 and Jak/Stat pathways. Altogether, these studies should provide important information on the mechanisms by which signals are transduced by the Type 1 IFN receptor in CML cells and advance our knowledge on the mechanisms of development of IFNa resistance. Identifying such mechanisms will facilitate the development of novel therapeutic approaches to overcome IFNa-resistance and the design of new pharmacologic agents for the treatment of CML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION & PROLIFERATION OF HEMATOPOIETIC STEM CELLS Principal Investigator & Institution: Lansdorp, Peter M.; Professor of Medicine; British Columbia Cancer Research Centre 601 W 10Th Ave Vancouver, Bc Timing: Fiscal Year 2002; Project Start 01-AUG-1990; Project End 31-MAY-2007 Summary: (provided by applicant): Hematopoietic stern cells (HSC), unlike e.g. embryonic stem cells, have a finite potential to divide. Limitations in the replication potential of HSC appear to be important in hematological disorders such as aplastic anemia and chronic myeloid leukemia. Such limitations could furthermore hamper the development of novel therapeutic strategies, including ex vivo stem cell expansion and gene therapy. Based on these considerations, studies that may help define and extend the replicative potential of HSC are important and a general interest. Previous studies with purified human "candidate" HSC funded by this grant have shown that the functional properties of HSC change dramatically during ontogeny and that the loss in HSC proliferative potential with age correlates with measurable shortening of telomeres. Here we propose to further examine the role of telomerase and telomeres in hematopoiesis. Specifically, we want to test the hypothesis that the replication history of HSC can be traced by studies of their telomere length. In order to test this hypothesis, we will examine the telomere length in subsets of purified HSC and their cultured progeny relative to defined populations of more mature cells using refined flow cytometry techniques developed in our laboratory. These techniques will also be used to further study the age related decline in telomere length in nucleated blood cells from normal individuals, patients with various hematological disorders and pedigrees of genotyped normal baboons. We will furthermore attempt to manipulate the telomere length in HSC using gene transfer and protein transduction strategies and study the
Studies
7
functional properties of cells with extended telomeres in vitro and in vivo. The specific aims are:1) To study the telomere length in purified HSC and nucleated blood cells from normal individuals and patients with various hematological disorders before and after therapy.2) To study the telomere length in nucleated blood cells from baboons in relation to their age and genotype.3) To study the effect of artificial telomere elongation and telomerase inhibition on the proliferation, differentiation and replicative potential of purified "candidate" HSC in vitro and in vivo.Taken together, these studies will provide crucial baseline information on the role of telomeres in the biology of HSC. Such information is relevant for a basic understanding of hematopoiesis as well as applications of stem cells in and outside hematology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION OF SIGNAL TRANSDUCTION PATHWAYS IN STABLE PHASE CHRONIC MYELOID Principal Investigator & Institution: Griffin, James D.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Chronic myeloid leukemias are caused by activated tyrosine kinase oncogenes, most often by BCR/ABL, or the related oncogenes TEL/ABL, TEL/JAK2, or TEL/PDGFR. The goal of this project is to understand in detail the signal transduction pathways activated by BCR/ABL and related oncogenes that are relevant for transformation of hematopoietic cells. Using BCR/ABL as the best-studied example, this kinase is believed to function by phosphorylating itself and adjacent cell proteins, and by phosphorylating other proteins that are brought in by adapter molecules. This results in activation of a variety of signaling pathways that ultimately block apoptosis, deregulate cell cycle control, alter adhesion and homing, and cause genetic instability. A particular focus of this project period will be phosphotidylinositol signaling, which we and others have shown is required for transformation, probably because of prominent effects on apoptosis and cell cycle deregulation. We would like to understand how PI3K is activated and determine the downstream targets particularly those related to viability signaling. Also, in preliminary studies we have shown that SHIP, an inositol 5-phophatase, is downregulated by BCR/ABL. SHIP activity would be expected to modulate the lipids that accumulated downstream of PI3K. This is of interest since a SHIP knock out mouse develops a myeloproliferative syndrome, suggesting that there may be certain PI3K products that are more important for hematopoiesis than others. Finally, efforts will be focused on understanding the differences in signaling by the 3 known forms of BCR/ABL, encoding p190, p210, or p230; and understanding the differences between BCR/ABL and v-ABL. In particular, pathways initiated because of phosphorylation of Y177 of BCR seem to be of particular interest, as this single tyrosine residue is needed to generate a myeloproliferative disorder in mice. Overall, identification of critical signaling intermediates will be useful for many reasons, but particularly to identify potential targets for drug development, especially for drugs that would be synergistic with STI571. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALLOIMMUNITY TO CML IN A NOVEL MURINE MODEL Principal Investigator & Institution: Shlomchik, Warren D.; Assistant Professor; Internal Medicine; Yale University 47 College Street, Suite 203 New Haven, Ct 065208047 Timing: Fiscal Year 2002; Project Start 01-SEP-1998; Project End 31-AUG-2003
8
Chronic Myelogenous Leukemia
Summary: (Applicant's Description): This proposal outlines a 5 year plan for the candidate to develop the necessary skills and experience to become an independent investigator studying the alloimmunology of bone marrow transplantation. Dr. Shlomchik is board certified in Internal Medicine and Hematology, and is board eligible in Oncology. He has been in the sponsor's lab for 3 years studying Graft-vs.Host Disease (GVHD), T cell tolerance post alloBMT, and methods of gene transfer into human T cells. Chronic myelogenous leukemia (CML) is uniquely sensitive to T cell alloimmune therapies, yet the scientific basis for CML's remarkable susceptibility is unknown. Understanding the details of this anti-CML response, including the nature of antigen presentation, critical effectors, and factors that render CML cells vulnerable to immune attack, may facilitate the development of strategies to enhance alloimmune responses against other less immunogenic neoplasms. The identification of factors that render CML sensitive have been impeded by the absence of: 1) tools needed to isolate individual components of alloimmune responses; and 2) a relevant murine CML model. The first obstacle can now be approached using mice deficient in genes critical for antigen presentation and T cell effector function. For example, the applicants have exploited mice lacking the beta-2-microblobulin gene to demonstrate that radioresistant host cells are critical for initiating GVHD responses. The second problem has been addressed by a new CML murine model wherein bone marrow infected ex vivo with retrovirus expressing the bcr-abl fusion cDNA is transferred into irradiated syngeneic recipients. They will combine these approaches to determine: 1) the identity of anti-CML effectors; 2) the identity of antigen presenting cells in anti-CML responses, and 3) the roles of molecules accessory for target cell vulnerability such as Fas and TNF-R by establishing CML in mice genetically deficient in them. Dr. Shlomchik's sponsor, Dr. Emerson, is chief of the hematology and oncology section. He has a Ph.D. in immunology and was scientific director of the alloBMT program at the University of Michigan. He has launched a new alloBMT program at Penn and is committed to Dr. Shlomchik's development into an independent clinician scientist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTILEUKEMIA ACTIVITY OF PERILLYL ALCOHOL Principal Investigator & Institution: Clark, Steven S.; Associate Professor; Human Oncology; University of Wisconsin Madison 750 University Ave Madison, Wi 53706 Timing: Fiscal Year 2002; Project Start 01-JAN-2000; Project End 31-DEC-2003 Summary: The Bcr/Abl oncogene encodes a tyrosine kinase that is expressed in leukemias that carry the Philadelphia chromosome translocation (Ph+). The kinase interacts with different cell signaling pathways to cause factor-independent growth, resistance to apoptosis and oncogenic transformation. These pleiotropic activities of Bcr/Abl affect the pathogenesis of Ph+ leukemias by inhibiting the normal rate of cell death and by enabling Ph+ cells to resist conventional chemotherapy that induces apoptosis in other leukemias. A central hypothesis of this proposal is that inhibition of signaling pathways downstream of the Bcr/Abl kinase should render leukemia cells dependent on growth factors and sensitive to apoptosis. Perillyl alcohol (POH) belongs to a new family of chemotherapy agents and has shown excellent therapeutic rations in rodent carcinoma models. The range of potential anti-tumor activities of POH overlaps with some signaling pathways that are affected by the Bcr/Abl kinase. Thus, POH is a logical compound to test for anti- leukemia activity in Bcr/Abl-induced leukemia. Preliminary experiments demonstrated that in Bcr/Abl-transformed cells, POH rapidly induced G1 arrest and apoptosis. In contrast, Bcr/Abl- transformed cells were resistant to apoptosis induced by different conventional chemotherapy agents. This anti-leukemia
Studies
9
activity of POH closely correlated with inhibition of the Raf-ERK signaling pathway downstream of Bcl/Abl. On the other hand, POH treatment did not affect other Bcr/Abl signals that are responsible for maintaining expression of c- Myc. Normally, expression of c-Myc is cell cycle regulated, however, when c-Myc expression is enforced during G1 arrest, cells undergo apoptosis. Therefore, POH may uncouple a Bcr/Abl signaling pathway through Raf that is necessary for maintaining cell growth, while not affecting other Bcr/Abl signals that induce constitutive c-Myc expression. This combination may lead to apoptosis in leukemia cells. This model will be evaluated further by examining 1) the role of the Bcr/Abl oncogene in sensitizing cells to POH, 2) how POH affects signaling through Raf, and 3) whether POH induces Myc-dependent apoptosis in leukemia cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ARSENIC BASED THERAPY OF BCR ABL POSITIVE LEUKEMIAS Principal Investigator & Institution: Bhalla, Kapil N.; Professor of Medicine; Moffitt Cancer Center; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2002; Project Start 15-JUN-2001; Project End 31-MAY-2004 Summary: The leukemic clone in virtually all of the patients with chronic myeloid leukemia with blast crisis (CML-BC) and approximately one-third of the adults with acute lymphoblastic leukemia (ALL) expresses the bcr-abl fusion gene encoded p210 and p185 Bcr-Abl tyrosine kinase (TK), respectively. Although the chemotherapeutic regimens or bone marrow stem cell transplantation employed against acute leukemias can also produce complete remissions in Bcr-Abl positive ALL and CML-BC, these remissions are not durable and the overall clinical outcome remains dismal. This creates a strong rationale to test novel strategies in this clinical setting. Arsenic Trioxide (As2O3 or AT) is clinically active against relapsed or refractory acute promyelocytic leukemia (APL), where it downregulates the levels of the fusion protein PML-RARdelta causing partial differentiation and apoptosis of APL cells. Recently, we have demonstrated that clinically achievable levels of AT can also reduce p210 or p185 Bcr-Abl fusion protein levels and induce apoptosis of CML-BC cells. Based on these findings, we propose to conduct a Phase II clinical-pharmacologic trial of AT (NCI/CTEP sponsored) as the induction therapy for relapsed and refractory; Bcr-Abl positive adult ALL and CML-BC. In vitro studies on the patient derived leukemic blasts are proposed to determine the molecular correlates of the clinical response and apoptosis induced by AT. We have also shown that STI571, a relatively specific inhibitor of Bcr-Abl TK activity, induces differentiation and apoptosis of Bcr-Abl positive leukemic cells. Therefore, we also propose to investigate the in vitro apoptotic and differentiation effects of a combination of AT and STI571 in Bcr-Abl positive leukemic blasts. The specific aims of this proposal are: AIM 1: To determine the clinical efficacy, i.e., the rate and duration of clinical and hematologic response and overall survival, secondary to treatment with daily intravenous AT in adult patients with Philadelphia chromosome (bcr-abl fusion gene) positive relapsed or refractory ALL or CML-BC. AIM 2: To determine the pharmacokinetic parameters of AT, i.e., AUC and Css and correlate these with the clinical and cytogenetic response in patients with Bcr-Abl positive ALL or CMLBC. AIM 3: To correlate the clinical response to AT with the decline in the bcr-abl mRNA levels determined by real-time RT-PCR. AIM 4: To correlate the clinical and in vivo molecular response to AT with AT-induced in vitro downregulation of Bcr-Abl and Akt protein levels, histone hyperacetylation as well as differentiation and apoptosis, utilizing the pre-treatment samples of leukemic blasts. AIM 5: To determine the in vitro differentiation and apoptotic effects of STI-571 alone and in combination with AT in the
10
Chronic Myelogenous Leukemia
pre-treatment samples of Bcr-Abl positive leukemic blasts. These in vitro and in vivo studies are designed to evaluate AT-based novel strategies against Bcr-Abl positive human leukemias. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ASSAYING TYROSINE KINASE ACTIVITY: A NEW PARADIGM Principal Investigator & Institution: Sims, Christopher E.; Physiology and Biophysics; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2004; Project Start 16-APR-2004; Project End 31-MAR-2005 Summary: (provided by applicant): New approaches are needed in the molecular analyses of the growth-promoting signal transduction pathways involved in the development and maintenance of cancer. The Laser Micropipet System (LMS), a new technology for the biochemical assay of kinases, holds the promise of directly assaying the activities of protein tyrosine kinases in primary patient cells. The LMS was developed for the assay of serine/threonine kinases in individual cells grown in tissue culture. This R21/R33 application proposes to expand the applications of this instrumentation to directly determine the activity of oncogenic tyrosine kinases in primary cells from patients. Assay of Bcr-Abl in chronic myelogenous leukemia (CML) will demonstrate the power of this tool for research, clinical, and pharmacologic applications. While this assay will be of value in the study of the biology and resistance mechanisms in CML, the studies will lay the groundwork for a new paradigm in the study of molecular mechanisms in cancer signal transduction and will have general applicability. The R21 phase of this proposal is designed to establish the feasibility of assaying Bcr-Abl activity and to demonstrate the necessary assay conditions for measurements in cells derived from a patient with CML. The specific aims are to: 1) identify and characterize a reporter of intracellular Bcr-Ab1 kinase activity, 2) define and optimize conditions for measuring Bcr-Ab1 activity in human cells, 3) compare reporter phosphorylation in cells expressing Bcr-Ab1 vs. cells lacking this kinase, and 4) demonstrate the feasibility of using primary patient cells in kinase assays. The goal of the R33 phase is to demonstrate the potential for the LMS-based kinase assay in applications for the study of the biology of pharmacologic resistance in CML, including from primary patient cells. The R33 specific aims are to: 1) develop a membranepermeant Bcr-Ab1 kinase reporter, 2) demonstrate the ability to detect imatinib resistance in CML cell lines, 3) determine Bcr-Ab1 activity in primary cells from patients with CML and their response to pharmacologic inhibition, and 4) determine if the assay can detect the emergence of imatinib resistance in CML patients and can differentiate the mechanisms of drug resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ATTACKING ANTHRAX ACTION BY BLOCKING RECEPTOR SIGNALING Principal Investigator & Institution: Chan, Joanne; Research Associate & Instructor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Application for R21, NOT-AI-02-023, Biodefense and Emerging Infectious Diseases Research Anthrax toxin, isolated from the bacterium, Bacillus anthracis, enters human cells and disrupts cellular function. The toxin consists of a receptor binding component, protective antigen (PA) which can associate with the enzymatic components, edema factor (EF) and/or lethal factor (LF) to form the anthrax
Studies
11
toxin. The toxin binds a cell surface receptor which mediates the internalization of the toxin complex. Recently, work from the laboratories of John Young and John Collier identified the receptor for the anthrax toxin, named the anthrax toxin receptor (ATR; Bradley et al., 2001). Since the ability of the anthrax toxin to cause harm is dependent upon receptor binding, targeting the anthrax receptor might provide additional therapies that could be useful even after suspected exposure to anthrax spores. In many cases, signaling downstream of cell surface receptors involves the activation of protein and lipid kinases. Successful use of the small molecule kinase inhibitor Gleevec in chronic myelogenous leukemia has shown that targeting kinases might provide an efficient means to treat various diseases. This goal of this project is to study the ATR signaling pathway in order to identify key effector molecules as targets for inhibition. The role of ATR in mediating toxin internalization will be dissected using biochemical and immunofluorescence methods in mammalian cells. The zebrafish will be used as an animal model to study ATR function in vivo and to assess its potential as an animal model for testing drugs aimed at blocking toxin action. The applicant has 3 specific aims which will be undertaken in collaboration with the Young and Collier labs. Aim 1. To investigate the role of the cytoplasmic domain of the anthrax receptor for potential therapeutic intervention. Aim 2. To determine the physiological role of the anthrax receptor by functional interference during normal embryonic development in the zebrafish. Aim 3. To examine anthrax toxicity in the zebrafish for use as an additional inexpensive model system for drug or vaccine testing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BCR/ABL SIGNALING IN HUMAN LEUKEMIAS Principal Investigator & Institution: Pendergast, Ann M.; Associate Professor; Pharmacology and Cancer Biology; Duke University Durham, Nc 27710 Timing: Fiscal Year 2002; Project Start 15-JUN-1994; Project End 31-JAN-2004 Summary: The long-term objective of this research is to identify the intracellular signaling pathways that are critical for oncogenic transformation by altered forms of the ABL tyrosine kinase. Oncogenic forms of ABL are linked to the development of human, murine and feline leukemias. Activation of ABL may occur as a consequence of chromosomal translocations. The chimeric BCR-ABL oncogene is produced by a reciprocal chromosomal translocation that fuses varying amounts of the BCR gene on chromosome 22 with sequences upstream of the second exon of the c-ABL gene on chromosome 9. Three different BCR-ABL proteins may be produced: P210 which is the causative agent of greater than 95 percent of chronic myelogenous leukemia (CML). P185 which is associated with a subset of acute lymphocytic leukemias (ALL), and P230 which is associated with chronic neutrophilic leukemia (CNL), a rare myeloproliferative disorder characterized by a mild hematologic phenotype. The P185 and P210 forms of BCR-ABL have been proposed to transform cells through their ability to enhance cell proliferation, block apoptosis, alter cell adhesion and increase cell motility. Multiple proteins have been identified as downstream targets of BCR-ABL. However, only a small subset of these proteins have been shown to play critical roles in the biological activities associated with BCR-ABL expression. The specific aims of this proposal are: 1) to test the hypothesis that the ubiquitin-dependent degradation of specific cellular proteins by the oncogenic BCR-ABL tyrosine kinases constitutes a novel mechanism for the functional inactivation of growth inhibitors/tumor suppressors, and 2) to identify intracellular signaling pathways that are differentially regulated by the oncogenic forms of BCR-ABL (such as P210) and by the weakly leukemogenic P230 protein that is associated with an indolent or benign clinical disease. Comparative analysis of the BCR-
12
Chronic Myelogenous Leukemia
ABL proteins may allow the identification of critical molecular components required for malignant transformation by BCR-ABL. Furthermore, our finding that oncogenic tyrosine kinases trigger the destruction of specific target proteins via the ubiquitin proteasome machinery provides a potentially important pathway for the elimination of growth inhibitors/tumor suppressors during tumor progression. Definition of this pathway may allow for the development of therapeutic reagents for the treatment of leukemias and other cancers that are caused by the activation of nonreceptor tyrosine kinases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BCR-ABL KINASE ASSAYS FOR STI571 SENSITIVITY OF RESPONSE Principal Investigator & Institution: Kron, Stephen J.; Associate Professor; Molecular Genetics & Cell Biol; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2003; Project Start 17-JUL-2003; Project End 31-DEC-2004 Summary: (provided by applicant): This phased innovation award proposal is focused on developing a robust approach to quantitative assay of specific protein tyrosine kinase activities from cancer cells. Our model is the oncogenic BCR-ABL fusion protein, the gene product of the t(9;22) Philadelphia chromosome (Ph1) translocation observed in the vast majority of Chronic Myelogenous Leukemia (CML) and in up to 30% of adults with Acute Lymphoblastic Leukemia and in other hematological neoplastic diseases. The activation of Abl kinase by fusion to BCR that is inferred to underly the malignant transformation of Phl positive CML is effectively opposed by the orally administered tyrosine kinase inhibitor (TKI) Imatinib Mesylate (IM, STI-571, Gleevec). The activity of IM as an Abl kinase inhibitor in vitro is thought to be the critical determinant of its efficacy in vivo. Nonetheless, a clinically useful assay for IM inhibition of BCR-ABL kinase activity in circulating CML leukemia cells is lacking. We propose to develop a protein/peptide chip-based assay for BCR-ABL that can detect the degree of inhibition by IM to evaluate dosing and drug resistance. Insofar as other activated tyrosine kinases may be critical mediators of malignancy in both leukemias and solid tumors, developing such an assay would be a powerful tool in evaluating other TKI drug candidates targeting these kinases for their efficacy in vivo. Thus, this project is directed at two major discovery objectives and three development objectives. First, in the initial project year, we intend to use our established methods for anti-phosphotyrosine antibodybased detection of purified Abl kinase activity on a peptide chip to 1) Recapitulate our Abl kinase assay with undiluted whole cell extracts from cell lines expressing BCR-ABL and 2) Use this assay to measure the inhibition of BCR-ABL by IM both in extracts and intact cells. During the development phase, we intend to use both BCR-ABL expressing cancer cell lines and circulating leukemic cells from treated patients as samples to 1) Optimize the BCR-ABL substrate and reaction conditions to enhance sensitivity and specificity of phosphorylation, 2) Examine alternative detection methods for BCR-ABL activity based on phosphospecific antibodies and thiophosphate targeted chemistry, and 3) Evaluate different chemistries for immobilizing BCR-ABL substrates on a surface and geometries for detection of phosphorylation. By these aims we intend to develop a highly versatile kinase assay system which can be applied to monitoring of patient response to IM and as a tool for discovery and testing of new TKI cancer drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BCR-ABL RNA LEVELS TO MONITOR STI571 LEUKEMIA THERAPY Principal Investigator & Institution: Press, Richard D.; Pathology; Oregon Health & Science University Portland, or 972393098
Studies
13
Timing: Fiscal Year 2003; Project Start 14-FEB-2003; Project End 31-JAN-2005 Summary: (provided by applicant): The recent discovery, validation, and accelerated FDA approval of the tyrosine kinase inhibitor STI571 (Gleevec) for the treatment of chronic myeloid leukemia (CML), the first such rationally-designed, small molecule cancer therapy, confirms the validity of the molecular targeting approach to cancer drugs. Aberrant CML cell growth is caused by the constitutive expression of the bcr-abl kinase, a chimeric fusion protein resulting from a leukemia-specific chromosomal translocation [t(9;22)]. STI571's targeted inhibition of this kinase activity specifically represses the leukemic clone without the typical toxicity of conventional nonspecific cancer drugs. Although >95% of chronic phase CML patients undergo a complete hematologic response to STI571, only a minority experience a complete cytogenetic response, the best current surrogate marker of long-term survival. After 18 months of daily STI571 therapy, approximately 28% of chronic phase patients lose their complete hematologic response. STI571 also induces an initial hematologic response in approximately 50-80% of CML patients with accelerated phase or blast crisis CML, but again these responses are typically only transient. This heterogeneity of responses suggests the pressing need for better laboratory methods to monitor and predict STI571 treatment efficacy to identify patients likely to have disease progression who may benefit from additional (more toxic) therapies. The considerable institutional resources in expertise and STI571-treated patient volume that have been built by co-investigator and STI571 co-developer Brian Druker represent a unique opportunity to develop and test novel laboratory methods to molecularly monitor STI571's treatment efficacy. This proposal's specific aims are then to: 1) validate a novel, quantitative, ultra-sensitive bcrabl RT-PCR assay for quantifying minimal residual disease in STI571-treated patients, 2) assess whether serial bcr-abl RNA levels in STI571-treated patients can be used to predict and/or monitor clinical disease progression, and 3) establish a storage bank of clinical samples from STI571-treated patients to enable future studies of STI571 drug resistance mechanisms. As STI571 is the first of perhaps many soon-to-come molecularly targeted cancer therapies, the successful achievement of these aims will likely serve as the model by which the efficacy of other novel therapies may be similarly monitored. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BCR-ABL SUBSTRATES AND INHIBITORS Principal Investigator & Institution: Clarkson, Bayard D.; Chief; Sloan-Kettering Institute for Cancer Res New York, Ny 100216007 Timing: Fiscal Year 2003; Project Start 10-JUL-2003; Project End 30-JUN-2008 Summary: It is the broad, long-term goal of this project to understand, on a molecular level, how the p210- bcr-abl protein tyrosine kinase activity ultimately causes a myeloid expansion in chronic phase Chronic Myelogenous Leukemia (CML), and to search for selective therapies efficacious for the treatment of CML. In order to accomplish this, the following Aims are proposed: (1) Expression of Bcr-Abl and its substrates in human primary hematopoietic cells will be determined during hematopoietic differentiation and maturation. CD34+ normal and CML progenitor cells and subpopulations will be stimulated with single and multiple cytokines that induce proliferation and maturation. Expression of Bcr-Abl and its substrates will be assessed and effects of specific inhibitors. (2) The role of SHIP-1 and SHIP-2 in Ber-Abl signaling will be examined. SHIP proteins will be constitutively targeted to the plasma membrane and the effects on Bcr-Abl mediated signaling will be determined in Rat1p210 cells. (3) The role of Dok-1 in c-kit signaling will be determined. The abilities of wt and mutant forms of Dok proteins to interfere with c-kit signaling will be analyzed. The kinase(s) that phosphorylates Dok
14
Chronic Myelogenous Leukemia
during c-kit stimulation will be identified as well as the site(s) of tyrosine phosphorylation. (4) Binding partners for SHIP proteins in normal and Bcr-Abl expressing hematopoietic cells will be isolated and identified. (5) Analogues of PD173955, a potent inhibitor of Bcr-Abl kinase, will be analyzed in vitro and in vivo. In collaboration with Drs. William Bornmann and John Kuriyan, we will design and synthesize PD173955 analogues and test their activity in hematopoietic cells in vitro and in animal models of CML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOLOGY AND TRANSPLANTATION OF THE HUMAN STEM CELL Principal Investigator & Institution: Mcglave, Philip B.; Professor and Director; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 25-AUG-1995; Project End 31-MAY-2005 Summary: The them of this competitive renewal is unchanged: Understanding the biology of human hematopoietic stem cell (HSC) and their progeny will lead to improved stem cell transplantation therapy for a variety of methal malignant and nonmalignant diseases. In Project 1, Dr. Catherine Verfaillie will perform in vitro and xenogeneic transplant experiments to determine how apoptosis, differentiation and proliferation affect symmetrical self-renewal of HSC. She will use this information to develop clinically relevant methods for HSC expansion and gene transfer applicable to clinical trials proposed in Projects 2 and 3. In Project 2, Dr. John Wagner will investigate engraftment of ex vivo expanded umbilical cord blood (UCB) HSC in a xenogeneic transplant model. He will conduct human transplantation trials using a single UCB graft containing a subpopulation of ex vivo expanded and genetically marked UCB. Alternatively, transplants will be performed with two HLA-identical UCB grafts-one expanded and genetically marked UCB. Alternatively, transplants will be performed with two HLA-identical UCB grants-one expanded ex vivo and one unmanipulated These studies will determine if ex vivo expansion of HSC has been achieved and what effects ex vivo expansion have on homing and engraft of HSC to the marrow. In Project 3, Dr. Daniel Weisdorf will examine how mobilization regimen, cell source (marrow or blood) and phenotype (CD34+ or CD34-) influence HSC capacity for expansion, gene transfer and transplantation. These studies will be performed in vitro, in mouse and sheep xenogeneic transplant models and in clinical trials of autologous transplant therapy for lymphoma. Human clinical transplant trials performed in PROJECTS 2 and 3 will also validate the use of surrogate in vitro and in vivo HSC assays. In Project 4, Dr. Jeffrey Miller will investigate the contribution of BCR/ABL-mediated defective natural killer based immune surveillance and therapy in chronic myelogenous leukemia (CML). He will then test our immunotherapy with normal, allogeneic NK cells following autologous HSC transplant therapy for CM;. Finally, our group has demonstrate that marrow stromal cells can be derived in vitro from a mesodermal progenitor cell (MPC), and that in Hurler syndrome MPC- derived stromal cells contain abnormal heparan sulfate (HS) which inhibits normal HSC growth. In Project 5, Dr. Charles Peters and his co- investigators will explore the role of abnormal HS in Hurler stroma on defective hematopoietic support. He will also perform clinical trials in which normal, allogeneic MPC are transplanted in combination with hematopoietic cells (MPC/HCT) in order to "cross/correct" Hurler stromal defects and improve HSC engraftment and clinical outcome. These projects are supported by administrative and biostatistical cores, as well as cores to provide cell collection and processing NOD/SCID and other mouse assays and production of vectors suitable of clinical gene transfer.
Studies
15
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CAAX PROCESSING ENZYMES AS ANTICANCER TARGETS Principal Investigator & Institution: Bergo, Martin O.; J. David Gladstone Institutes Box 419100, 365 Vermont St San Francisco, Ca 94103 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Many intracellular signaling proteins (e.g., the Ras and Rho proteins) and several nuclear lamins terminate with a carboxyl-terminal CAAX motif. CAAX proteins undergo three sequential posttranslational modifications. First, the cysteine (i.e., the C of the CAAX motif) is farnesylated or geranylgeranylated by a pair of cytosolic enzymes--farnesyltransferase (FTase) and geranylgeranyltransferase I (GGTase I). Second, the last three amino acids (i.e., the -AAX) are cleaved off by Ras and a-factor converting enzyme (Rcel), an integral membrane protease of the endoplasmic reticulum (ER). Third, the newly exposed carboxyl-terminal isoprenylcysteine is methylated by another ER protein, isoprenylcysteine carboxyl methyltransferase (Icmt). These posttranslational modifications render the C-terminus of CAAX proteins more hydrophobic, enhancing the attachment of the proteins to membrane surfaces and facilitating certain protein-protein interactions. Activating Ras mutations have been detected in 30% of all human cancers, and are common in leukemia and myeloproliferative diseases. Inhibitors of FTase have been used to treat cancers that harbor mutationally activated Ras proteins. Unfortunately, K-Ras and N-Ras--the Ras isoforms most often implicated in human cancers--are readily geranylgeranylated by GGTase I in the setting FTase inhibition. This alternate isoprenylation pathway has focused attention on other enzymes in the pathway, such as GGTase I, Rcel, and Icmt. Surprisingly, there are no data on the impact of inhibiting these other enzymes on the development of cancer in mice. In this project, this void will be addressed. In preliminary studies, mice harboring both a Cre-inducible latent oncogenic Kras2 allele (KrasLsL) and the inducible Mx1-Cre transgene have been generated. Induction of Cre in those mice activates the latent Ras allele and results in a full-fledged, lethal, myeloproliferative disease that is reminiscent of chronic myelogenous leukemia or juvenile myelomonocytic leukemia in humans. Recently, conditional "floxed" alleles for the posttranslational processing enzymes (FTase, GGTase I, Rcel, and Icmt) have been generated. Thus, it is now possible to breed mice in which Cre expression can be used to simultaneously activate the latent oncogenic K-Ras allele and inactivate the CAAX processing enzymes. Using these mice, we will define the impact of defective CAAX processing on the development, progression, and lethality of Ras-induced myeloproliferative disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELL SURVIVAL PATHWAYS AND INHIBITORS IN LEUKEMIA Principal Investigator & Institution: Eastman, Alan R.; Professor and Associate Director; Pharmacology and Toxicology; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2002; Project Start 30-JAN-2002; Project End 30-NOV-2003 Summary: (provided by applicant): Tumors characteristically exhibit mutations that enhance cell proliferation and survival. Two well-recognized cell survival pathways are RAF to MEK to ERK and PI3-kinase to Akt. Many inhibitors of these pathways are now in clinical trials or at earlier stages of development. However, early results suggest these inhibitors are more likely to suppress growth than kill the tumor cells. Our recent
16
Chronic Myelogenous Leukemia
observations have demonstrated that such inhibitors may be more valuable when used in combination with more traditional anticancer agents. Specifically, it has been shown that a MEK inhibitor can dramatically enhance the rate of apoptosis induced by vinblastine in myeloid leukemia ML-1 cells and HL6O cells. However, U937 cells are insensitive to the MEK inhibitor but are sensitized to vinblastine by an inhibitor of PI3kinase. These observations have led to the hypothesis that different leukemias preferentially use different survival signaling pathways, and that by defining which pathway a specific leukemia uses, effective drug combinations can be individualized for that patient. The goal of this project is to study freshly-isolated human leukemia cells and define the frequency with which they are sensitized to chemotherapy by inhibitors of these two cell survival pathways. The specific aims are to assay leukemia cells for phosphorylation of ERK and Akt as indicators of the signaling pathways used, and to combine inhibitors of these signaling pathways with vinca alkaloids ex vivo to determine the rate of induction of apoptosis. Additional experiments will determine whether normal leukocyte progenitors, which do not have an oncogene-enhanced cell survival pathway, are resistant to these drug combinations thereby suggesting such a therapy may be selective for the tumor. Finally, activation of Jun N-terminal kinase (JNK) will be assayed in leukemia patients receiving vincristine therapy, to confirm that this pathway is activated at drug concentrations tolerated by patients. Activation of the JNK pathway is necessary for the enhanced apoptosis induced by inhibitors of the Erk and Akt pathways. Successful completion of these aims will identify which leukemia patients might benefit from administration of inhibitors of these signaling pathways, and facilitate the design of clinical trials to test their efficacy in combination with other anticancer agents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMMUNITY CLINICAL ONCOLOGY PROGRAM Principal Investigator & Institution: Locker, Gershon Y.; Chief; Evanston Northwestern Healthcare Evanston, Il 60201 Timing: Fiscal Year 2002; Project Start 01-SEP-1983; Project End 31-MAY-2003 Summary: (Applicant's Description) Evanston Hospital Corporation which has been renamed as Evanston Northwestern Health care (ENH), has been a CCOP since 1093 and has participated in studies of the Eastern Cooperative Oncology Group (ECOG), the National Surgical Adjuvant Breast and Bowel Program (NSABP), and propose to accrue patients to the Gynecology Oncology Group (GOG). It accrued 259 patients with 272 credits to therapeutic trials between June of 1992 to May of 1997. ENH also contributed non-COP patients to NIH-sponsored studies on brain tumors. ENH investigators have chaired ECOG protocols in genitourinary, breast, and hematologic malignancies. They have also chaired steering committees and served in leadership roles in these groups. Currently, Dr. Ann Thor is on the Executive and directs the ECOG Pathology Coordination Office. Dr. David Calls chains the Health Behavior and Practices Committee and the Outcomes Subcommittee. The CCOP has participated in approved cancer control projects in the NSABP-sponsored breast cancer prevention trial with tamoxifen, the Prostate Cancer Prevention Trial, and other cancer control studies. During the 5 years, 279.5 cancer control credits were awarded. ENH investigators have been active in several cancer control projects outside the CCOP pertaining to epidemiology, diagnosis, "diagnostic marker" and dietary manipulation. These include a NCI funded study of low- fat diet in post-menopausal breast cancer, and the Women's Health Initiative, treatment of post-mastectomy arm lymphedema. The CCOP has been reorganized to increase accrual by: recruitment of new investigators, adding Swedish
Studies
17
Covenant Hospital as an affiliate, and GOG as a research base. Efforts are underway to encompass minority enrollment. A 24-bed Clinical Pharmacology Unit sponsored by Searle is operation, with the PI on the advisory committee. We have expanded our education activities through Grand Rounds and lecture series. In the last 4 years, ENH investigators published 63 papers and 10 abstracts pertaining to clinical cancer treatment and control. A research effort in cellular and molecular biology has been developed with the establishment of a program in molecular genetics. Thus, a vertical integration, e.g., from laboratory studies to delivery of care in the local community is being sought. Support is asked for ENH's continued participation in the CCOP. Funding is sought for continued accrual of patients to cancer therapy and cancer control studies of the ECG, NSABP, and GOG. Thus, our participation in cancer control and therapeutic trials will promoter medical advances as well as stimulate better patient care. These in turn will impact favorably on the level of knowledge of staff and physicians within the community. Since 1983, we have successfully participated in the CCOP program, and our record and proposed changes promise continued success in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--CLINICAL RESEARCH SUPPORT COMPONENT Principal Investigator & Institution: Stone, Richard M.; Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-MAR-2003 Summary: (provided by applicant): The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with myeloid malignancies including acute myeloid leukemia, myelodysplastic syndrome, and chronic myeloid leukemia. To achieve this objective, tumor cells and other relevant clinical samples from patients will be collected, catalogued, and distributed to the relevant projects for analysis of the expected therapeutic targets and other molecules that might be important in prognosis or pathophysiology. Secondly, a clinical infrastructure is required to carry out the clinical trials described in Project 5 and additional clinical studies that will emanate from the developmental approaches outlined in Projects 1, 8, 9 & 10. Clinical Research Core resources are required to carry out these functions which extend beyond direct patient care and the clinical laboratory. Without the clinical research support provided in the Core it would be impossible to coordinate the proper collection of multiple research specimens, the adherence to novel complex therapeutic schedules and timely follow-up of patients enrolled on research studies. Also critical to this success of the project is the collaboration of individuals in the Core with the staff from the Biostatistics Core who will provide a quality control system for specimen tracking, computerized data entry, quality of control data and will assist in the design and analysis of the clinical research protocols. The purpose of the Clinical Research Support Core is to provide the following services that will be utilized by all the clinical research studies: 1. To collect research specimens and coordinate patient follow-up at Dana- Farber Partners Cancer Center and collaborating institutions. 2. To act as liaison with outside physicians, hospitals, and biotechnology companies to coordinate the collection of research specimens and follow-up data. 3. To insure that study parameters are followed, ancillary specimens are collected on time and processed properly, confirm eligibility, and patient registration. 4. To insure the accuracy of submitted data from outside sources. 5. To provide data management for the collection of individual patient information. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
18
•
Chronic Myelogenous Leukemia
Project Title: CORE--LEUKEMIA TISSUE BANK Principal Investigator & Institution: Caligiuri, Michael A.; Professor and Director; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: (provided by applicant): The CALGB Leukemia Tissue Bank (LTB) serves as a centralized tissue bank of blood and bone marrow specimens procured from patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL) and other hematologic malignancies enrolled on CALGB treatment protocols. The specific aims of this proposal will be accomplished through CALGB protocol 9665, a protocol for the procurement of relevant tissue specimens. The associated work will be performed in the laboratory of Michael Caligiuri, M.D. at The Ohio State University. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CTCL STAGING USING GENE EXPRESSION PROFILES Principal Investigator & Institution: Showe, Louise C.; Associate Professor, Director Genomics c; Wistar Institute Philadelphia, Pa 191044268 Timing: Fiscal Year 2002; Project Start 30-SEP-1999; Project End 31-MAR-2004 Summary: The cutaneous T-cell lymphomas (CTCL) including Mycosis fungoides (MF) and Sezary syndrome (SS) are indolent lymphomas that progress in stages, starting with skin lesions, sometimes proceeding through a leukemic phase with circulating tumor cells and eventually spreading to the visceral organs. Treatments for CTCL vary in efficacy even for patients with what appears to be similar level of disease, emphasizing the likely existence of undetectable heterogeneity. These characteristics added to a the availability of a large archive of patient samples make it a good candidate for tumor staging by molecular profiles. SS, the leukemia form of CTCL will be the initial focus of these studies as it provides easy access to large numbers of purified malignant cells. RNA from 10 patients, with diverse patterns of disease presentation and progression, will be analyzed during the first year against arrays of cDNA probes for 20,000 sequence verified Unigene clusters in order to determine the global gene expression patterns of these cells. Samples will be selected from newly diagnosed SS patients and from an archive of viably frozen SS cells including samples collected at progressive stages of disease over a period of greater than 10 years. Since CTCL cells represent Th-2 T-cells, RNA from healthy donor PBL, stimulated to develop a TH-2 phenotype will be used as controls. Genes that are over or under-expressed in patient RNAs, compared to controls, will be candidate tumor markers for a reduced panel of genes that will be used to screen a larger group of patient samples. In the second phase of the study, 100 patients will be selected for gene expression studies with a reduced panel of 1000-2000 genes. These expression profiles will be analyzed, using statistical techniques, to identify groups of genes that behave in a similar fashion in subsets of patients. The results of these analyses will be a putative diagnostic panel of genes whose expression levels describe classes of tumors. The correlation between expression levels and tumor groups will be confirmed using alternative methods for measuring gene expression. Finally, clinical information from patient histories will be compared with tumors clustered by gene expression levels to determine whether important clinical outcomes, e.g., responsiveness to treatment, can be predicted from the specific gene expression patterns. Concurrent with the above studies, samples from patients with MF, the skin-associated early form of CTCL, will be queried with the panel of genes identified as being diagnostic for SS to determine
Studies
19
whether the same genes are also sufficient to characterize different classes of MF. If novel gene clusters are found, they will be added to the data base of candidate markers. If not, up to 10 MF patients will be analyzed on 20,000-gene filters for genes whose expression pattern distinguishes MF from SS patients. If found, these will be added to the panel of candidate SS genes. Finally, techniques will be developed to assay expression profiles in a clinical setting. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYTOKINE MEDIATED DIFFERENTIATION THERAPY Principal Investigator & Institution: Smith, B D.; Oncology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: Dr. Smith is a junior faculty member at Johns Hopkins Oncology Center who has spent the past several years developing an understanding of the basic biology of drug resistance in acute leukemia. His observations have clearly pointed to the association between anti-apoptotic signals and drug resistance in both in vitro and in vivo studies. He has also been involved in developing clinical strategies to overcome the drug resistance that results from inhibited apoptosis. His career development plan is to obtain formal training in the theory and methods of clinical investigation leading to a Master of Health Sciences degree, while conducting translational research with mentorship from Richard Jones, M.D., the Director of the Bone Marrow Transplantation Program. Steven Piantadosi, M.D, Ph.D. will serve as co-mentor with expertise in epidemiology, biostatistics, and clinical trial design. It is now clear that signals that block apoptosis are important mechanisms by which cancers are pan-resistant to cytotoxic anti- cancer agents and result in poor clinical outcomes. Our preliminary data suggest that growth factor-mediated differentiation therapy is one strategy that may circumvent resistance secondary to anti-apoptotic signals. The net effect of growth factors on a tumor cell population is determined by a balance of their pleiotropic effects on cell self-renewal, survival, and differentiation. Preferential enhancement of selfrenewal and/or survival could hasten tumor progression; conversely, selective induction of differentiation would exhaust the neoplastic clone. We have found that growth factors induce selective terminal differentiation of chronic myeloid leukemia (CML) at doses that normal hematopoetic progenitors require for optimal growth. Moreover, agents that induce growth arrest, including interferon and bryostatin-1 enhance growth factor- mediated differentiation of CML and other myeloid malignancies in vitro. Based on pre-clinical work that suggests growth factor- mediated induction of differentiation is an effective anti-tumor strategy in pan-resistant myeloid malignancies, three clinical trials of growth factor-mediated differentiation therapy are proposed: 1) GM-CSF + autologous BMT for CML, 2) interferon + GM- CSF in chronic phase CML and 3) bryostatin-1 + GM-CSF in refractory myeloid leukemias. Throughout the course of our proposed trials, we will have the opportunity to further study the biologic impact of growth factor-mediated differentiation. Our current data suggest that the anti-tumor effects of our therapy results from terminal differentiation, however, the agents we are studying in the clinical trials (e.g., GM-CSF, interferon, bryostatin-1) also have immunomodulatory effects which may contribute to an anti- tumor effect. A major objective of our studies will be to evaluate the relative roles that induction of differentiation and immunomodulation play in the anticipated anti-tumor effects of the growth factors and cytostatic agents in the clinical trials. One intriguing possibility is that the induction of differentiation and immunomodulation could be potentially linked. It is now clear that CML, and even AML, progenitors can be differentiated in vitro into
20
Chronic Myelogenous Leukemia
dendritic cells (DC) by cytokines that include GM-CSF; moreover, these leukemic DC can stimulate autologous anti-leukemic T cell responses in vitro. Thus, it is possible that strategies that induce differentiation of myeloid malignancies could lead to eradication of the malignant clone via both induction of terminal differentiation and enhanced immunologic anti-leukemic activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DESIGN OF ABL SH2 AND SH3 INHIBITORS FOR LEUKEMIA Principal Investigator & Institution: Overduin, Michael J.; Associate Professor; Pharmacology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 19-APR-2001; Project End 31-MAR-2003 Summary: (provided by applicant) This project targets the src homology domains of the Abl oncogene for rational anti-cancer drug design. The team consists of a partnership between my structural biology research group at the University of Colorado and a drug discovery program at OSI Pharmaceuticals. This biotechnology company has developed a series of peptidomimetic compounds as novel anticancer agents targeted at signaling domains responsible for the localization and regulation of kinases and phosphatases. My laboratory is determining the three-dimensional structures of complexes of lead compounds bound to src homology 2 (SH2) and src homology 3 (SH3) domains by nuclear magnetic resonance (NMR) spectroscopy. The specific targets are the SH2 and SH3 domains of Abl, an oncogenic tyrosine kinase for which inhibitors are in phase II clinical trials. The SH2 domain is inhibited by a pyridone derivative that mimics its natural phosphotyrosine ligand, and the SH3 domain is inhibited by spirolactam-based compound that resembles its polyproline ligands. These templates possess affinities and binding modes comparable to physiological ligands, as demonstrated by nuclear magnetic resonance spectroscopy (NMR) and surface plasmon resonance (SPR). Modifications of these lead compounds that enhance selectivity and potency will be suggested based on protein structures, NMR and SPR data, and computational modeling. Synthetic organic chemistry expertise and access to combinatorial libraries is provided by OSIP. This complementary partnership will allow the rational optimization of lead compounds with significant therapeutic potential for cancers including chronic myelogenous leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DOK IN CELL GROWTH AND P210 BCR-ABL SIGNALING PATHWAYS Principal Investigator & Institution: Van Aelst, Linda; Associate Professor; SloanKettering Institute for Cancer Res New York, Ny 100216007 Timing: Fiscal Year 2003; Project Start 10-JUL-2003; Project End 30-JUN-2008 Summary: The broad long term goal of this project is to define the molecular mechanism(s) by which p62(dok) exerts its effect(s) on p210bcr-abl-mediated transformation and cell proliferation in general, and to obtain a better understanding of the establishment of the myeloproliferative phenotype of p210 bcr-abl in CML at a molecular level. p62(dok) is a protein identified as being constitutively tyrosine phosphorylated in chronic phase progenitor cells of CML patients and has been found to be a common substrate of many receptor and membrane-associated tyrosine kinases. Several lines of evidence indicate that p62(dok) plays a negative role in growth factorinduced cell proliferation, and in p210bcr-abl mediated transformation. An intriguing
Studies
21
possibility is that p62(dok) could influence the establishment or duration of the chronic phase of CML. In light of this, the characterization of the mechanism(s) by which p62(dok) exerts its effect on growth factor and p210bcr-abl-mediated signaling is essential, as is comprehensive knowledge of bcr-abl-induced signaling pathways, and aberrations therein. To this end, we propose the following specific aims: 1) To map and compare the sites of p62(dok) tyrosine phosphorylated by p210 bcr-abl with those phoshorylated upon PDGF stimulation, 2) To define mechanisms by which p62(dok) [suppresses PDGF-triggered proliferation and p210bcr-abl-nduced transformation, 3) To identify and characterize p62(dok)-interacting signaling components which mediate the negative effect of p62(dok) on PDGF-triggered proliferation and p210bcr-abl-induced transformation, 4) To define signal transduction pathways affected by p210 bcr-abl by microarray analysis and clustering resulting data, and 5) To characterize the target genes involved in the p210 bcr-abl signal transduction pathways identified. This project offers biochemical, molecular and cellular approaches to the study of p62(dok) with respect to its involvement in CML and to the identification of bcr-abl target genes. The health-relatedness of this project is that defining the role of p62(dok) in p210 bcr-abl signaling, and the identification of novel target genes of bcr-abl, will contribute to a better understanding of the establishment of human CML. Furthermore the identification of novel target genes of p210 bcr-abl signaling may provide new potential targets for therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DOK PROTEINS IN ONTOGENESIS AND LEUKEMOGENESIS Principal Investigator & Institution: Pandolfi, Pier Paolo; Professor; Sloan-Kettering Institute for Cancer Res New York, Ny 100216007 Timing: Fiscal Year 2003; Project Start 10-JUL-2003; Project End 30-JUN-2008 Summary: Chronic myelogenous leukemia (CML) is characterized by the presence of the chimeric p210bcr-abl protein which shows elevated protein tyrosine kinase activity relative to the normal c-abl tyrosine kinase. Although many of the p210bcr-abl substrates have now been identified, the relevance of these phosphorylation events in the pathogenesis of CML and the normal function of these p210bcr-abl substrates and are still poorly understood. The focus of this proposal is to elucidate, in vivo in the mouse, the functions of three p210bcr-abl phosphorylation targets, Dok1, 2 and 3, and to determine how these relate to the pathogenesis of CML by a direct genetic approach with the following Specific Aims: 1) To define, in single knock out mice and null cells, the role of Dok1, 2, 3 in ontogenesis and hemopoiesis. We have disrupted the Dok 1, 2, 3 genes and mice lacking their functions (-/-, null) have been generated. Ontogenesis and hemopoiesis will be studied in these mutants. 2) To define in double or triple knock-out mutants the role of Dok1, 2, 3 in ontogenesis and hemopoiesis. We will intercross the various Dok-/- mice among them in order to generate double or triple knock-out mutants. We will define the developmental role of these genes and their role in hemopoiesis by characterizing the embryonic and adult phenotype resulting from their concomitant inactivation. 3) To establish the role of Dok proteins in leukemia and cancer promotion/progression. We will examine spontaneous or physically/chemically induced tumorigenesis as well as leukemogenesis by p210bcr-abl in the various K.O. mutants and in double and triple Dok-/- mutants. We will cross Dok1-/- mutants with mice lacking Nf1 or Pten gone products to test whether Dok1 cooperates with these proteins in tumor suppression. 4) To identify genes critical for Dok1, 2 and 3 function and for CML pathogenesis. We will utilize purified cell populations from our single,
22
Chronic Myelogenous Leukemia
double and triple K.O. mutants to identify, on a comparative basis, target genes relevant for their function. We will test whether these genes are also deregulated in CML blasts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FLAVOPIRIDOL AND IMATINIB IN BCR/ABL+ LEUKEMIA Principal Investigator & Institution: Grant, Steven; Professor of Medicine, Biochemistry, And; Internal Medicine; Virginia Commonwealth University Richmond, Va 232980568 Timing: Fiscal Year 2003; Project Start 11-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Recent evidence suggests that neoplastic cells are particularly susceptible to a strategy involving simultaneous interruption of survivalassociated signal transduction and cell cycle regulatory pathways. Consistent with this notion, we have observed in preclinical studies that the cyclin-dependent kinase inhibitor flavopiridol (NSC 649890) interacts synergistically with the Bcr/Abl kinase inhibitor imatinib (STI571; Gleevec) to induce mitochondrial injury, caspase activation and apoptosis in Bcr/Abl+ human leukemia cells, including those highly resistant to imatinib. These events are associated with multiple perturbations in survival signaling and cell cycle-related pathways, including down-regulation of Mcl-1 and Bcl-xL, reduced expression of cyclin D1, activation of JNK, and inactivation of CREB and Stat5. Based upon these findings, a multi-institutional Phase I trial has been developed in which patients with progressive CML (chronic and accelerated phase) or CML-BC or Philadelphia chromosome+ AML or ALL will be treated with escalating doses of daily imatinib in conjunction with flavopiridol administered as a 1-hr infusion weekly x 3 q month. The goals of this Phase I trial are to define the MTD for these agents, characterize dose-limiting toxicities, and gain preliminary information regarding activity of the regimen. Correlative laboratory studies will test the hypothesis that in vivo administration of imatinib in conjunction with flavopiridol will induce perturbations in apoptotic regulatory proteins in peripheral blood Bcr/Abl+ cells (e.g., diminished expression of Mcl-1, Bcl-xL, and cyclin D1, inactivation of Stat5 and CREB, activation of JNK) similar to those observed in Bcr/Abl+ cell lines exposed to these agents in vitro. Other studies will investigate a) effects of the imatinib/flavopiridol regimen on Stat5 phosphorylation of Bcr/Abl+ peripheral blood cells by flow cytometry; b) the pharmacokinetics of imatinib and flavopiridol when administered together; and c) the presence of Bcr/Abl mutations as well as increased Bcr/Abl expression/activity in cells from imatinib-resistant patients, and their possible relationship to imatinib/flavopiridol pharmacodynamics. Information derived from this trial will provide a foundation for a successor Phase II trial and correlative laboratory studies which will address issues of regimen activity and imatinib/flavopiridol molecular interactions more definitively. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENE EXPRESSION PROFILE OF PROGRESSION & RESPONSE IN CML Principal Investigator & Institution: Radich, Jerry P.; Full Member; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 30-SEP-1999; Project End 31-MAR-2004 Summary: Chronic myeloid leukemia (CML) is a hematopoetic stem cell disease with distinct biological and clinical features, presenting as a relatively clinically benign state ( chronic phase ), which invariably evolves to an incurable aggressive disease ( blast crisis ). Treatment can range from low intensity chemotherapy to the curative yet potentially lethal therapy of bone marrow transplantation (BMT). Unfortunately little is known
Studies
23
about the molecular events that trigger the evolution of chronic phase to blast crisis. Thus, tailoring therapy to individual patient s risk is impossible. This proposal aims to identify changes in gene expression that occur in the evolution of the chronic phase to blase crisis, as well as discovering gene expression patterns that are associated with good outcomes to conventional interferon-based therapy. Specifically, we will: 1) optimize and validate the expression array technology, then 2) use mRNA expression arrays to identify genes involved in the progression of chronic phase to blast phase CML; and 3) identify genes associated with good or poor outcome following conventional interferon-based therapy. These studies will allow us to begin to study the biology of CML transformation, and understand at a genetic level why some patients respond to conventional therapy, while other patients are refractory to therapy, and quickly transform to highly aggressive disease. The identification of low v high risk patients will allow theraphy to be appropriately tailored to each individual s disease. In addition, the application of large-scale expression analysis in this model system will be ideal to iron out unforeseen technical problems, and thus the experience gained may be very valuable in future investigations other more complex tumor systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GRAFT REJECTION Principal Investigator & Institution: Mcniece, Ian K.; Professor; Oncology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 08-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Non-myeloablative transplants are being used increasingly for a number of diseases, including Non Hodgkins lymphoma, Hodgkin's disease, myeloma, acute leukemia, chronic lymphoytic leukemia (CLL) and chronic myelogenous leukemia (CML). A reduction in toxicity compared to fully myeloabative allogeneic stem cell transplantation is stimulating the use of this strategy particularly for older patients. Donor engraftment is achieved in the majority of patients, however, a significant number of patients, particularly those with myelodisplastic syndrome (MDS) experience secondary loss of donor engraftment. This can be fatal for some patients due to the prolonged pancytopenia that follows. There are several possibilities for the loss of donor engraftment; 1) donor graft rejection by recipient T cells, 2) late donor graft failure due to insufficient stem cells in the graft, or 3) dominance of recipient stem cells due to competitive repopulation. In allogeneic transplants to support high dose chemotherapy, graft failure/graft rejection occurs early after transplant within the first month, however, for patients that achieve early donor engraftment secondary graft failure/graft rejection is rare and only occurs in less than 5% of patients [1,2]. In contrast, nearly a 100% of patients receiving mini-allogeneic transplants achieve donor engraftment within 2 months of transplant. Graft failure/graft rejection occurs at 2 to 4 months post transplant in approximately 15% of mini-allogeneic recipients. We hypothesize that loss of donor grafts in non-myeloablative stem cell transplant (NST) recipients can occur due to rejection of the donor cells by recipient T cells and/or low numbers of donor stem cells in the graft resulting in secondary graft failure. The aim of this proposal is to develop methods to evaluate graft rejection and determine the mechanisms responsible for late donor graft failure in recipients of NST. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
24
•
Chronic Myelogenous Leukemia
Project Title: HEMATOPOIETIC TRANSFORMATION BY TYROSINE KINASE FUSIONS Principal Investigator & Institution: Gilliland, D Gary.; Associate Professor; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): The overall hypothesis of this proposal is that a detailed characterization of the signal transduction properties of constitutive activated tyrosine kinases associated with human leukemias will identify the critical targets that are required for transformation of hematopoietic cells. These targets can then be exploited for the development of novel therapeutic approaches to leukemia. During the previous funding period, we accomplished each of the goals that were set forward. In particular, we cloned and characterized the transforming properties of a spectrum of tyrosine kinase fusions associated with recurring chromosomal translocations in human leukemias, using both cell culture systems and murine models of leukemia. These include, in addition to the TEL/PDGFbetaR and TEL/ABL fusions, the HIP1/PDGFbetaR, H4/PDGFbetaR, TEL/JAK2 and TEL/TRKC fusion proteins. The availability of a spectrum of constitutively activated tyrosine kinases provides a unique opportunity to identify critically important pathways of transformation through comparative analysis of the signal transduction pathways and target genes activated by these fusion proteins, with validation in animal models. In Specific Aim 1, we will address the hypothesis that characterization of the signal transduction pathways and target genes activated by TEL/PDGFbetaR, TEL/JAK2, TEL/TRKC, and TEL/ABL, and BCR/ABL, will identify critical pathways and targets that are required for transformation. We will utilize standard approaches to analysis of signal transduction, as well as expression arrays. In Specific Aim 2, we will test the hypothesis that the putative critical effectors of transformation identified in Specific Aim 1 can be evaluated and validated in our model systems. We will utilize a combination of approaches that focus on inhibition of transformation in cell culture systems, as well as murine bone marrow transplant models of leukemia using hematopoietic progenitors from donor mice are that are genetically deficient in one or more of the putative targets. In Specific Aim 3, we will test the hypothesis that acute leukemia phenotypes are a collaboration between constitutively activated tyrosine kinases and transcription factor fusion genes such as AML1/ETO, AML1/EVI1 and NUP98/HOXA9. We hypothesize that coexpression of tyrosine kinase fusions and transcription factor fusions will cause an acute leukemia phenotype in murine models, and that these leukemias will retain sensitivity to specific tyrosine kinase inhibitors. This proposal will provide insights into signal transduction and target genes critical for transformation of hematopoietic cells, as well as novel therapies for leukemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMMUNOTHERAPY AFTER TRANSPLANT TO PREVENT RELAPSE
AUTOLOGOUS
STEM
CELL
Principal Investigator & Institution: Miller, Jeffrey S.; Professor; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: This study proposes a series of clinical and related preclinical investigations to minimize peritransplant tumor burden and to reduce the chances of posttransplantation recurrence of certain lymphomas and of other cancers. Autologous IL-2 activated natural killer cells have been shown to fill a broad spectrum of tumor targets.
Studies
25
Thus, autologous lymphocytes may have anti-tumor activity which may be most effective in a minimal residual disease setting indeced by autologous transplantation. In this study, we will test the safety and tolerance of subcutaneous, low dose IL-2 +/- GMCSF on an outpatient basis in subjects who have had an autologous transplant for lymphoma, breast cancer, chronic myelogenous leukemia, or multiple myeloma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INDUCTION AND MANIPULATION OF HUMAN CML IN NOD/SCID Principal Investigator & Institution: Conrad, Patricia D.; Children's Research Institute 700 Children's Dr Columbus, Oh 432052664 Timing: Fiscal Year 2002; Project Start 20-SEP-1999; Project End 31-AUG-2003 Summary: This proposal describes an intensive, five-year training program designed to allow the principal investigator to successfully bridge the gap between clinical and basic science training. The ultimate goal of the performance of this training will be to achieve scientific independence in the fields of normal and malignant hematopoiesis. Dr. Conrad is board certified in pediatrics and is currently a third year pediatric hematology/oncology fellow at the Children's Hospital of Philadelphia. She has been working for the last 18 months in the laboratory of Stephen G. Emerson, M.D., Ph.D. During this time, Dr. Conrad has intensively pursued laboratory investigation and is ready for the next phase of training, progressively independent work. The candidate's research has focused on 1) investigating functional and biological properties of umbilical cord blood (UCB) hematopoietic stem cells (HSCs) and 2) establishing the NOD/SCID assay using cord blood as the source for stem cells. UCB stem cells are not identical to their bone marrow or peripheral blood counterparts, and seem to act as a more primitive population. Immunodeficient mice, including NOD/SCID, have become the preferred in vivo assay for HSCs. Chronic myelogenous leukemia (CML) is believed to be a myeloproliferative disorder of stem-cell origin. Therefore, experiments designed to investigate fundamental questions relating to pathogenesis of CML will be optimized utilizing a system of UCB HSCs and NOD/SCID mice. Dr. Conrad's sponsor, Dr. Emerson, is division chief of the hematology/oncology section at the University of Pennsylvania. He holds a Ph.D. in cell biology and immunology and was scientific director of the alloBMT program at the University of Michigan. He has significantly contributed to and remains committed to Dr. Conrad's growth into a physician scientist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LEUKEMIA ANTIGENS FOLLOWING DONOR LEUKOCYTE INFUSION Principal Investigator & Institution: Wu, Catherine J.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2005 Summary: The infusion of donor lymphocytes (DLI) induces remission in approximately 75 percent of patients with relapsed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation. The efficacy of DLI reveals that immune responses against leukemia cells can be mounted in the absence of complicating chemotherapy or radiation treatment, and is thus a unique model for studying tumor immunity. How DLI mediates this anti-leukemic effect is unclear. T cells are required for this response, but their antigenic targets are unknown. Recent reports have demonstrated the presence of autoantibodies reactive to various tumors and have
26
Chronic Myelogenous Leukemia
utilized autologous sera to identify novel tumor-associated antigens, which were later shown to be recognized by T cells as well (for review, see Old et al., 1998). Our preliminary results reveal that an analogous approach may succeed in identifying CMLassociated antigens in patients who have responded to DLI. In our trial which used CD4+-DLI to treat relapsed CML, many patients were observed to develop marked elevations in their peripheral B cell number and frequent lymphocytosis and plasmacytosis on bone marrow biopsies, suggesting the presence of a potent B cell response. Immunoscreening of a CML cDNA expression library with high titer post-DLI sera identified eight gene products with antibody reactivity to patient sera collected after but not before DLI. Herein, we propose to characterize the humoral and cellular response to these DLI-associated targets. The CML cDNA expression library will be further screened with other patients' post-DLI sera in order to expand the panel of DLIassociated antigens. Our questions will focus on determining whether the identified antigens are shared among DLI-treated patients (in effort to understand whether leukemia-specific targets or host-donor differences explain the basis of anti-tumor immunity), on delineating the time course of antibody response; and on ascertaining whether the presence of antibody reactivity correlates with a clinical response to DLI, or to the development of graft-versus-host disease (GVHD). To gain insight into whether the identified genes play a role in leukemogenesis, the genes will be fully sequenced, and differential expression between normal and malignant cells will be examined by Northern analysis. Lastly, because T cells are critical to DLI, the gene products will be tested for their ability to induce an antigen- specific T cell response in CML patients' peripheral blood leukocytes in culture. The experiments described in this proposal will lead to a deeper understanding of the mechanisms underlying the antitleukemic effect of DLI and provide a basis for improved diagnosis and treatment of CML and potentially other hematological malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LEUKEMOGENESIS BY ABL AND OTHER ONCOGENES Principal Investigator & Institution: Baltimore, David; Institute Professor; None; California Institute of Technology Mail Code 201-15 Pasadena, Ca 91125 Timing: Fiscal Year 2002; Project Start 15-DEC-1989; Project End 31-DEC-2004 Summary: This proposal has 5 parts representing 5 on-going efforts by different groups of junior investigators in the laboratory. They are: 1. Conditional Abl knockout. Having knocked out both the Abl and Arg genes and found that one of the two genes is needed for development beyond embryonic day 10, we plan to construct a conditional knockout of Abl on an Arg-deficient background so that the roles of the genes in later stages of mouse development and function can be examined. 2. Abl in C. elegans. Abl function has been investigated in mice and Drosophila but the putative functions of the gene are so variable that examination of another organism is warranted. We have chosen C. elegans because its entire genome is known and it is possible to examine it genetically at very high resolution. 3. NF-kappaB control of transcription. While there is much fragmentary knowledge of the genes controlled by NF-kappaB, a global analysis of gene expression in cells with defined genetic lesions in the NF-kappaB-related proteins will give more precise knowledge of which genes are controlled and by which subunits. 4. NF-kappaB activation by TANK and TBK1. There are numerous pathways of NFkappaB activation but none are known in precise detail. We have found a new kinase, TBK1, that interacts with TANK and appears to act along with TRAF proteins and may phosphorylate them. A deeper knowledge of the details of the biochemistry of these events could help to understand the precise mechanisms of NFkappaB activation. 5.
Studies
27
ATR kinase. This very large kinase has been implicated in checkpoint control of the cell cycle in mammalian cells. We have knocked out the gene for this protein and the mice die very early in gestation, in a manner similar to mice lacking the BRCA genes. We plan to construct a conditional allele of this gene to examine in more detail its function and, in particular, its relation to p53, BRCA1 and 2, and Chk1. These studies are all aimed at a deeper understanding of both the processes of oncogenic transformation and the normal development and function of mammals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MDS NORDIAN GAMMACELL-40 EXACTOR WHOLE ANIMAL IRRADIATOR Principal Investigator & Institution: Monroe, John G.; Professor; Pathology and Lab Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2003 Summary: Funds are requested for a MDS Nordian Inc. Gammacell-40 exactor selfcontained low dose rate research animal (rodent) irradiator to support the ongoing NIHfunded individual-initiated research programs in a new state of the art animal facility located within a recently erected research building (BRBII) on the campus of the University of Pennsylvania School of Medicine. Twelve core laboratories comprise the list of the major users of the requested instrument. Each have laboratories in the BRBII and will house their mice and perform ongoing experiments requiring whole animal irradiation and extended maintenance of irradiated animals in ongoing experiments in the animals in the basement of this building. These core laboratories will constitute the majority (>75%) of the usage of the irradiator. In addition, there is a group of over 25 additional users that will utilize this instrument on an infrequent (<25% basis. This latter group is comprised of NIH-funded faculty from University of Pennsylvania School of Medicine associated departments, institutes, and hospitals in addition to other faculty with laboratories in the BRBII. Although two other similar instrument are available on the campus, a specific need for this additional instrument arises because the new animal facility in which the animals of the core user group are housed is a closed facility in which the animals taken to other buildings for irradiation cannot be returned to the investigator's designated area. As a consequence, it is impossible to perform experiments that are either long-term requiring maintaining the animals beyond a single day after irradiation, or require comparison of irradiated and reconstituting models, bone marrow chimeras, induction of immunodeficiency, among others. The University of Pennsylvania School of Medicine has already made a significant financial commitment to support the procurement of this instrument. At a cost of over $33,000, the school has committed funds for an ongoing service contract to maintain and service the instrument, committed funds to compensate an individual to oversee the day to day operation of the instrument, and agree to pay for the moving and setup costs for the irradiator. Scientific oversight will be accomplished by a committee comprised of the PI of the proposal, the scientific director of the Abrahamson Family Cancer Research Institute, and two faculty representatives from the core user group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MICROFLUIDIC POINT-OF-CARE CANCER CELL ANALYZER Principal Investigator & Institution: Battrell, C. F. Fred.; V.P. Operations; Micronics, Inc. 8463 154Th Ave Ne, Bldg F Redmond, Wa 98052 Timing: Fiscal Year 2004; Project Start 08-MAR-2004; Project End 31-AUG-2004
28
Chronic Myelogenous Leukemia
Summary: (provided by applicant): Micronics, Inc., and Xtrana, lnc., will develop an inexpensive point of care cancer marker detection device. The device will integrate and automate blood sample preparation, cell sorting and enrichment by microcytometry, antigen (CD marker) analysis, and both DNA sequence and gene expression analysis. Micronics has developed a technology platform for performing microfluidic processes on laminate-based disposables. The technology comprises microfluidic cartridges assembled from plastic laminates, a computer-controlled fluid driver system, pneumatic and passive on-chip valving capability using accurate Iow-pulsatility pumps, and computer software to control fluid motion in the cartridge. Xtrana has developed a novel series of products and applications centered around unique capabilities in nucleic acid sample preparation. Key to the sample preparation is a family of materials, referred to as Xtra Bind, that bind nucleic acids essentially irreversibly, but still allow the bound DNA or RNA to be amplified using conventional methods like PCR. The project will require research and proof-of-principle experiments in the area of microfluidic cell marker identification and sorting, as well as in on-chip cell lysing and microfluidicsbased nucleic acid amplification and detection. Specifically, experiments involving fluorescence detection on micro-cytometer card, accurate counting and display of fluorescent beads of different sizes as well as beads conjugated with antigen, tagged by antibody and counted on micro-cytometer will be performed initially, followed by sorting/fluorescence gating on micro-cytometer. At the same time, Xtrana will develop the protocols for the Xtra BindTM BCR/ABL mRNA expression measurement and will experimentally determine limit of detection and linear range of detection of bcr/abl mRNA transcripts for control cell lines spiked into white blood cells or blood. In Phase II, an instrument capable of BCR/ABL gene translocation diagnostic of chronic myeloid leukemia (CML) and the associated chimeric mRNA expression will be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MIGRATION AND ADHESION OF CHRONIC MYELOGNEOUS LEUKEMIA C Principal Investigator & Institution: Verfaillie, Catherine M.; Professor; Medicine; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, Mn 554552070 Timing: Fiscal Year 2002; Project Start 01-AUG-1994; Project End 31-DEC-2003 Summary: Beta1-integrins in part support adhesion and migration of NL CD34+ cells to BM stroma and fibronectin (FN). NL CD34+ cell adhesion /migration is also influenced by chemokines, such as SDF-1alpha. The molecular mechanism(s) underlying integrin and chemokine dependent adhesion and migration of NL CD34+ cells are not known. Preliminary studies from our lab suggest involvement of PI3-kinase and the GTPase Cdc42 in these processes. CML is a stem cell leukemia characterized clinically by premature circulation of a massively expanded malignant CD34+ cell population in the blood. CML is caused by the Bcr/Abl oncogene. Although numerous studies have described alterations in signal pathways induced by Bcr/Abl in cell lines, the mechanism(s) underlying the features characteristic for chronic phase CML are not understood. Our lab has shown that (a) CML CD34+ cells adhere less and migrate more over FN than NL CD34+ cells which is not caused by decreased beta1-integrin expression. (b) In CML, the cell cytoskeleton is constitutively activated which decreases the mobility of integrins in the cell membrane. (c) CML CD34+ cell adhesion nor migration is affected by chemokines, such as SDF-1alpha. (d) GTPases and PI3-K, thought to play a role in NL CD34+ cell adhesion and migration, may be constitutively activated in CML and contribute to the aberrant adhesion and migration of CML CD34+ cells. (e) In CML CD34+ cells we have detected abnormally spliced and potentially
Studies
29
dominant negative, isoforms of the focal adhesion kinase Pyk2. (f) Suppression of Bcr/Abl with antisense ODNs reverses these abnormalities and transfer of Bcr/Abl cDNA in cell lines induces these anomalies, strongly suggesting that Bcr/Abl is responsible for decreased integrin mobility and affinity, adhesion and increased migration. These observations support the following hypotheses (l) Engagement of beta1-integrins and stimulation of CXCR4 via SDF-1alpha activates Pyk2- H. This leads to the activation of signal pathways such as PI3-K, which activates the GTPases Cdc42 and Rac2 responsible for adhesion and migration of CD34+ cells. (2) Constitutive phosphorylation and activation of some of these signal molecules as a result of Bcr/Abl in CML HPC underlies the aberrant adhesion and migration seen in CML. We will test these hypotheses in the following specific aims: SA l. Characterize expression and function of Pyk2-H in CD34+ HPC. SA 2. Examine role of Cdc42 and Rac1/2, PI3-K, and Pyk2 in beta1-integrin- and SDF-1alpha mediated adhesion and migration of CD34+ HPC. SA 3. Examine effect of p210-Bcr/Abl on the function and interactions of GTPases, PI3-K, and Pyk2 leading to the decreased adhesion and enhanced migration characteristic of CML. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR AND CELLULAR ANAYLSIS OF T CELLS DURING DLI Principal Investigator & Institution: Margolis, David A.; Associate Professor; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2002; Project Start 25-SEP-1998; Project End 31-AUG-2004 Summary: The potential of the graft versus leukemia (GVL) effect to cure leukemia is illustrated by the success of adoptive immunotherapy with donor leukocyte infusions (DLI) to treat patients who have relapsed with CML after an allogeneic bone marrow transplant. Understanding the immunologic mechanisms underlying this could lead to a significant advancement in the treatment of leukemia in both children and adults through adoptive immunotherapy. The following hypothesis will be tested in the proposed research project: The therapeutic effect of DLI is mediated by a distinguishable population of donor-derived, MHC- restricted T cells responding to both allogeneic and leukemia-specific stimuli. Three Specific Aims are proposed: 1) To characterize at cellular and molecular levels the T cell response to a leukemia-specific peptide (bcr-abl) in the absence (autologous) and presence (allogeneic) of various degrees of major and minor histoincompatibility; (2) To characterize at cellular and molecular levels the T cell response to intact CML cells, compare this response to that generated by the bcr-abl peptide, and evaluate how alloreactivity alters these responses; and (3) To assess the repertoire of T cells in the peripheral blood of patients given DLI for CML and compare the in vivo T cell repertoire to that identified in vitro in Specific Aims 1 and 2 to distinguish alloreactive and leukemia-reactive T-cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR DETECTION AND MONITORING OF LEUKEMIA Principal Investigator & Institution: Stock, Wendy; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 13-MAY-2003; Project End 31-MAR-2009 Summary: (provided by applicant): The major translational goals of molecular diagnostic and minimal residual disease (MRD) studies in the CALGB Leukemia Correlative Science Committee (LCSC) are to identify new prognostic groups and to
30
Chronic Myelogenous Leukemia
utilize this information to adapt therapy to improve treatment outcome. We propose to consolidate all molecular diagnostic and MRD monitoring studies into a comprehensive "Molecular Detection and Monitoring Core" that will provide high quality data to Leukemia Committee clinical trials and to other LCSC projects and cores. The work will be performed in three disease-specific laboratories: Dr. Stock's laboratory (University of Chicago) for ALL and CML; Dr. Slack's (Roswell Park) laboratory for APL; and Dr. Gribben's (Dana Farber) laboratory for CLL. Several goals are proposed for Project 5. First, we will continue to utilize Real-time PCR technology for the prospective molecular detection of specific disease subsets and evaluation of MRD, correlating these findings with response to novel therapies as they are tested in the next generation of CALGB leukemia trials in ALL, APL, CML, and CLL. We propose that assessment of response using quantitative MRD monitoring as a surrogate endpoint provides unique clinical insights that will be particularly relevant as we perform the first generation of molecularly targeted CALGB leukemia trials described below in detail. A second goal of Project 5 is to validate the use of quantitative MRD monitoring as an independent prognostic marker of outcome for patients with acute and chronic leukemia. Prospective MRD evaluation of large, uniformly treated patient cohorts is essential for identification and validation of a "threshold" level of MRD that may distinguish patients at high (or low) risk of relapse. We also propose, for the first time in CALGB Leukemia studies, to utilize MRD monitoring to adapt and individualize post-remission therapy. A fourth goal of this Project is closely linked to Project 3, Gene Profiling Studies in Leukemia. As new molecular "signatures" characterizing novel disease subsets are identified by gene profiling studies in Project 3, we will evaluate expression levels of new "molecular signature" genes in ALL, AML and CLL, using Real-time reverse transcriptase (RT)-PCR methodology. The correlation of gene expression using Real-time RT-PCR with microarray findings will be useful for validating these data and will provide important new diagnostic and prognostic information about new molecular genetic subsets that may be used to adapt therapy in future CALGB treatment trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODEL FOR PH-POSTIVE CML AND ALL Principal Investigator & Institution: Heisterkamp, Nora C.; Professor; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 900276062 Timing: Fiscal Year 2002; Project Start 01-SEP-1991; Project End 31-MAR-2004 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEUROFIBROMATOSIS TYPE 1 GENE REGULATES MYELOPOIESIS Principal Investigator & Institution: Clapp, David W.; Associate Professor; Pediatrics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-APR-1997; Project End 30-JUN-2007 Summary: (provided by applicant): Mutatons in the NF1 tumor suppressor gene cause neurofibromatosis type 1 (NF-1). NF1 encodes a GTPase activating protein (GAP) for p21 ras (Ras) called neurofibromin. Neurofibromin converts p21 ras from its active GTP to its inactive GDP bound conformation. Individuals with NFl have a propensity to acquire benign and malignant tumors. Additionally, children with NFl are predisposed to juvenile myelomonocytic leukemia (JMML). A hallmark of myeloid progenitors (CFU-GM) from JMML bone marrow cells is their propensity to hyperproliferate in
Studies
31
response to low doses of the growth factor granulocyte macrophage colony stimulating factor (GM-CSF). Homozygous disruption of Nfl is lethal in utero; however we found that murine Nf1 -deficient fetal hematopoletic cells show an abnormal pattern of CFUGM growth and hyperactivation of Ras effectors in response to multiple growth factors, including GM-CSF and stem cell factor (SCF), the ligand for the c-kit receptor tyrosine kinase. C-kit is encoded by the murine dominant white spotting locus, W). Since the W and Nfl loci appeared to function along a common developmental pathway, mice with mutations at both loci were generated. We found that haploinsufficiency of Nfl partially rescued the mast cell and coat color defects in W41 mice. These data offered genetic evidence that haploinsufficiency at Nfl modulates cell fates in vitro and in vivo in two lineages that are affected in individuals with NFl. The results support the emerging concept that heterozygous inactivation of tumor suppressor genes may have important biological effects.While loss of neurofibromin increases p21 ras activity in specific cell lineages, identification of alterations in distinct p21 ras effector pathways that control proliferation and survival in NF1-deficient cells is incomplete and critical for understanding disease pathogenesis. Most previous studies argue that loss of neurofibromin results in increased activation of the classical p21 ras-Raf-Mek-ERK pathway. However, we have preliminary data to support an alternative biochemical model where the growth advantage of Nfl1-deficient cells is mediated through increased signals from p21 ras to the small Rho GTPase, Rac2, a Rac isoform expressed only in hematopoietic cells. We propose studies to examine how activation of p21 ras and Rac isoforms cooperate to alter the biology of Nfl +/- mast cells and Nf 1 -/- stem and myeloid progenitor cells utilizing mice with genetic mutations in these loci. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEW ENGLAND PEDIATRIC ONCOLOGY CONSORTIUM Principal Investigator & Institution: Ferguson, William S.; Rhode Island Hospital (Providence, Ri) Providence, Ri 029034923 Timing: Fiscal Year 2002; Project Start 01-JAN-1981; Project End 31-DEC-2002 Summary: The specific aims of the New England Pediatric Oncology Consortium (NEPOC) are: Development and enhanced productivity of a consortium of regional pediatric cancer centers (Brown University/Rhode Island Hospital; Dartmouth University/Dartmouth-Hitchcock Medical Center; Harvard University/Massachusetts General Hospital; SUNY at Stony Brook/Children's Medical Center at Stony Brook; University of Vermont/Medical Center Hospital-Vermont Regional Cancer Center) for the purposes of: A. Contributing to the understanding and treatment of children and adolescents with malignancies through: 1. Input into national cooperative studies through membership in the Pediatric Oncology Group (POG): a. Patient accrual: Achieve significant number and quality of patient entries on protocols; b. Study development and evaluation: Assist in the development of new protocols through committee memberships, institutional reviews of proposed protocol designs, analysis of study results, and proposal of new protocols for POG implementation based on NEPOC studies; c. Administration: Accept responsibilities for POG administrative functions. 2. Cooperative efforts within NEPOC (New England Pediatric Oncology Consortium) in studies of joint interest in the areas of childhood malignancies, particularly toward developing potential pilot studies for POG. B. Enhancement of the care of children and adolescents with cancer in the geographical areas served by the member institutions through: 1. Assuring comprehensive and modern management of children and adolescents with malignancies as a benefit of membership in POG; 2. Sharing staff expertise and investigative facilities at each of the member institutions; 3. Joint efforts in
32
Chronic Myelogenous Leukemia
promotion of education of the local community in the area of cancer in children and adolescents. Through a centralized administration, this Consortium integrates the activities and resources (staff, facilities, patients) at each institution into a single program aimed at achieving these goals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NK RECEPTORS AND BONE MARROW TRANSPLANT OUTCOME Principal Investigator & Institution: Hsu, Katharine C.; Sloan-Kettering Institute for Cancer Res New York, Ny 100216007 Timing: Fiscal Year 2004; Project Start 27-JAN-2004; Project End 31-DEC-2008 Summary: (provided by applicant): Dr. Katherine C. Hsu is a junior faculty member at Memorial SIoan-Kettering Cancer Center, whose research interest is in the impact of killer immunoglobulin-like receptors (KIR) on allogeneic hematopoietic stem cell transplantation. AIIogeneic hematopoietic stem cell transplantation (AHSCT) is a valuable therapy for acute leukemias and chronic myelogenous leukemia. Natural killer (NK) cells may influence early and late post-transplant complications, such as graft-versus-host disease (GVHD), disease relapse, and viral infection. The overall objective of this study is to gain insight into the influence of NK killer Ig-like receptors (KIR) on AHSCT outcome. Typing for the 14 known genes encoding activating and inhibitory KIR will be performed for transplant donors and recipients from HLA-A, -B, and -DR-matched allogeneic transplants. Dr. Hsu hypothesizes that KIR genotypes can predict NK-mediated influence on AHSCT outcome: lack of donor activating KIR genes will predispose to post-transplant viral infection and to disease relapse for certain leukemias but not others; donor-recipient inhibitory KIR gene disparity will influence disease relapse/survival in patients receiving transplants from HLA-C disparate donors (KIR epitope mismatched); and donor-recipient KIR gene disparity may influence engraftment and GVHD in nonmyeloablative transplants. Dr. Hsu aims to address these hypotheses through: 1) determining the influence of donor KIR on overall survival and post-transplant complications in patients receiving T-cell depleted HLA-identical sibling AHSCT for CML and AML; 2) determining in a multi-center analysis, the influence of donor KIR genotype and donor-recipient KIR disparity in patients undergoing unrelated AHSCT; and 3) evaluating prospectively the influence of NK receptors, including both donor and host KIR, on engraftment, GVHD and overall survival in patients undergoing transplants with non-myeloablative conditioning. Dr. Hsu has two mentors, Dr. Bo Dupont and Dr. Richard O'Reilly who have previously served as mentors for both clinical research and basic research scientists. Dr. Glenn Heller is the biostatistician for the proposed studies. As her immediate goals, Dr. Hsu hopes to demonstrate conclusively the influence of the activating KIR on transplant outcome and to identify in which clinical setting the inhibitory KIR may play a role in affecting transplant outcome. In addition, she seeks to understand the interplay between donor and recipient NK cells in non-myeloablative transplants and to determine if KIR may direct their interaction and influence on transplant outcome. Eventually, she hopes to utilize this information to develop adoptive cell therapy using NK cells. Dr. Hsu intends to develop a career as an independent investigator in the field of NK cell immunogenetics and allogeneic hematopoietic stem cell transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: NONMYELOABLATIVE ALLOTRANSPLANTS
HEMATOPOIETIC
STEM
33
CELL
Principal Investigator & Institution: Storb, Rainer F.; Member and Professor/ Program Head; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 18-MAR-2002; Project End 30-NOV-2006 Summary: (provided by applicant): Traditional allogeneic hematopoietic stem cell transplantation (HSCT) for treatment of patients with hematological malignancies relies on maximally tolerated doses of systemic chemoradiation to both eradicate cancer and achieve host immunosuppression. The allografts then serve to rescue patients from treatment-induced marrow aplasia and contribute a graft-versus-tumor effect of uncertain magnitude. Associated toxicities have limited HSCT to younger, medically fit patients with therapy administered on specialized hospital wards. This age restriction has excluded most patients with myeloid leukemias and B cell malignancies from transplantation. To address this limitation, we have developed a nonmyeloablative transplant approach applicable to elderly or medically infirm patients in which the burden of tumor eradication has been shifted from cytotoxic agents to the graft-versustumor effect. Using a large randombred canine model, we have shown that the intense conditioning regimens customarily used for host immunosuppression in HSCT could be largely replaced by optimizing postgrafting immunosuppression with a combination of mycophenolate mofetil and cyclosporine, which not only served to control serious graftversus-host disease (GVHD) but, as importantly, reduced the magnitude of the hostversusgraft reaction. The current clinically used conditioning regimen consists of only 2 Gy of total body irradiation (TBI) and three doses of fludarabine. The preliminary clinical results have shown that this nonmyeloablative regimen was safe and minimally toxic in patients otherwise excluded from HSCT because of age or medical infirmity. In a majority of patients, transplants were carried out entirely in the outpatient setting. Importantly, impressive anti-tumor responses have been seen. Given the consistent allogeneic engraftment with minimal toxicity, we propose to extend the preliminary observations with two specific aims: 1) In patients with CML we will establish the efficacy of nonmyeloablative related HSCT for inducing long-term remissions through graftversus- leukemia effects without undue long-term complications from GVHD, and 2) we will extend the application of nonmyeloablative HSCT to include elderly recipients of unrelated grafts. We anticipate that, in later grant years, we shall carry out Phase II studies in younger patients followed by Phase III studies in which the nonmyeloablative HSCT approach is compared to standard HSCT. We anticipate that future graft-versus-tumor effects can be made more specific by the use of donor lymphocyte clones specific either for CML-specific antigens or host minor histocompatibility antigens associated with malignant cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL FUSION PROTEIN IN CMML Principal Investigator & Institution: Ross, Theodora S.; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2002; Project Start 10-FEB-1998; Project End 31-JAN-2003 Summary: (Applicant's Description): The TEL-PDGFBR fusion protein was identified as the protein product of a t(5;12) translocation in a patient with chronic myelomonocytic leukemia (CMML). The protein fuses the amino portion of TEL with the transmembrane and cytoplasmic domains of the PDGFBR. TEL, a member of the ETS family of
34
Chronic Myelogenous Leukemia
transcription factors, has subsequently been described as a common site of rearrangement in multiple forms of leukemia. This is not yet the case for the PDGFBR. The applicants find, however, in the Preliminary Results, that another patient with CMML has a novel t(5;7) translocation. Southern blotting analysis has identified a breakpoint in this patient at the same genomic localization in the PDGFBR as the t(5;12) translocation. Their hypothesis is, that in this patient, as for the t(5;12) TEL-PDGFR patients, PDGFBR is constitutively activated by fusion with a 7q24 partner. Although rare (as for identification of TEL), the PDGFBR fusion partner at 7q24 may identify a gene involved in a broader group of malignancies. Also, in light of the facts that other patients with CMML have PDGFR containing fusions and the region of 7q24 is frequently deleted in MDS, the cloning, characterization and manipulation of this fusion protein is paramount. Hence, in Specific Aim 1, they will use anchored PCR to clone the breakpoint. Their specific oligos will come from the known PDGFBR sequence. In Specific Aim 2, they will obtain a full length cDNA and determine the relevance of this by performing ribonuclease protection assays and mapping back to chromosome 7. Finally, for Specific Aim 3 they propose to characterize the fusion protein by determining its transforming, activity(s) and biological properties using mutational and biochemical analyses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL PATHWAYS FOR BCR-ABL TRANSFORMATION Principal Investigator & Institution: Whitehead, Ian P.; Microbiol & Molecular Genetics; Univ of Med/Dent Nj Newark Newark, Nj 07107 Timing: Fiscal Year 2003; Project Start 03-APR-2003; Project End 31-MAR-2007 Summary: Chromosomal rearrangements that fuse amino terminal sequences of the Bcr protein to carboxyl terminal sequences of the Abl tyrosine kinase (p210 Bcr-Abl) are associated with virtually all cases of chronic myelogenous leukemia (CML). Whereas the contribution of Abl encoded sequences to Bcr-Abl-mediated leukemogenesis are relatively well understood, the contribution from the Bcr encoded sequences is unclear. For example, several in vitro studies have identified catalytic activities within the amino terminus of Bcr, yet the relationship of these activities to the in vivo functions of Bcr, and Bcr-Abl, are not known. We have recently completed two studies which suggest that Bcr may contribute to the transforming activity of Bcr-Abl in ways that were not previously realized. First, we have identified a functional interaction between Bcr and the oncogenic transcription factor c-Myc. The disruption of this interaction may account for the elevated levels of c-Myc expression that are observed in Bcr-Abl transformed cells. Consistent with this, we have observed that c-Myc protein levels are sensitive to the dosage of Bcr in a CML-derived leukemic cell line. Second, we have demonstrated that the central RhoGEF domain of Bcr (which is retained in Bcr-Abl) contains in vivo catalytic, signaling and transforming activity. Importantly, a similar catalytic activity is observed within the context of p210 Bcr-Abl. The objective of this proposal is to characterize these new activities, and determine their fates within the context of Bcr-Abl. Specifically, we propose to (1) determine if the association of Bcr with the c-Myc transcription factor has functional consequences that contribute to Bcr-Abl-mediated transformation, and (2) determine whether the transforming and catalytic activities that we have mapped to the RhoGEF domain of Bcr contribute to Bcr-Abl-mediated transformation. The results from these studies should contribute substantially to our knowledge of the molecular basis of Philadelphia chromosome positive leukemias. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: OVERCOMING TRANSPLANTATION
GENETIC
BARRIERS
IN
STEM
35
CELL
Principal Investigator & Institution: Hansen, John A.; Professor and Member; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 18-MAR-2002; Project End 30-NOV-2006 Summary: (provided by applicant): The goal of this project is to increase access to hematopoietic stem cell transplants (HSCT) from normal volunteer or partially matched family member donors for patients lacking an HLA identical sibling, and to improve the safety and efficacy of these alternative donor transplants for patients with hematological malignancy. HSCT from alternative donors are associated with greater risk of severe graft-versus-host disease (GVHD), morbidity, and non-relapse mortality than HSCT from HLA identical siblings. In the past, these differences have been partly due to inadequate methods for detecting HLA sequence polymorphisms capable of inducing allograft reactions causing graft failure and GVHD. Advances in DNA-based typing technology have provided powerful tools for detecting genetic differences between patients and donors, but the greater sensitivity achieved has created ambiguities in the definition of an acceptable match. Previous studies have demonstrated the advantages of better matching; however, the limits of safe mismatching are poorly defined. The studies proposed here will continue to examine this question and aim to determine the degree of mismatching for HLAA, B, C, DR and DQ that can be tolerated without significantly increasing the risk of severe GVHD or transplant-related mortality. Other genes encoding immune regulator molecules may also affect transplant outcome by modifying the severity of GVHD and regimen-related toxicity (RRT). Investigations will be undertaken to determine if genetic variation in these genes may explain the different degrees of toxicity seen in individual patients. The problems of RRT and transplantrelated mortality (TRM) will be addressed through two approaches, modifying the conditioning regimen and minimizing the severe neutropenia usually associated with myeloablative regimens. One phase I/II trial will evaluate the safety and efficacy of substituting fludarabine for cyclophosphamide in a regimen containing busulfan. A second phase I/II trial will evaluate the ability of growth factor mobilized peripheral blood stem cells (PBSC) to mitigate RRT and TRM by improving the speed and quality of donor cell engraftment. Clinical trials will also be undertaken to determine if modifications to the pretransplant conditioning regimen can mitigate the risk of graft failure associated with donor HLA incompatibility, and future trials will evaluate new approaches for controlling GVHD in the presence of recipient HLA disparity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF CHRONIC MYELOGENOUS LEUKEMIA Principal Investigator & Institution: Pear, Warren S.; Associate Professor; Pathology and Lab Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 18-JAN-1999; Project End 31-DEC-2003 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PATIENTS, CLINICS, AND SYSTEMS: SCREENING FOR ALCOHOL Principal Investigator & Institution: Chang, Grace; Associate Professor of Pyschiatry; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 24-SEP-1999; Project End 31-AUG-2004
36
Chronic Myelogenous Leukemia
Summary: The majority of patients with alcohol problems present to general medical and other clinical settings, rather than directly to alcohol treatment. The consequences of untreated alcohol problems are well known, and include a whole range of medical and social complications. The identification and treatment of alcohol problems, when patients present for prenatal care, emergency services, or a medical appointment, has been a longstanding clinical research interest. A Midcareer Investigator Award in Clinical Research would allow the applicant to focus on patient-oriented research interests during a critical professional period. The purpose of the current project, "Alcohol Abuse in Bone Marrow Transplant," is to test the hypothesis that alcohol abuse or dependence has an adverse impact on survival after bone marrow transplant, the second most frequent major organ transplant in the United States and the transplant with the least limited donor organ supply. A prospective cohort study of 124 patients with Chronic Myeloid Leukemia undergoing allogeneic bone marrow transplant is underway. The purpose of the proposed project, "Alcohol Screening in Medicaid Managed Care," is to test the hypothesis that routine alcohol and substance abuse screening of Medicaid members at health plan (HMO) enrollment is less effective than alcohol and substance abuse screening at the HMO primary care site. A sample of 2,000 Medicaid enrollees screened at enrollment will compared with a sample of 715 patients who will be screened for alcohol and substance abuse as they initiate care at primary care HMO sites. Their utilization of alcohol and substance abuse treatment, psychiatric and medical treatment for 12 months subsequent to screening will be compared. A sample of 150 patients with positive primary care screens will be studied more intensively. Both of these studies will focus on patients, but will have important practice and policy implications, as transplant medicine and managed care are increasingly prevalent and underscore the need for alcohol and drug screening of patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Lauer, Stephen J.; Professor of Pediatrics; Pediatrics; Emory University 1784 North Decatur Road Atlanta, Ga 30322 Timing: Fiscal Year 2002; Project Start 01-JAN-1978; Project End 31-MAR-2003 Summary: The Pediatric Oncology Program at Emory University is the only comprehensive children's cancer center in Georgia and one of the largest of its kind in the Southeast. It serves a racially, ethnically, and socioeconomically diverse population from metropolitan Atlanta, the State of Georgia, and other states including Alabama, Arkansas, the Carolinas, Florida, and Mississippi. Since the inception of the Pediatric Oncology Group (POG), Emory is consistently one of the largest single-institution contributors to POG clinical and laboratory studies. Emory is a center for Phase I and pilot POG trials and has initiated numerous protocols that have subsequently been implemented by POG. The specific aims of the Emory POG Program are: l) to continue as a major source of patients for POG-sponsored Phase I, pilot, groupwide, and intergroup studies; 2) to provide leadership by its investigators as POG Study Coordinators, Co- coordinators, and Core Committee members; 3) to develop innovative institutional clinical trials on which to base future POG investigations; and 4) to maintain strong basic and translational research programs in pediatric oncology. To address these aims, Emory investigators are Coordinators for several major POG studies, including standard-risk new ALL (#9405), high-risk new ALL (#9006), salvage chemotherapy in relapsed neuroblastoma (#9140), and chemotherapy vs. autologous bone marrow transplantation (ABMT) in AML (#8821). Emory POG members actively participate in POG Core Committees, Subcommittees, and new protocol development.
Studies
37
Institutional pilot studies include therapy of relapsed AML with idarubicin and chlordeoxyadenosine, treatment of relapsed solid tumors with high-dose busulfan/melphalan and ABMT, transplantation of haploidentical CD34+ cells for relapsed ALL or AML, and vincristine plus dose-escalated cyclophosphamide and infusions of peripheral blood-derived progenitor cells in refractory solid tumors. Complementary laboratory research activities include molecular biology of ALL (mechanisms of IL-6- mediated autocrine growth and aberrations in tumor-suppressor genes); in vitro sensitivity of leukemia cells to antineoplastic agents mid biological response modifiers; mechanisms of resistance of AML cells to alkylating agents; molecular neuro-oncology; and xenogeneic models to evaluate normal and neoplastic human hematopoiesis. Investigators at Emory are participating in the POG laboratory study of methotrexate metabolism by ALL cells (ALinC #16) and coordinate the study of alterations in p53 tumor-suppressor gene pathways in relapsed ALL (SIMAL #l0). Taken together, these activities of the Emory POG Program will continue to contribute to our knowledge of the biology, therapy, and prevention of neoplastic diseases in infancy, childhood and adolescence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Grier, Holcombe E.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 30-SEP-1986; Project End 31-DEC-2002 Summary: The principal activity of this grant is to improve the care and treatment of children with cancer by participating in the Pediatric Oncology Group (POG). The three specific goals of the participation of the Dana-Farber Cancer Institute/Children's Hospital (DFCI/CH) and Maine Children's Cancer Program (MCCP) are to 1) enter and follow children with malignancies on appropriate Pediatric Oncology Group (POG) protocols 2) provide leadership in planning and executing POG protocols and 3) provide pilot clinical studies and scientific leadership to POG. 1) Patient entry: the referral patterns at the two institutions has not changed and the commitment to POG protocols remains high. Therefore, patients accrual will continue at the high level previously noted over the last grant period. 2) Leadership within POG: Drs. Weinstein and Grier respectively are the disease chairs for the Myeloid and Sarcoma Committees. The disease committee chairs have primary responsibility for all scientific and clinical activities within POG. Investigators from these institutions are currently or were in the last cycle chairs for 7 separate POG protocols and co chairs of 35 more. They also have 18 positions on disease or discipline committees within POG. Enthusiasm remains strong, and involvement at the current level will continue. 3) Pilot POG protocols and scientific leadership: Scientific leadership is detailed in part above. Dr. Arceci provided scientific leadership for and analyzed the samples of the MEC protocol (#9222) that piloted the use of multidrug resistance reversal agents (cyclosporine) in relapsed AML. This protocol provided the background for the about to open group wide AML up-front protocol (#9394) that will randomize whether or not patients will receive cyclosporine during maintenance therapy. DFCI ALL protocols have provided the background for one of the arms of the proposed new T- cell protocol (#9404). In addition, the background for the current stereotactic protocol (#9373) was in part developed at the Joint Center for Radiation Therapy and the DFCI. Finally, POG has embarked on a major effort to study the autologous transplant protocols for ALL (#9421) developed at the DFCl. Finally Dr. Lipshultz ran at DFCI/CH the pilot studies of late cardiac toxicity
38
Chronic Myelogenous Leukemia
from anthracyclines that provides the background data for the randomized trial of enalapril for patients with elevated after load. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Meyer, William H.; Pediatrics; University of Oklahoma Hlth Sciences Ctr Health Sciences Center Oklahoma City, Ok 73126 Timing: Fiscal Year 2002; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: Children's Hospital of Oklahoma (CHO) at the University of Oklahoma is a member institution of the Pediatric Oncology Group. One of our primary goals is the enrollment of the majority of pediatric patients with cancer in the state of Oklahoma in a cooperative cancer program (POG). Participation in group studies guarantees optimal care for these patients and the opportunity to study in depth the natural history of childhood cancer, develop effective therapeutic regimens, and evaluate the toxicity. and effectiveness of new anti-cancer agents in the treatment of childhood cancer. In addition to the POG studies, institutional non- therapeutic protocols have been developed, i.e., evaluation of leukemic therapy on the central nervous system of newly diagnosed leukemic patients and longitudinal evaluation of coping mechanisms with stress among patients and parents of children with cancer. For all these programs, patient resources and scientific expertise are available in Children's Hospital of Oklahoma. The team at the University of Oklahoma is multidisciplinary. It consists of pediatric hematologistsoncologists, radiation therapists, radiologists, pediatric surgeons, immunologists, pathologists and psychologists. All protocols are reviewed by the Institutional Review Board and informed consent is obtained on all patients entered into these protocols. Protocol compliance remains a high priority. The evaluability rate for the last four years averaged 92.5%. St. Francis Hospital of Tulsa was previously considered a branch of CHO. At the request of the POG Operations Office, Tulsa has applied to become an affiliate institution. The University of New Mexico is also affiliated with the University of Oklahoma. It serves an economically disadvantaged population (native American Indians) which needs to be included in the population studied by cooperative cancer groups. The Pathology Department at the University of New Mexico has special expertise in molecular diagnostic hematopathology and in solid tumors which can benefit the research efforts of the Pediatric Oncology Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Steuber, C P.; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-JAN-1978; Project End 31-DEC-2002 Summary: The concept of the pediatric cooperative cancer group was introduced over 30 years ago because of the rarity of pediatric malignant diseases and the vital importance of controlled trials to improve the outcome for such patients. For such a group to succeed, the collaborative contributions of individuals from a large variety of specialties and fields of research are absolutely essential. This multimodal organized approach to the treatment of childhood cancer through the cooperative group has welldemonstrated its value. The Section of Pediatric Hematology-Oncology at Baylor College of Medicine has been involved in the genesis of this kind of clinical research and has participated in the activities at even level. The current goals of the Section regarding cancer prevention, treatment, and research have lead to the recent development of the
Studies
39
Texas Children's Cancer Center. The Center is a joint effort of Texas Children's Hospital and Baylor College of Medicine and is committed to providing the finest possible patient care, education and research in the areas of pediatric and adolescent cancer and hematological disorders. Major expansion of the clinic and research lab facility is underway. New faculty are being recruited to expand the current research program in the areas of gene therapy, bone marrow transplantation, molecular biology, clinical pharmacology, and experimental therapeutics. Additional personnel including data managers, pediatric nurse practitioners, and research personnel have been recruited to support the new faculty members and the expanded programs. In addition, outreach efforts are making the Center known to communities in Texas that would benefit from a service dedicated to the treatment of children with cancer. The development of the Texas Children's Cancer Center will enhance Baylor's contributions to the Pediatric Oncology Group (POG) by expanding the research and treatment programs that have so successfully contributed to POG throughout the years, by developing new and innovative treatment and research programs, and by increasing study populations for those programs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Breitfeld, Philip P.; Pediatrics; Duke University Durham, Nc 27710 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The goal of the proposed research is to determine optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators in a consortium of medical institutions in North Carolina and West Virginia in collaborative multidisciplinary clinical cancer research protocols generated through the Pediatric Oncology Group. The proposed research grant will allow for the continued participation of Duke University Medical Center, Charlotte Memorial Hospital, East Carolina University School of Medicine and West Virginia University School of Medicine in Pediatric Oncology Group activities. These activities involve studies of the epidemiology and tumor biology of selected neoplasms and the natural history and optimum multimodal therapy of all childhood malignancies. Cooperative studies among physicians from a group of medical centers allow for rapid accrual of a statistically significant number of children with cancer in order to define quickly both those avenues of biologic research which have immediate clinical relevance and those therapeutic approaches which provide prolonged disease-free survival. Through participation in cooperative studies, the entire medical community engaged in the care of children with cancer has a focal point to provide not only improved patient care but also improved multidisciplinary teaching and research. Our objectives for the coming years are: 1) to develop new protocols for the immunologic stratification and chemotherapeutic management of patients with malignant lymphoproliferative and myeloproliferative disorders; 2) to develop protocols for specific brain tumor therapy which take advantage of our expanding knowledge of the biology and pharmacologic sensitivity of human brain tumors in vitro and in vivo; 3) to expand our studies of the pharmacologic agents which influence intermediary metabolism, using our in vitro data as the basis for drug scheduling in clinical trials; 4) to expand our innovative groupwide epidemiology studies to include studies of neuroblastoma and T-cell malignancies which include laboratory investigation (immunologic, biochemical and cytogenetic) where relevant; 5) to expand our multidisciplinary therapeutic research efforts in other
40
Chronic Myelogenous Leukemia
pediatric malignancies; and 6) to expand our outreach programs for patient care and education through our regional consortium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kung, Faith H.; Associate Professor; Pediatrics; University of California San Diego La Jolla, Ca 920930934 Timing: Fiscal Year 2002; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Link, Michael P.; Professor; Pediatrics; Stanford University Stanford, Ca 94305 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The overall goal of this research proposal is for Stanford University, the University of Arizona, and the Kaiser Permanente Medical Centers of the South San Francisco Bay Area to continue their active involvement in Pediatric Oncology Group research activities. Stanford faculty and the University of Arizona faculty have already assumed key leadership positions in POG and have or have had major roles in the scientific and administrative aspects of the Group. Further, Stanford, the University of Arizona, and Kaiser have maintained excellent performance ratings in their participation in POG studies and have received commendations for the large numbers of evaluable patients placed on therapeutic protocols. Specifically: l) We plan to
Studies
41
continue to enter patients on appropriate POG studies where they exist. The number of patient entries from Stanford has increased each year as appropriate POG studies become available. We anticipate that between 65 and 80 patients will be entered on front-line therapeutic studies each year from Stanford in addition to patients who will be entered from the affiliates; in addition, 40-50 patients or more will be entered on POG non-therapeutic studies. 2) We anticipate that the activities of individual investigators from Stanford and the University of Arizona will continue and increase during the period of this research proposal. Currently, our faculty serve as study coordinators for front- line therapeutic studies in lymphoma and leukemia, and they have coordinated and analyzed data from recently closed protocols in osteosarcoma, lymphoma, leukemia, and Ewing's sarcoma. Our faculty also serve key scientific and administrative roles as Group Vice Chair, Disease and Discipline Committee Chairmen and CoChairmen, as members of Disease and Discipline Core Committees, and as members of the Executive Committee. Thus, our faculty are in position to influence the future direction of the scientific activities of POG. 3) We anticipate that involvement of Stanford faculty in the laboratory scientific activities of POG will continue. The laboratories of Drs. Link and Cleary have served as immunology reference laboratories and molecular biologic reference laboratories for leukemia studies of POG. 4) We anticipate that non-POG related laboratory and clinical research conducted at Stanford University and its affiliates will become increasingly relevant to POG activities. Some of these activities have already been incorporated into POG laboratory and therapeutic studies and others are targeted for incorporation into future POG studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Kavan, Petr; Montreal Children's Hospital 2300 Tupper St Montreal, Pq Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The Pediatric Oncology Group (POG) is a multi-disciplinary, multiinstitutional research community which collaborates to increase knowledge of and improve treatment for cancer and leukemia in children and adolescents. The Montreal Children's Hospital/McGill University (MCH), a founding member, requests funding for itself and its two affiliates, the Children's Hospital of Eastern Ontario (CHEO) and the University of Sherbrooke Medical Center (USMC) to continue to participate fully in administrative and scientific activities of the POG during the next 5 years. We expect to enroll a total of 70 patients a year on therapeutic protocols for childhood leukemias, lymphomas, solid tumors and brain tumors, with continued emphasis on Phase I and II studies of new agents and coordination or co-coordination of a minimum of 13 protocols. We expect to enroll 110 patients per year on non-therapeutic studies of cancer etiology, epidemiology, biology, psychologic impact and late effects of therapy with particular emphasis on the pharmacology and molecular pharmacology of methotrexate in acute lymphoblastic leukemia (ALL). We will comply with all requirements of the POG constitution, with MR regulations governing ethical conduct of clinical research and with OPRR and IRB requirements for informed consent and protection of subjects from research risks. In addition to an anticipated doubling of patient accruals since 5 years ago, our major contributions to POG research will include: confirmation that the extent of accumulation of methotrexate polyglutamates by lymphoblasts in B-progenitor cell ALL correlates with event-free survival (EFS) and characterization of the mechanisms regulating this metabolism (Whitehead); promotion of new agent drug development through New Agents and Pharmacology Committee leadership
42
Chronic Myelogenous Leukemia
(Whitehead and Bernstein) and protocol coordination (Bernstein, Baruchel); introduction of stereotactic and fractionated stereotactic radiation therapy in brain tumors (Freeman); coordination of treatment protocols of newly-diagnosed and relapsed B-progenitor cell ALL (Abish, Bernstein); introduction of new agents and combinations in recurrent lymphoid disease as Sub-committee Chair, Lymphoid Relapse (Bernstein); chemotherapy and surgery of brain tumors (Baruchel, Ventureyra); and study of the biology, including p53 gene mutations, and treatment of HIV-related lymphomas (Baruchel, Whitehead). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Castleberry, Robert P.; Professor of Pediatrics; Pediatrics; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-MAR-1979; Project End 31-DEC-2002 Summary: The University of Alabama at Birmingham (UAB) is a leading contributor to the ongoing clinical and basic research activities of the Pediatric Oncology Group (POG) which are focused upon improving the care and cure for children with cancer. Current results of these trials are in some cases already published and are available in the Progress Report. The leadership from UAB in POG is evident in several areas: l) through enrollment of substantial numbers of assessable patients on Phase I, II and III therapeutic trials, including multidiscipline (surgery, chemotherapy, and radiotherapy) management studies; through participation in and development of Group-wide biological studies of selected hematopoietic and solid malignancies; through evolving, coordinating and reporting data from POG therapeutic trials; and by providing discipline and disease committee, and administrative leadership within the group. UAB will continue to enroll all eligible patients on active POG therapeutic and biological studies, including phase I investigations, and maintain high evaluability. UAB investigators will continue to coordinate clinical trials for children with neuroblastoma, bone tumors, and juvenile chronic myelogenous leukemia (JCML) and to assess the therapeutic utility of IL6. Further, UAB investigators will be principal to the development of new studies in neuroblastoma, brain tumors, JCML and acute myelogenous leukemia. UAB will continue to supervise laboratories for POG in the following areas: 1) Banded chromosomal analysis in newly diagnosed patients with lymphoid leukemia; 2) A required reference laboratory for children with JCML (POG #9265) studying the pathogenesis of myeloproliferation; 3) A required serum/plasma repository (POG #9047) with clinical and demographic data referenced on a computer data base; and 4) A non- mandatory reference laboratory to evaluate the biological and clinical significance of rnicrotubular associated protein (MAP) and tubulin isotype expression in neuroblastoma. UAB investigators will continue their scientific and administrative leadership roles on the Neuroblastoma and Other Embryonal Tumors, Myeloid Disease Core, Biologic Response Modifier Core, Executive, Principal Investigator Core, Clinical Research Associate Core, and Diagnostic Imaging Core Committees. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Luchtman-Jones, Lori; Pediatrics; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2002; Project Start 01-JAN-1978; Project End 31-DEC-2002
Studies
43
Summary: The Washington University Medical Center in St. Louis is one of the 39 full member institutions, 48 affiliate, 12 consortia and 9 CCOP institutions of the Pediatric Oncology Group who has pooled their patient resources and scientific expertise to study the natural history of childhood cancer, develop and compare effective therapeutic regimens and investigate the toxicity and effectiveness of new anticancer agents in the treatment of children with cancer. Additionally tumor specimens and occasionally normal tissue and blood samples are collected to determine more about the basic cancer biology and pathology of the disease. Group studies are ongoing in epidemiology, cancer control, pharmacology and pharmacokinetics. The investigators at the Washington University Medical Center include pediatric oncologists, radiologists, radiation oncologists, cytogenetists, neurologists, surgeons, and pathologists. All children with malignant disease are placed on cooperative group protocols if they are eligible and if informed consent is obtained. Data accessioned at the time the patient is placed on study protocol, during the study, and when off therapy is submitted to the Group Statistical Office for data analysis, interpretation and eventual publication. The investigators at Washington University Medical Center serve in multiple administrative and research capacities for the Group. The diagnostic studies, pathological findings, surgical procedure and therapeutic plan for all new patients and patients who relapse are discussed at the weekly Tumor Board Conference. The Principal Investigator has a phase I contract and works with 16 other POG institutions to establish the maximum tolerated dose of a new agent along with the pharmacology and, if indicated, the biologic response of the agent. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Ravindranath, Yaddanapudi; Pediatrics; Wayne State University 656 W. Kirby Detroit, Mi 48202 Timing: Fiscal Year 2002; Project Start 01-JUN-1981; Project End 31-DEC-2002 Summary: This proposal is a request for funding for our continued involvement in the Pediatric Oncology Group (POG). The aims and objectives are to find better means of management for malignant diseases in children and adolescents, and thus increase disease-free survival rates. The Children's Hospital of Michigan (CHM) provides diagnostic evaluation and multimodal therapy for children throughout the State of Michigan. While there is one other Pediatric Oncology facility in the State, the Hematology/Oncology service sees almost all children and adolescents with malignant disease who live in the greater metropolitan Detroit area, and also sees large numbers of such children referred from other parts of the State (and from Canada) regardless of their ability to pay. Until 1979, the oncology service at CHM remained "independent". In September 1979, the CHM oncology team joined the pediatric division of the Southwest Oncology Group and in January 1981 joined the Pediatric Oncology Group, which appears to have even a greater potential for development of better treatment regimens for childhood malignant disease. At the time of referral and/or admission to CHM for possible malignancy, each child is seen and evaluated by the appropriate oncology team members. Following appropriate diagnostic evaluation, each child is presented and discussed at the Tumor Board, which meets weekly and is attended by pediatric oncologists, pathologists, radiologists, surgeons, surgical subspecialities, and radiotherapists. A plan of action is outlined for each child's management. All such children are registered with POG, and whenever judged appropriate, children are entered on POG treatment protocols. By our participation in such a cooperative children's cancer group, our investigators are able to share new information and ideas
44
Chronic Myelogenous Leukemia
and gain access to new multimodal therapy regimens and investigational drugs which hopefully provide the best available care to these children. Our objectives in the coming years are: 1) increased participation in POG cancer biology and epidemiology studies; 2) to continue our leukemia biology studies particularly pharmacology studies in AML/T ALL, and 3) to develop new strategies for treatment of brain tumors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP Principal Investigator & Institution: Cohn, Susan L.; Associate Professor of Pediatrics; Children's Memorial Hospital (Chicago) Chicago, Il 606143394 Timing: Fiscal Year 2002; Project Start 01-DEC-1978; Project End 31-DEC-2002 Summary: The objectives of this project are to enroll children with cancer in clinical trials, to develop clinical trials and study the biologic behaviors of childhood cancer, and to improve and evaluate the disease- free survival of patients enrolled in these clinical trials. In order to achieve these goals, the member institutions of the Pediatric Oncology Group (POG) meet biannually to discuss, develop, and implement clinical trials for the most common childhood malignancies and to supply the reference research laboratories of the proper material or tissue necessary for the research. Since 1989, CMH has been one of the member institutions of POG who is actually involved in the accrual of children with cancer to clinical trials. CMH's faculty is also involved in the coordination of studies either as the Principal Investigator or co-Investigator. These protocols are POG 9443, POG 9240/41/42, POG 9135/6, POG 9410, NTWS #5. Participation in administrative activities within POG include the POG Chairperson, the POG Executive Officer, the Head of the Neuroblastoma Biology Committee, the Head of the Neuroblastoma Bone Marrow Transplant Working Group, along with members of the following committees: Non- Hodgkin's Lymphoma, Neuroblastoma, Bone Marrow Transplantation, Hodgkin's Disease, New ALL, Wilms' Tumor, Nursing, and Surgery, Radiotherapy, and Pathology Disciplines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC ONCOLOGY GROUP ACTIVITIES Principal Investigator & Institution: Winick, Naomi J.; Professor of Pediatrics; Pediatrics; University of Texas Sw Med Ctr/Dallas Dallas, Tx 753909105 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: This grant application seeks continued support for the Pediatric Oncology Group (POG) activities of The University of Texas Southwestern Medical Center (UT Southwestern) Consortium, which consists of UT Southwestern (Dallas), Cook-Ft. Worth Children's Medical Center (Ft. Worth), and Scott & White Clinic (Temple). Since joining POG in 1981, this partnership of children's cancer treatment and research centers in North Texas has grown to become POG's largest contributing member with regard to patients enrolled on therapeutic studies (over 100 annually). During the current grant cycle, consortium investigators have held administrative and scientific leadership positions on major Group committees, including Executive Committee, Principal Investigator's Committee, New ALL Committee, T-cell Committee, and Lymphoid Relapse Committee. UT Southwestern Consortium investigators have also served or are serving as study coordinators on multiple POG treatment protocols studying ALL (newly diagnosed patients with B-lineage and T-cell disease as well as following relapse), non-Hodgkin's lymphoma, bone marrow transplantation and new agents being explored in Phase I-II trials. UT Southwestern Consortium investigators have also had
Studies
45
prominent roles in the arenas of data management, protocol development, molecular and pharmacologic monitoring in authorized POG reference laboratories, and supportive care. Results of pilot projects conducted at UT Southwestern have been instrumental in the construct of group-wide treatment strategies, especially involving use of methotrexate for B-lineage ALL. To support the UT Southwestern Consortium's continued commitment to POG research during the next 5 years, this new grant proposal describes personnel and facilities in the 3 consortium centers. Specifically, during 1996-2000 the Consortium aims to advance POG research by: (l) enrolling as many patients as possible on POG treatment, biological classification, and epidemiology protocols; (2) collecting, recording, and submitting research data in an accurate and timely fashion; (3) providing administrative and scientific expertise to the Group through continued active participation on major committees, including service as disease committee chairs and protocol coordinators; and (4) continuing to conduct innovative in-house pilot studies for subsequent use by the Group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP MEMBERSHIP Principal Investigator & Institution: Schwartz, Cindy L.; Associate Professor; Oncology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: The aim of this research is to improve the treatment of childhood cancer through participation in organized clinical trials with fellow members of the Pediatric Oncology Group. In addition, we intend to expand our understanding of these diseases by collaborative laboratory investigations. Multiple projects are described which reflect the intense commitment of our faculty to work within the Pediatric Oncology Group. Our faculty are leaders of the POG commitments in ALL phenotyping, Neuropathology, Bone Tumors, Hodgkins disease, Rhabdomyosarcoma, Radiation Oncology, Bone Marrow Transplantation, Myeloid disease, Germ Cell Tumors, Late Effects of Childhood Cancer Therapy, and Multiple Drug Resistance. Pediatrics is the program that describes patient accrual and protocol activity within the division of Pediatric Oncology at Johns Hopkins under the supervision of Dr. Cindy Schwartz as POG PI. The disciplines of Radiation Oncology, Pathology, Pediatric Surgery, Orthopedic Surgery, Neurosurgery and Nursing also play a major role in patient accrual and protocol activity. In addition, Fairfax Hospital under the direction of Dr. Jay Greenberg is an active affiliate of our institution. With the limited numbers of children admitted with any single oncologic diagnosis to an individual institution, it is clear that cooperative clinical research is required if significant advances are to be made. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PEDIATRIC ONCOLOGY GROUP PARTICIPATION Principal Investigator & Institution: Pui, Ching-Hon; Acting Chairman; St. Jude Children's Research Hospital Memphis, Tn 381052794 Timing: Fiscal Year 2002; Project Start 01-JAN-1982; Project End 31-DEC-2002 Summary: We propose continued participation in the Pediatric Oncology Group (POG). Our goals are as follows: (1) to improve cure rates for children with cancer through participation in Phase I, II, and III clinical trials designed to test new agents or concepts; and (2) to participate in laboratory-based research aimed at clarifying the basis of drug resistance and pathogenetic mechanisms of childhood cancers. We are committed to Group participation because we believe: (1) that collaborative efforts are both desirable
46
Chronic Myelogenous Leukemia
and necessary for study of childhood cancers, since all are relatively rare; and (2) that well-designed randomized clinical trials provide the most definitive test of efficacy and general applicability of new therapies and that pooled intellectual resources are advantageous as well. Our contribution to the Group can be categorized as follows: (1) contribution of selected patients (those with rare tumors or less common stages of other cancers, n approximately 80-100/year) to Group studies; (2) administrative and scientific leadership (e.g., disease or discipline committee chairs, and protocol coordinators); (3) provision of multiple reference laboratories (flow cytometry analyses of leukemia and solid tumors, cell bank, AML cytogenetics, pharmacokinetics/pharmacodynamics, molecular genetics of leukemia and solid tumor); (4) regular presentation of results of in-house research to the group. Since our center has an unusually large number of patients and staff (both clinical and basic), the latter contribution assumes unusual importance. We have an extensive in-house developmental therapeutics program which is independent of, but complementary to, the Group's clinical research programs. We also have extensive programs in basic research. The aim of these programs, to determine the pathogenesis of pediatric neoplasia, is expected to positively influence the Group's central goal -- curing children with cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP STUDIES Principal Investigator & Institution: Mclean, Thomas W.; Pediatrics; Wake Forest University Health Sciences Winston-Salem, Nc 27157 Timing: Fiscal Year 2002; Project Start 01-APR-1991; Project End 31-DEC-2002 Summary: The overall objective of the proposed research effort is to continue work towards determining the optimum care for children with all types of cancer. The research mechanism involves participation by pediatric investigators at the Bowman Gray School of Medicine in the development and execution of collaborative multidisciplinary clinical protocols of the pediatric Oncology Group. The proposed research grant will support the continued participation of the Bowman Gray School of Medicine as a full member of the pediatric Oncology Group. Our accomplishments in the past grant period are described in detail in the proposal. Our institutional goals for the five year period of this grant include: (1) continuing our high level of patient accrual and excellent clinical contributions to the POG including our outstanding patient evaluability and protocol compliance which has merited a letter of commendation from the operations office at every 6-month analysis in the past (2) maintaining our institutional involvement in POG leukemia studies and our representation on the new ALL core committee (3) continuation and further development of our multi-disciplinary institutional commitment to POG Hodgkin's disease activities (4) a major role on the POG cytogenetics committee including optimal use of our new reference laboratory status (5) increased institutional development of late effects studies in collaboration with the POG late effects efforts (6) expansion of our efforts in neuro-oncology including increased enrollment on brain tumor studies and investigator roles on the POG brain tumor committee (7) use of in situ studies of tumor cell ploidy in collaboration with POG and other investigators (8) continued contributions to the administrative aspects of the POG. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: CANCER CTR
PEDIATRIC
ONCOLOGY
GROUP--MIDWEST
47
CHILDREN'S
Principal Investigator & Institution: Camitta, Bruce M.; Pediatrics; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2002; Project Start 01-JAN-1983; Project End 31-DEC-2002 Summary: The primary objective of the Midwest Children's Cancer Center is to reduce the incidence of and mortality from childhood cancers. This is approached by: 1) providing the best possible patient care (diagnostic and therapeutic; 2) education of medical and nonmedical groups as to the types of, treatments for, and availability of care for different childhood cancers; and 3) clinical and laboratory research. Investigators at the Cancer Center include specialists in pediatric oncology, surgery, orthopedic surgery, neurosurgery, radiology, radiation therapy, pathology, neurology, psychology and nursing. All new patients are discussed at a multidisciplinary Tumor Board. The children are then treated on Pediatric Oncology Group (POG) or institutional protocols. Results are analyzed and reported regularly. The purpose for the Midwest Children's Cancer Center's participation in POG are: l) to enhance the probability of achieving the above objectives by collaboration with other institutions in the design and execution of clinical protocols; and 2) to evaluate, through laboratory investigations, aspects of tumor biology which result in successful and unsuccessful therapy. Pediatric tumors are relatively rare. The POG is composed of more than 50 member institutions. By pooling resources, biologic and therapeutic studies on these uncommon tumors are facilitated. Similar collaboration permits more rapid development of new drugs. In addition, participation in a common milieu promotes dissemination of information between institutions and investigators. If all children with cancer receive the best possible care, morbidity and mortality will be minimized. The Midwest Children's Cancer Center has been a major contributor to POG by: 1) patient accrual; 2) coordination of POG protocols; 3) institutional pilot studies that were advanced to POG studies; and 4) participation in POG disease and administrative committees. In the next grant period we will continue each of these activities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM Principal Investigator & Institution: Barredo, Julio C.; Professor; Pediatrics; Medical University of South Carolina P O Box 250854 Charleston, Sc 29425 Timing: Fiscal Year 2002; Project Start 15-JUN-1996; Project End 31-DEC-2002 Summary: (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in
48
Chronic Myelogenous Leukemia
neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: POSTTRANSCRIPTIONAL MESSENGER RNA
REGULATION
OF
ONCOGENE
Principal Investigator & Institution: Brewer, Gary A.; Professor; Molecular Genetics & Microbiol; Univ of Med/Dent Nj-R W Johnson Med Sch Robert Wood Johnson Medical Sch Piscataway, Nj 088545635 Timing: Fiscal Year 2002; Project Start 01-JUL-1990; Project End 30-NOV-2006 Summary: (provided by applicant): Our major goal is to understand how the levels of mRNAs encoding cytokines and oncoproteins are regulated, because sustained synthesis of these gene products can favor cell growth rather than differentiation, a hallmark of the neoplastic phenotype. Many cytokine and proto-oncogene mRNAs exhibit extremely short half-lives which limits their use as templates for translation. Moreover, the half-lives of their mRNAs are frequently subject to regulatory control. Their decay is controlled in part by A+U-rich elements (AREs) located in the 3'-UTR. AREs target mRNAs for rapid degradation usually via a sequential, 3'-to-5' pathway involving rapid removal of the poly(A) tract followed by degradation of the mRNA body. Candidate 3'-5' activities include a deadenylase, such as PARN; the exosome, which is a large complex of exoribonucleases; and the proteasome, which appears to possess an ARE-specific ribonuclease activity. We are interested in why and how AREs target mRNAs for rapid degradation and what factors are involved in this process. Toward these ends, we utilized a previously described cell-free mRNA decay system, which reconstitutes cellular decay processes, to biochemically dissect the degradation machinery. We identified and purified the ARE-binding factor AUF1 from K562 cells, a human chronic myeloid leukemia cell line Ectopic expression of AUF1 reverses the inactivation of ARE-directed mRNA decay in hemin-treated K562 cells, supporting an in vivo role for AUF1 in mRNA destabilization. In cells AUF1 exists in complexes with other cellular proteins, such as the translation initiation factor eIF4G, the hspfhsc7O heat shock proteins, and poly(A)binding protein. AUF1 is also ubiquitinated. Under the stress of cell culture at elevated temperatures, heat shock proteins like hsp7O may prevent AUF1 from recruiting the mRNP to both the ubiquitin-proteasome pathway and ribonucleolytic degradation activities resulting in stabilization of ARE-mRNAs. Thus, our central hypothesis is that binding of AUF1 to an ARE promotes the assembly of an mRNA-protein complex that recruits the proteasome and ribonucleolytic activities to the mRNA for its destruction. We plan to utilize our cell-free mRNA decay system along with the reagents and expertise gained from our studies of AUF1 so far to further test, validate, refine, and if necessary, modify our central hypothesis of AUF1 function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRESENILINS IN TUMORIGENESIS AND NEURODEGENERATION Principal Investigator & Institution: Zheng, Hui; Associate Professor; Center on Aging; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2004; Project Start 20-APR-2000; Project End 31-JAN-2008 Summary: (provided by applicant): Mammalian presenilins consist of two homologous proteins: PS1 and PS2. They are indispensable for the proteolytic processing of a variety of substrates including Notch and the amyloid precursor protein (APP), molecules that
Studies
49
play critical roles in cell fate determination and Alzheimer's disease (AD) pathogenesis, respectively. In addition, PS1 associates with beta-catenin---a multi-functional protein involved in cell adhesion, Wnt signaling and tumorigenesis. The original application was aimed at investigating the role of PS 1-beta-catenin pathway in skin tumorigenesis and dissecting the PSI-mediated activities in vivo. We have achieved all of our objectives within the grant-funding period. We reported that PS 1 facilitates beta-catenin turnover. As such, loss of PS 1 is associated with enhanced beta-catenin signaling, activation of its downstream target cyclin D1, accelerated cell proliferation and skin tumorigenesis in mice. Using our novel human PS1 "rescue" system in which expression of wild-type PSI could rescue the mouse PS1 null lethal phenotype, we established that a) PS 1 in Notch processing and beta-catenin interaction can be genetically and functionally uncoupled; and b) Aspartate 257 of PS 1 is critical for Notch and APP proteolysis, thus providing strong support that these two pathways are mediated through the same mechanisms. Two important findings emerged during the course of the study: a) We discovered a widespread role of presenilins in regulating cell proliferation and tumorigenesis: Presenilin deficiency leads to age-dependent myeloproliferative defect indicative of human chronic myelogenous leukemia (CML). Investigating the nature of the defect and determining the molecular mechanisms of presenilins in hematopoiesis is one of the research topics of the current application; b) We established a potent and specific regulation of cyclin D1 by presenilins in both mitotic cells and developing neurons. This observation, combined with the fact that activation of cyclin D1 is an early marker in degenerating neurons of AD patients, leads to an appealing hypothesis that compromised presenilin function, by genetic or environmental insults could result in deregulation of cyclin D1 and unscheduled cell cycle re-entry, with the outcome of neoplasia in peripheral tissues and neurodegeneration in the central nervous system. This competitive renewal is aimed at experimental approaches to test this hypothesis using our powerful mouse genetic systems. The studies combined will significantly advance our understanding of the molecular mechanisms underlying presenilin activities in tumorigenesis, neurodegeneration and AD pathogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROGRESSION OF CHRONIC MYELOGENOUS LEUKEMIA Principal Investigator & Institution: Dessain, Scott K.; Massachusetts General Hospital 55 Fruit St Boston, Ma 02114 Timing: Fiscal Year 2002; Project Start 01-JUL-2000; Project End 31-AUG-2002 Summary: (Applicant's Description): A career development award will provide the opportunity to obtain in depth training and experience in the essentials of cancer and hematology research. The proposed training involves didactic study, professional meetings, and collaborations with leaders in the fields of cancer and leukemia research. The goal of the research plan is to provide an opportunity to learn basic techniques in the study of cancer and malignant hematologic diseases, to learn to think creatively and analytically, and to develop the skills necessary to develop a successful independent research program. The combination of Dr. Robert A. Weinberg as a primary sponsor and Dr. George Q. Daley as a co-sponsor will provide outstanding mentorship. Dr. Weinberg has an established record of training outstanding investigators. Dr. Daley has a strong background in the study of human leukemias and as a clinical hematologist he provides an excellent role model of a physician-scientist. The educational opportunities and the resources that the Whitehead Institute for Biomedical Research provides are outstanding, and will complement the strong mentorship of Dr. Weinberg and Dr. Daley. The proposed research seeks to explain the clinical course of chronic
50
Chronic Myelogenous Leukemia
myelogenous leukemia (CML). CML initially manifests as a clinically manageable chronic phase disease, characterized by a hyperproliferation of relatively normal cells. CML inevitably progresses to blast phase, a virtually u n t reatable acute leukemia. The genetic changes responsible for the progression to blast are unknown. The Weinberg laboratory has recently developed a model for cooperating oncogenes in human cells, demonstrating that primary human cells can be transformed by the combination of a viral oncogene, a ras oncogene, and the t e l o merase gene. This experimental system yields a model of human carcinogenesis that can be used to formulate a number of specific, testable hypotheses that may explain the progression of chronic phase CML to blast phase. Building on the observation that human chronic phase and blast phase cells engraft differently in the immunocompromised NOD/SCID mouse, hypotheses regarding the progression of chronic phase CML can be tested in vivo. The first two parts of the research address the role of telomerase in the natural history of CML. The second two parts explore the role of oncogenes in the pathogenesis of blast phase CML and attempt to build a multi-step model to explain the progression of chronic phase CML to blast phase. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RESISTANCE OF CML STEM CELLS TO STI571 (GLEEVEC) Principal Investigator & Institution: Bhatia, Ravi; City of Hope/Beckman Research Institute Helford Building Duarte, Ca 910103000 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Chronic myelogenous leukemia (CML) results from malignant transformation of a hematopoietic stem cell. Malignant cells in CML are characterized by the t (9; 22) translocation resulting in the BCR/ABL gene rearrangement. The BCR/ABL protein has constitutively activated protein-tyrosine kinase activity, which is essential for transformation in CML. STI571 (STI, Gleevec), an inhibitor of the BCR/ABL tyrosine kinase, has shown a high degree of activity in all stages of CML in early clinical studies. However, a significant proportion of patients treated with STI do not achieve cytogenetic responses. Moreover, for patients who achieve cytogenetic responses following STI therapy, it is not known whether responses to STI will be durable and result in prolongation of survival. Our preliminary studies indicate that persistent BCR/ABL positive progenitor cells can be detected even in responsive patients in complete cytogenetic remission, indicating that they may be at risk for relapse. We hypothesize that lack of cytogenetic response to STI treatment will correlate with in vitro observations of reduced inhibition of leukemic progenitor growth and reduced suppression of BCR/ABL activated signaling mechanisms by STI. We further hypothesize that the burden of persistent malignant progenitors in patients in cytogenetic response following STI treatment will predict for durability of response. We will determine the relationship between cytogenetic response or lack of response to STI treatment and laboratory assessments of STI-induced inhibition of leukemic progenitor growth and BCR/ABL signaling activities (Specific Aim 1). Development of predictors of non-responsiveness may allow upfront identification of patients requiring alternative treatment approaches. We will also determine the relationship between persistent malignant progenitors in patients with cytogenetic responses to STI and durability of response and risk of relapse, and investigate mechanisms underlying persistence of malignant progenitors (Specific Aim 2). These studies will determine the efficacy of STI in targeting malignant primitive hematopoietic progenitors and may lead to the development of surrogate markers for long-term response. The long-term goal of these
Studies
51
studies is to allow optimal use of STI, alone or in combination, in the treatment of CML and improve overall outcomes of treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE LEUKEMOGENESIS
OF
RNA-BINDING
PROTEINS
IN
BCR/ABL
Principal Investigator & Institution: Perrotti, Danilo; Comprehensive Cancer Center; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JUL-2007 Summary: (provided by applicant): Shuttling hnRNPs control the fate of eukaryotic mRNAs throughout their journey from the active site of transcription to that of translation; thus, gain or loss of their function in hematopoietic cells might result in altered hematopoiesis and/or emergence of leukemia. In BCR/ABL-expressing cells, there is a marked increase in the levels of different RNA binding proteins including FUS, hnRNP A1, hnRNP E2 and hnRNP K, four shuttling hnRNPs involved in the regulation of mRNA biogenesis, processing, nuclear export, and translation. Ectopic expression and/or inhibition of the activity of FUS, hnRNP A1 and hnRNP E2 affects the proliferation, survival, and differentiation of normal and BCR/ABL-expressing cells, suggesting that enhanced expression/activity of certain RNA-binding proteins plays an important but as yet unrecognized role in BCR/ABL leukemogenesis. Thus, the objective of this proposal is: 1) To investigate the mechanisms regulating hnRNP E2 and hnRNP A1 expression/function in BCR/ABL-expressing cells. 2) To identify hnRNP A1 and hnRNP E2-associated mRNAs encoding proteins differentially expressed in CMLblast crisis and CML-chronic phase cells. 3) To determine the BCR/ABL-dependent mechanisms regulating the expression/function of hnRNP K and determine whether hnRNP K function(s) is(are) required for BCR/ABL-induced leukemogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEQUENCE CHROMOSOMES
BASED
FISH
ANALYSIS
OF
PHILADELPHIA
Principal Investigator & Institution: Knoll, Joan H.; Children's Mercy Hosp (Kansas City, Mo) 2401 Gillham Rd Kansas City, Mo 64108 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant) One of the most prevalent abnormalities in leukemia patients, the Philadelphia chromosome, a translocation of the ABL1 oncogene on chromosome 9 to the BCR gene on chromosome 22, occurs in adult chronic myelogenous leukemia and childhood acute chronic leukemia. In addition to the translocation, the commercial ES-probe used in clinical cytogenetics laboratories sometimes detects deletions of DNA sequences upstream of the ABL1 gene on the derivative 9 chromosome (in 1/10 to 1/3 of patients). These deletions appear to be prognostic for early blast crisis. We hypothesize that these deletions result in hemizygosity of additional genes adjacent to ABLI. These deletion breakpoints can be refined with high- resolution fluorescence in situ studies (scFISH), which uses short single copy (sc) DNA probes designed from the draft genome sequence. Chromosomal preparations of patient specimens diagnosed with Philadelphia chromosomes in clinical cytogenetic laboratories will be analyzed with these probes. ScFISH, which has been developed in our laboratories, provides an unprecedented level of resolution for delineating sequences associated with inherited chromosomal rearrangements by FISH (Rogan, Cazcarro, Knoll, 2001; Knoll, Cazcarro, Rogan, 2000). We have developed and
52
Chronic Myelogenous Leukemia
validated single copy DNA probes (quickly and without cloning) for FISH analysis of more than 20 distinct chromosomal regions. We aim (1) to develop scFISH probes for ABL1 oncogene, BCR and their adjacent regions from the draft genome sequence and verify their locations by FISH; (2) to compare results with scFISH probes to those obtained using the commercially available ES-probes for t(9;22) on the same patient specimens; and (3a) to categorize cytogenetically positive t(9;22) into molecular subgroups based on the sizes of deletion centromeric to ABL1 and the breakpoints within the BCR gene, (3b) to determine if there are preferential sites of breakage on chromosome 9 adjacent to ABL1, and to localize these sites. In contrast with scFISH probes, commercial reagents detecting this translocation routinely used in clinical laboratories comprise large multigenic segments. We anticipate that both the commercial and scFISH probes will detect the chromosomal translocation in some patients, however, only the scFISH probes are expected to delineate deletions in sequences immediately adjacent to ABL 1, and to distinguish the major and minor sites of breakage in the BCR gene that correspond to chronic myelogenous leukemia and acute lymphocytic leukemia, respectively. The proposed study will delineate the chromosomal regions that undergo breakage in these types of leukemia and will establish whether there are common deletion breakage intervals on the translocated chromosome 9. Our long range goal is to classify patients based on the sites of translocation and deletion size, and then to determine if the disease complications can be attributed to the loss of specific genes adjacent to ABL1. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SIGNALING PATHWAYS UTILIZED BY V-ABL AND BCR-ABL Principal Investigator & Institution: Calame, Kathryn L.; Professor; Microbiology; Columbia University Health Sciences Po Box 49 New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 20-JAN-1999; Project End 31-DEC-2003 Summary: Mutant forms of the Abelson tyrosine kinase, v-Abl and BCR-ABL, cause malignant transformation in many mammalian species including humans. Understanding the signaling paths utilized by v-Abl and BCR-ABL is key to understanding the mechanisms by which they cause malignancy. The goal of this Program Project is to study three particular aspects of signaling by v-Abl and BCR-ABL. Project #1, led by Dr. Stephen Goff, will study the role of a newly discovered Ablbinding protein, Abi-l is probably important in early signaling events which link Abl tyrosine kinase activity to downstream effectors which link Abl tyrosine activity to downstream effectors, particularly Ras. Project #2 led by Dr. Paul Rothman, will determine the role of the recently discovered activation of Janus kinases (Jaks) by v-Abl. Jaks represent an alternative signaling path, utilized by normal cytokines, which may be important for Abl transformation. Project #3, led by Dr. Kathryn Calame will study recently discovered connections between regulation of cell cycle and V- Abl including vAbl dependent induction of cyclin D mRNA, v-Abl-dependent decrease in p27 protein and p53-dependent inhibition of v-Abl transformation. In each of these projects the molecular mechanisms and functional importance for Abl-dependent transformation of different signaling pathways will be determined. The projects will be supported by three scientific cores and one administrative core. The first Core will provide standardized virus stocks, monoclonal antibodies and Abelson transformed cell lines to all projects. The second Core will provide care and breeding of mice nullizygous for genes involved in the pathways under study. The third Core will supply primary cells from patients with Chronic Myelogenous Leukemia to individual projects, supported by the Cores, will be shared among the projects so that collaborative experiments can be performed to
Studies
53
determine how signaling by each of the pathways under study is related to the others. The knowledge gained by this Program Project will not improve our understanding of Abelson-dependent transformation but will also help us understand general mechanisms of oncogenesis and signal transduction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPAN-XB AS AN IMMUNOLOGIC TARGET FOR CML Principal Investigator & Institution: Lim, Seah H.; Internal Medicine; Texas Tech University Health Scis Center Health Sciences Center Lubbock, Tx 79430 Timing: Fiscal Year 2004; Project Start 01-JUN-2004; Project End 31-MAY-2008 Summary: (provided by applicant): There is abundant of evidence to suggest that chronic myeloid leukemia (CML) can be modulated by the effector cells in the immune system, suggesting the potential for the use of immunotherapy for patients with CML, either as a therapy following standard treatment to maintain disease remission or as part of leukemia-specific donor lymphocyte infusion to reduce the risk of leukemia relapse after allogeneic stem cell transplant. Unfortunately the antigens suitable for this purpose are yet to be defined. We have recently found that the testicular-specific antigen, SPAN-Xb, is aberrantly expressed by leukemia cells from CML patients. We have also found that in these patients, high IgG directing at SPAN-Xb protein could be detected in the serum. We have generated a recombinant SPAN-Xb protein and murine MoAbs against the protein. We have also demonstrated that SPAN-Xb recombinant protein could be used to induce HLA-A2-restricted CTLs from a healthy donor. These CTLs are not only SPAN-Xb-specific; they also killed fresh HLA-A2+ CML cells, providing the rationale for the present proposal. In this application, we hypothesize that SPAN-Xb is a target for immunotherapy of CML. To test this hypothesis, we will: 1. Use a combination of real time PCR and immunocytochemistry to determine the frequency and levels of SPAN-Xb gene and protein expression in CML. We will determine if there is any correlation between gene and protein expression in the CML population and also between the levels of gene and protein expression within individual patients. 2. We will serially determine any correlation between the de novo SPAN-Xb immunity and disease status of the patients. We will study HLA-A2+ SPAN-Xb+ CML patients and correlate the intensity of B- and T-cell immunity to the response to treatment. 3. We will determine the feasibility of generating SPAN-Xb-specific CTLs from healthy donors and SPAN-Xb+ CML patients with common HLA-class I phenotypes. We will characterize these CTLs in types of their phenotypes, cytokine profiles, activities against CML cells and inhibitory effect on CML colony formation. Successful completion of the proposal will therefore provide the basis for the clinical translation of SPAN-Xb. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SPECIFIC ADOPTIVE IMMUNOTHERAPY OF MALIGNANT DISEASES Principal Investigator & Institution: Greenberg, Philip D.; Professor of Medicine; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 18-MAR-2002; Project End 30-NOV-2006 Summary: (provided by applicant): The antitumor activity of human T cells, as definitively demonstrated by donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation (HSCT), has provided impetus for developing T cell therapy as a modality to treat leukemia. However, identifying immunogenic antigens expressed by leukemic cells has been a major obstacle. Self-proteins
54
Chronic Myelogenous Leukemia
overexpressed by cancer cells have been shown in some settings to induce T cell responses with avidity sufficient to recognize transformed cells but not normal cells which express lower levels of the protein. The best candidate self-proteins are the subset which are oncogenic and/or associated with maintenance of the malignant phenotype, as these may be indispensable to the leukemia. Two proteins, WT1 and Proteinase 3/myeloblastin (PR3/MBN), expressed by acute leukemias and CML respectively, have recently been demonstrated in animal models, and preclinical and clinical studies, to potentially fulfill criteria for oncogenicity, immunogenicity, and safety as targets. Our laboratory has extensive experience with adoptive transfer of cloned T cells, which can facilitate analysis of candidate antigens by establishing in vivo qualitative and quantitative responses not readily achieved by other means. This approach can not only help define the therapeutic potential of specifically targeting a selected antigen, but determine the possible risks and toxicities to normal tissues, and the magnitude of response that would need to be achieved by alternative approaches such as vaccination. The proposed experiments are designed to evaluate the immunogenicity of the WT1 and PR3/MBN proteins, and to determine if adoptive transfer of CD8+ CTL clones specific for these antigens can mediate an antileukemic effect without toxicity to the recipient. The specific aims are to: 1. Determine if CD8+ T cells specific for WT1 and PR3/MBN and capable of selectively recognizing leukemic cells can be isolated from an MHC diverse population of normal individuals and patients with leukemia. 2. Determine if expanded numbers of CD8+ CTL specific for immunogenic epitopes from WT1 and PR3/MBN are present in leukemic patients prior to and following HSCT. 3. Determine if the transfer of donor-derived CD8+ CTL specific for PR3/MBN into patients with CMLAP or CML-BP that has relapsed post-allogeneic HSCT is safe and can mediate an antitumor effect. 4. Determine if the transfer of donor-derived CD8+ CTL specific for WT1 into patients with AML or ALL that has relapsed post-allogeneic HSCT is safe and can mediate an antitumor effect. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SRC FAMILY TYROSINE KINASES IN TUMOR CELL SIGNALING Principal Investigator & Institution: Smithgall, Thomas E.; Associate Professor; Molecular Genetics & Biochem; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2004; Project Start 01-JUL-2004; Project End 30-JUN-2008 Summary: (provided by applicant): Bcr-Abl is the oncogenic tyrosine kinase expressed as a result of the Philadelphia translocation in chronic myelogenous leukemia (CML). Src family kinase inhibitors and dominant-negative mutants block Bcr- Abl-induced transformation of myeloid progenitor cells, strongly suggesting that Bcr-Abl cooperates with Src in CML pathogenesis. Experiments proposed here will investigate the molecular mechanisms that regulate the interaction of Bcr-Abl with Src kinases, determine whether Src kinases affect Bcr-Abl kinase activity and sensitivity to the antiCML drug STI-571 (Gleevec), and look at the genetic requirement for Src kinases in a model system for CML: Aim 1: Test the hypothesis that association with Bcr-Abl is sufficient to induce Src kinase activation. Recent data from our laboratory show that interaction with Bcr-Abl involves Src family kinase SH2 and SH3 domains, suggesting that association with Bcr-Abl may be sufficient to induce sustained Src kinase activation in vivo. Using fibroblast and myeloid cell transformation assays, we will test this idea by co-expressing Hck and Lyn with regions of Bcr-Abl previously shown to bind to these myeloid Src family members in vitro. Identification of the Bcr-Abl regions essential for Src family kinase activation will define a novel molecular surface for anti-CML drug
Studies
55
design. Aim 2: Test the hypothesis that Src kinases phosphorylate Bcr-Abl in vivo and modulate its kinase activity and sensitivity to inhibition by STI-571. Preliminary data show that Src kinases directly phosphorylate the c-Abl kinase domain on the activation loop tyrosine in vitro. Bcr-Abl mutants lacking Src family kinase phosphorylation sites and selective inhibitors will be used to determine whether Src family kinases affect BcrAbl activity and sensitivity to STI-571, which selectively inhibits the inactive conformer of Abl. Aim 3: Test the genetic requirement for Src family kinases in Bcr-Abl signal transduction and STI-571 sensitivity. The transforming activity of Bcr-Abl will be assessed in hematopoietic colony-forming assays of bone marrow cells from mice lacking the three major myeloid Src family members (Hck/Lyn/Fgr), all of which interact with Bcr-Abl. Triple-knockout cells will also be used to address the requirement for Src family members in coupling Bcr-Abl to Stats and other downstream effectors as well as sensitivity to STI-571. Successful completion of these studies will provide strong validation of myeloid-specific Src kinases as targets for second-generation anti-CML drug development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STAT ACTIVATION IN LEUKEMIAS Principal Investigator & Institution: Zuckerman, Kenneth S.; Professor; Internal Medicine; University of South Florida 4202 E Fowler Ave Tampa, Fl 33620 Timing: Fiscal Year 2002; Project Start 01-FEB-2001; Project End 31-JAN-2006 Summary: (Applicant's Abstract) The first purpose of this project is to understand the molecular mechanisms responsible for the constitutive activation of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signal transduction pathways in some cases of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML). The second purpose of this project is to determine the importance of constitutive JAK2/STAT5 activation in development and maintenance of the leukemic phenotype, both in vitro and in vivo. The primary hypotheses being tested are that specific activating mutations that lead to constitutive activation of JAK/STAT signal transduction pathways are responsible for the development and/or maintenance of leukemic cell survival and proliferation, and that, in leukemic cells expressing constitutively activated STAT5, inhibition of STAT5 activation or function. Three specific aims are proposed to test these hypotheses. Specific Aim 1 is to determine the mechanism(s) of constitutive activation in the HEL/Dami and Meg-01 human leukemic cell lines. Specific Aim 2 is to determine whether constitutive JAK/STAT signaling pathway activation plays an important role in maintenance of the leukemic phenotype of primary human AML cells. Specific Aim 3 is to determine the ability of double-stranded "decoy" oligonucleotides containing the STAT5 binding domain to inhibit the unregulated survival and proliferation of leukemic cells in vivo. The models to be tested include: (1) human HEL/Dami and Meg-01 cell lines implanted in sublethally irradiated NOD/SCID mice; (2) tet-off bcr/abl transgenic mice, which develop leukemia when mice are deprived of tetracycline in their drinking water (obtained from Dan Tenen); and (3) mice transplanted with bone marrow cells transfected with TEL/JAK2 or TEL/ABL retroviruses, which result in development of leukemias that have constitutively activated STAT5. These studies should lead to new understanding approaches for treatment of leukemias in which STAT activation plays a role in maintenance of the leukemic phenotype. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
56
•
Chronic Myelogenous Leukemia
Project Title: STUDIES OF BCR/ABL LEUKEMOGENESIS IN MICE Principal Investigator & Institution: Van Etten, Richard A.; Director, Hematologic Malignancies; Cbr Institute for Biomedical Research 800 Huntington Ave Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (Adapted from the investigator's abstract) The human Philadelphia (Ph) chromosome-positive leukemias, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia, are among the most common hematological malignancies, and current therapy for these diseases is inadequate. Expression of the product of the t(9;22) Ph chromosome, the BCR!ABL fusion gene, in the hematopoietic system of mice by generation of transgenic mice or through retroviral transduction and transplantation of bone marrow has demonstrated that BCR/ABL is a leukemia specific oncogene and the direct cause of CML. The long term objective of this application is a more complete molecular and genetic understanding of the pathophysiology of human Ph-positive leukemias, particularly the myeloproliferative disease CML. These goals will be accomplished by the use of a retroviral bone marrow infection/transplantation mouse model system that accurately and quantitatively models both human CML and Ph-positive B-lymphoid leukemia, and will have two Specific Aims. In the first Aim, the signaling pathways important for leukemogenesis by BCR/ABL will be identified by testing BCR/ABL mutants, by further analysis of the requirement for direct binding of the Grb2 adapter protein by the Bcr/Abl fusion protein, and through the use of mice with germline mutations in signaling molecules. In the second Aim, the bone marrow target cells that initiate the CML-like disease and B-lymphoid leukemia induced by BCR/ABL will be characterized and isolated by physical and immunological methods. These investigations will add important new information to our understanding of these leukemias, that would be difficult if not impossible to obtain from studies in vitro, in cultured cells, or in primary human CML cells. This knowledge will be valuable for improving the diagnosis and treatment of the Ph-positive leukemias. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TARGETED TREATMENT OF LEUKEMIA WITH SPECIFIC CTL CLONES Principal Investigator & Institution: Ho, William Y.; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 06-SEP-2002; Project End 30-JUN-2007 Summary: (provided by applicant): Standard therapies for leukemia such as chemotherapy and hematopoietic stem cell transplantation (HSCT) have significant toxicities due their lack of specificity. Adoptive T cell immunotherapy targeting leukemia-associated antigens has the potential to selectively eliminate leukemic cells with minimal toxicity to normal tissues. Two candidate target antigens, WT1 and Proteinase 3 (PR3 or Myeloblastin), are selectively over expressed in many types of leukemias. Aims of this project include (1) to determine whether the number and function of WT1 or PR3-specific CD8+ cytotoxic T cells (CTL) in the blood of leukemia patients receiving HSCT correlate with disease remission, (2) to develop reliable and efficient methods for generating WT1 and PR3-specific CTL clones from normal donors using autologous peptide-loaded dendritic cells (DC), (3) to determine whether these clones are able to selectively inhibit the growth of leukemic but not normal cells in both in vivo and in vitro systems, (4) to initiate a Phase I clinical trial in patients with acute leukemia that has relapsed after HSCT to determine whether the transfer of donor-
Studies
57
derived WT1-specific CTL clones is safe and can mediate an anti-leukemia effect, and (5) to initiate a similar Phase I trial in relapsed CML patients using PR3-specific clones. Using both WT1 and PR3-derived MHC-peptide tetramers, this proposal seeks to identify specific CTL in the blood of leukemia, patients undergoing HSCT, to isolate and expand high-avidity CTL clones from donor-derived, DC-stimulated cell lines for use in adoptive immunotherapy, and to track WT1 and PR3-specific CTL clones in the blood of patients after infusion. Clones will be assayed for safety and efficacy prior to clinical trials using in vitro colony forming assays and the NOD/SCID mouse model of leukemic engraftment. The long-term goal of this project is to determine whether the adoptive transfer of WT1 or PR3-specific CTL clones is a safe and effective treatment for leukemia. As a Research Associate at the Fred Hutchinson Cancer Research Center and Acting Instructor in the University of Washington Department of Medicine, the candidate is in an ideal environment in which to receive both didactic and practical training related to clinical investigation. In order to develop an independent career in patient-oriented translational research, the candidate will pursue ongoing coursework in clinical trial design, biostatistics, epidemiology, ethics, and the responsible conduct of research, in addition to continuing his preclinical studies and designing and implementing the Phase I clinical trials outlined in this proposal. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THERAPY OF CML Principal Investigator & Institution: Champlin, Richard E.; Professor and Director, Bone Marrow Tran; Hematology; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-DEC-1989; Project End 31-MAY-2003 Summary: Eight projects and eight cores are proposed forming a translational research program with the goal of advancing the treatment of chronic myelogenous leukemia. Projects 1-3 involve 1) clinical investigation of novel chemo- and biologic therapies, 2) allogeneic blood and marrow transplantation focusing on enhancement of graft-versusleukemia and improving the therapeutic index of preparative regimen, and 3) Use of "leukemic" dendritic cells to generate autologous anti-leukemic T-cells for adoptive immunotherapy. Projects 4 and 5 are designed to improve the safety and effectiveness of allogeneic transplants for CML. The allogeneic graft-versus-leukemia effect can independently produce prolonged remissions in CML patients,b ut its efficacy is limited by the development of graft-versus-host disease. Project 4 studies the induction of GVL using lymphocytes transduced with Herpes virus thymidine kinase which renders them sensitive to the antiviral drug ganciclovir; if GVHD occurs the effectors cells can be ablated by ganciclovir treatment. In a preclinical murine model, the hypothesis that this strategy can abrogate GVHD while retaining GVL will be tested and strategies for optimally employing TK transduced donor lymphocyte infusions will be developed. Project 5 focuses on development of less toxic preparative regimens to achieve engraftment of allogeneic stem cell grafts and strategies to induce GVL without GVHD in histoincompatible recipients. Projects 6 and 7 examine the function of the bcr-abl tyrosine kinase and molecular strategies to block its transforming effects. Project 8 examines abnormalities in DNA methylation which occur in the course of CML and their significance for therapeutic intervention. Core A is for administration. Core B provides biostatistical support for the program. Core C is for minimal disease detection using fluorescence in situ hybridization (C1) or quantitative polymerase chain reaction (C2). Core D is for cell culture assays, in vitro (D1) and in a NOD-SCID murine model
58
Chronic Myelogenous Leukemia
(D2). Core E provides flow cytometry support and Core F is the sample collection, processing and distribution core. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSCRIPTION FACTOR REGULATION BY THE BCR/ABL ONCOGENE Principal Investigator & Institution: Calabretta, Bruno; Professor; Microbiology and Immunology; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: Transcription factor regulation by the BCR/ABL oncogene Human hematological malignancies are characterized by well- defined genetic abnormalities responsible for the generation of autonomous growth signals or the aberrant transduction of these signals from the cytoplasm to the nucleus. The BCR/ABL oncoproteins, the leukemia-specific gene products of the Philadelphia chromosome (Ph1) translocation, induce and maintain the leukemic phenotype through their deregulated tyrosine kinase activity; such activity is essential for recruitment and activation of multiple pathways that transduce signals leading to growth factorindependent proliferation, inhibition of apoptosis, and altered differentiation of myeloid precursor cells. The mechanisms of activation of the cytoplasmic downstream effectors of BCR/ABL are understood in some detail, but much less is known on the pathways leading to transcription factor regulation. This application focuses on investigating the BCR/ABL-dependent pathways leading to changes in the expression of c-Myb and C/EBPalpha, two transcription factors involved in the regulation of proliferation, survival, and differentiation of hematopoietic cells. Specifically, we will: 1) Investigate mechanisms of the enhanced expression/activity of c-Myb by: a. determining sequence requirements and enzymatic pathways that regulate ubiquitination and/or proteasomedependent degradation of c-Myb in normal and BCR/ABL-expressing hematopoietic cells. b. identifying the interacting proteins promoting the ubiquitin/proteasomedependent degradation of c-Myb. c. determining whether the activity of proteins promoting c-Myb degradation is modulated in BCR/ABL-expressing cells. 2) Assessing the effects of degradation-resistant c-Myb mutants on proliferation, survival, and differentiation of hematopoietic cells. 3) Assessing leukemic samples for the presence of c-myb mutations within domains involved in protein degradation. 4) Investigating the mechanisms whereby BCR/ABL suppresses the expression of the granulocytic differentiation regulator C/EBPalpha. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TREATMENT OF CHILDHOOD CANCER Principal Investigator & Institution: Brecher, Martin L.; Roswell Park Cancer Institute Corp Buffalo, Ny 14263 Timing: Fiscal Year 2002; Project Start 01-JUL-1980; Project End 31-DEC-2002 Summary: Cooperative trials in pediatric cancer patients have played a major role in the remarkable improvement in cure of childhood cancers. Because most childhood cancers are rare, it is only through this mechanism that adequate numbers of patients can be accrued in reasonable lengths of time for randomized controlled studies. The Department of Pediatrics at Roswell Park Cancer Institute (RPCI) has actively participated in cooperative group trials via the Pediatric Oncology Group (POG) to answer treatment questions which would be impossible to answer were we to conduct
Studies
59
only single institution studies. Some pediatric solid tumors are so rare that national intergroup studies are required. We also participate in these intergroup studies. RPCI investigators are coordinators for a number of POG protocols including front-line studies for the treatment of advanced Hodgkin's disease, advanced small non- cleaved cell lymphoma, non-rhabdomyosarcoma soft tissue sarcomas, acute lymphoblastic leukemia in relapse, the National Wilms Tumor Study, brain tumors in infants, and the Intergroup Ewing's Sarcoma Study. Roswell Park investigators have also developed POG phase II studies of continuous infusion 5-fluouracil and the combination of cisplatin, ifosfamide and etoposide. Roswell Park investigators chair the Wilms Tumor Committee, the Neuroscience Subcommittee of the Brain Tumor Committee, and cochair the Pathology Discipline Core Committee, as well as being active on a number of other POG Core Committees. They have made major contributions over the last few years in the areas of solid tumor oncology, neuro- oncology and the treatment of lymphoid malignancies. We are strongly committed to the interdisciplinary approach to pediatric cancer and have established collaboration with the necessary clinical specialties including Radiation Medicine, Pediatric Surgery, Pediatric Neurology, Neurosurgery, and Orthopedic Surgery, as well as with researchers in immunology, pharmacology and molecular biology. As more children are cured of their cancers, the identification and prevention, when feasible, of complications of therapy have become imperative. We have been a major contributor to the identification and understanding of the long-term medical and psychosocial effects of the treatment of leukemia, Hodgkin's disease, and a number of solid tumors, both through the cooperative group mechanism and through institutional studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “chronic myelogenous leukemia” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for chronic myelogenous leukemia in the PubMed Central database: •
3 4
A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes. by Seong DC, Sims S, Johnson E, Howard OM, Reiter B, Hester J, Talpaz M, Kantarjian H, Deisseroth A.; 1990 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=296917
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
60
Chronic Myelogenous Leukemia
•
Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34 + cell proliferation: BCR /ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. by Jiang Y, Zhao RC, Verfaillie CM.; 2000 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27060
•
Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. by Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, Nowell PC, Cohen PA, Czerniecki BJ.; 1999 Aug 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17888
•
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. by Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON.; 1985 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=397362
•
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues. by Huhn RD, Posner MR, Rayter SI, Foulkes JG, Frackelton AR Jr.; 1987 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=305098
•
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. by Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.; 2002 Aug 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125018
•
Disruption of the estrogen receptor [beta] gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. by Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Makela S, Warner M, Gustafsson JA.; 2003 May 27; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=164509
•
Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. by Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG.; 1991 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=295821
•
Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints. by Croce CM, Huebner K, Isobe M, Fainstain E, Lifshitz B, Shtivelman E, Canaani E.; 1987 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=299252
•
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. by Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin R.; 1990 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=53305
•
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the
Studies
61
Philadelphia chromosome. by Mes-Masson AM, McLaughlin J, Daley GQ, Paskind M, Witte ON.; 1986 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=387222 •
p53 in chronic myelogenous leukemia in acute phase. by Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, Goldman J, Zaccaria A, Berrebi A, Canaani E.; 1991 Jul 15; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=52069
•
Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells. by Naldini L, Stacchini A, Cirillo DM, Aglietta M, Gavosto F, Comoglio PM.; 1986 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=367710
•
Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). by Nagel S, Schmidt M, Thiede C, Huhn D, Neubauer A.; 1996 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=146207
•
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562. by Collins SJ, Groudine MT.; 1983 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=384135
•
T cells recognizing leukemic CD34 + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. by Smit WM, Rijnbeek M, van Bergen CA, Fibbe WE, Willemze R, Falkenburg JH.; 1998 Aug 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=21477
•
Treatment of marrow stroma with interferon-alpha restores normal beta 1 integrindependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1 alpha. by Bhatia R, McGlave PB, Verfaillie CM.; 1995 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=185281
•
Unresponsiveness of Primitive Chronic Myeloid Leukemia Cells to Macrophage Inflammatory Protein 1[alpha], an Inhibitor of Primitive Normal Hematopoietic Cells. by Eaves CJ, Cashman JD, Wolpe SD, Eaves AC.; 1993 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48116
•
Variable expression of the translocated c-abl oncogene in Philadelphia-chromosomepositive B-lymphoid cell lines from chronic myelogenous leukemia patients. by Konopka JB, Clark S, McLaughlin J, Nitta M, Kato Y, Strife A, Clarkson B, Witte ON.; 1986 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=323663
62
Chronic Myelogenous Leukemia
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with chronic myelogenous leukemia, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “chronic myelogenous leukemia” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for chronic myelogenous leukemia (hyperlinks lead to article summaries): •
A 41-year-old woman with chronic myelogenous leukemia. Author(s): Antin JH. Source: Jama : the Journal of the American Medical Association. 2003 August 27; 290(8): 1083-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12941682
•
A case of acute myeloid leukemia with t(7;11)(p15;p15) mimicking myeloid crisis of chronic myelogenous leukemia. Author(s): Kawakami K, Miyanishi S, Nishii K, Usui E, Murata T, Shinsato I, Shiku H. Source: International Journal of Hematology. 2002 July; 76(1): 80-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12138901
•
A case of hypoplastic chronic myelogenous leukemia initiating with pancytopenia. Author(s): Matsuda M, Miyazato H, Ueda S, Morita Y, Sakaguchi M, Tatsumi Y, Maeda Y, Kanamaru A. Source: International Journal of Hematology. 2002 April; 75(3): 335-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11999367
•
A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL. Author(s): Onozawa M, Fukuhara T, Takahata M, Yamamoto Y, Miyake T, Maekawa I. Source: Annals of Hematology. 2003 September; 82(9): 593-5. Epub 2003 July 24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12898186
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
Studies
63
•
A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. Author(s): Moore H, Li NK. Source: Journal of Theoretical Biology. 2004 April 21; 227(4): 513-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15038986
•
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. Author(s): Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C. Source: The New England Journal of Medicine. 2003 May 29; 348(22): 2265-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12773665
•
A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Author(s): Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI. Source: Genes, Chromosomes & Cancer. 2003 July; 37(3): 291-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12759927
•
A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia. Author(s): Oudat R, Khan Z, Glassman AB. Source: Archives of Pathology & Laboratory Medicine. 2001 March; 125(3): 437-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11231500
•
Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis. Author(s): Yamaguchi M, Yamamoto K, Miura O. Source: Genes, Chromosomes & Cancer. 2003 November; 38(3): 269-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14506703
•
Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance. Author(s): Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, Dan K. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2002 February; 16(2): 170-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11840282
64
Chronic Myelogenous Leukemia
•
Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. Author(s): Mc Gee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC, Zisterer DM. Source: The Journal of Biological Chemistry. 2002 May 24; 277(21): 18383-9. Epub 2002 February 20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11856743
•
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. Author(s): Jin Huh H, Won Huh J, Myong Seong C, Lee M, Soon Chung W. Source: American Journal of Hematology. 2003 November; 74(3): 218-20. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14587058
•
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Author(s): Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P. Source: Blood. 2002 March 15; 99(6): 1971-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11877268
•
Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. Author(s): Sharathkumar A, Thornley I, Saunders EF, Calderwood S, Freedman MH, Doyle J. Source: Journal of Pediatric Hematology/Oncology : Official Journal of the American Society of Pediatric Hematology/Oncology. 2002 March-April; 24(3): 215-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11990309
•
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Author(s): Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M. Source: Cancer. 2003 October 1; 98(7): 1430-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14508830
•
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Author(s): Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2003 June; 9(6): 1972-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796358
Studies
65
•
Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. Author(s): Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI, Kim T. Source: J Biochem Mol Biol. 2002 July 31; 35(4): 377-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12296996
•
Aseptic necrosis of both femoral heads as first symptom of chronic myelogenous leukemia. Author(s): Kraemer M, Weissinger F, Kraus R, Beer M, Kunzmann V, Wilhelm M. Source: Annals of Hematology. 2003 January; 82(1): 44-6. Epub 2002 December 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12574965
•
Asymptomatic pericardial effusion in chronic myelogenous leukemia. Author(s): Kadikoylu G, Onbasili A, Barutca S, Tekten T, Bolaman Z. Source: Leukemia & Lymphoma. 2003 April; 44(4): 723-5. Erratum In: Leuk Lymphoma. 2003 July; 44(7): 1265. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12769352
•
ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Author(s): Zander AR, Kroger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baurmann H, Bornhauser M, Ehninger G, Fauser AA, Kiehl M, Trenschel R, Ottinger HD, Bertz H, Berger J, Kolb HJ, Schaefer UW. Source: Bone Marrow Transplantation. 2003 August; 32(4): 355-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12900771
•
BCR rearrangement-negative chronic myelogenous leukemia revisited. Author(s): Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 June 1; 19(11): 2915-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11387365
•
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Author(s): Chu S, Holtz M, Gupta M, Bhatia R. Source: Blood. 2004 April 15; 103(8): 3167-74. Epub 2003 December 11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15070699
66
Chronic Myelogenous Leukemia
•
BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Author(s): Salesse S, Verfaillie CM. Source: Oncogene. 2002 December 9; 21(56): 8547-59. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476301
•
BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Author(s): Salesse S, Verfaillie CM. Source: Molecular Cancer Therapeutics. 2003 February; 2(2): 173-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12589034
•
Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells. Author(s): Fernandez-Luna JL. Source: Apoptosis : an International Journal on Programmed Cell Death. 2000 October; 5(4): 315-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11227211
•
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Author(s): Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. Source: Blood. 2003 January 15; 101(2): 690-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12509383
•
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Author(s): Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Source: Cancer Research. 2003 September 15; 63(18): 5716-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14522890
•
Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature. Author(s): Vaiopoulos G, Terpos E, Viniou N, Nodaros K, Rombos J, Loukopoulos D. Source: American Journal of Hematology. 2001 January; 66(1): 57-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11426495
•
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphianegative myeloproliferative disorders. Author(s): Cortes J, Kantarjian H. Source: Cancer. 2004 May 15; 100(10): 2064-78. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15139047
Studies
67
•
Bilateral alveolar infiltrates in a 29-year-old man with chronic myelogenous leukemia. Author(s): Cheng SL, Kuo PH, Yang PC, Luh KT. Source: Chest. 2002 December; 122(6): 2238-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12475870
•
Bilateral sensorineural hearing loss as a first symptom of chronic myelogenous leukemia. Author(s): Genden EM, Bahadori RS. Source: Otolaryngology and Head and Neck Surgery. 1995 October; 113(4): 499-501. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7567031
•
Biologic and clinical aspects of autologous stem cell transplantation with mobilized peripheral blood cells in chronic myelogenous leukemia. Author(s): Frassoni F. Source: Current Oncology Reports. 2000 March; 2(2): 144-51. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11122836
•
Biphenotypic blast crisis of chronic myelogenous leukemia: abnormalities of p53 and retinoblastoma genes. Author(s): Ishikura H, Yufu Y, Yamashita S, Abe Y, Okamura T, Motomura S, Nishimura J, Nawata H. Source: Leukemia & Lymphoma. 1997 May; 25(5-6): 573-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9250829
•
Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. Author(s): Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C. Source: American Journal of Hematology. 2004 April; 75(4): 231-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15054816
•
Bone marrow cytogenetic complete remission achieved by interferon-alpha plus cytarabine ocfosfate therapy in a patient with chronic myelogenous leukemia during extramedullary blast crisis. Author(s): Gotoh A, Miyazawa K, Uchida Y, Sashida G, Kawakubo K, Kuriyama Y, Ohyashiki K. Source: International Journal of Hematology. 2002 February; 75(2): 191-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11939268
68
Chronic Myelogenous Leukemia
•
Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. Author(s): Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2001 June 15; 19(12): 2994-3009. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11408494
•
Bone marrow reconstitution with normal autologous cells demonstrated by VNTR analysis after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Author(s): del Rosario Uriarte M, Bonomi R, Azambuja C, Seuanez HN. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 December; 11(12): 2213-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9447845
•
Bronchiolitis obliterans organizing pneumonia in a patient with chronic myelogenous leukemia developing after initiation of interferon and cytosine arabinoside. Author(s): Patel M, Ezzat W, Pauw KL, Lowsky R. Source: European Journal of Haematology. 2001 November-December; 67(5-6): 318-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11872080
•
Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia. Author(s): O'Brien SG, Goldman JM. Source: Blood. 1998 February 1; 91(3): 1091-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9446673
•
Busulfan systemic exposure relative to regimen-related toxicity and acute graftversus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Author(s): Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Source: Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2002; 8(9): 477-85. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12374452
•
Candida arthritis in a patient with chronic myelogenous leukemia (CML) in blastic transformation, unresponsive to fluconazole, but treated effectively with liposomal amphotericin B. Author(s): Turgut B, Vural O, Demir M, Kaldir M. Source: Annals of Hematology. 2002 September; 81(9): 529-31. Epub 2002 August 16. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12373355
Studies
69
•
Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Author(s): Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M. Source: Cancer. 2002 October 15; 95(8): 1673-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12365015
•
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Author(s): Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F, Rios MB, Hayes K, Cortes J. Source: Cancer. 2003 November 1; 98(9): 1905-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14584073
•
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Author(s): Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 July; 17(7): 1211-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12835715
•
Chronic myelogenous leukemia molecular signature. Author(s): Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Source: Oncogene. 2003 June 19; 22(25): 3952-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12813469
•
Chronic myelogenous leukemia shapes host immunity by selective deletion of highavidity leukemia-specific T cells. Author(s): Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Source: The Journal of Clinical Investigation. 2003 March; 111(5): 639-47. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12618518
•
Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. Author(s): Liu LG, Tanaka H, Ito K, Kyo T, Ito T, Kimura A. Source: American Journal of Hematology. 2003 December; 74(4): 268-72. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14635208
70
Chronic Myelogenous Leukemia
•
Chronic myelogenous leukemia with p190BCR-ABL expression: the missing link with monocytosis. Author(s): Ohtake S. Source: Intern Med. 2002 December; 41(12): 1092-3. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12521192
•
Chronic myelogenous leukemia. Author(s): O'Dwyer ME. Source: Current Opinion in Oncology. 2003 January; 15(1): 10-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12490756
•
Chronic myelogenous leukemia. Author(s): Druker BJ, O'Brien SG, Cortes J, Radich J. Source: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2002; : 111-35. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12446421
•
Chronic myelogenous leukemia: a review and update of therapeutic strategies. Author(s): Garcia-Manero G, Faderl S, O'Brien S, Cortes J, Talpaz M, Kantarjian HM. Source: Cancer. 2003 August 1; 98(3): 437-57. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12879460
•
Chronic myelogenous leukemia: elements of conventional chemotherapy and an overview of autografting in the treatment of the chronic phase. Author(s): Lauta VM. Source: Medical Oncology (Northwood, London, England). 2003; 20(2): 95-116. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12835513
•
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia. Author(s): van Deventer HW, Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, Shea TC. Source: American Journal of Hematology. 2002 November; 71(3): 184-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12410573
•
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Author(s): Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Source: Leukemia Research. 2003 July; 27(7): 661-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12681367
Studies
71
•
Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Author(s): El-Ouriaghli F, Sloand E, Mainwaring L, Fujiwara H, Keyvanfar K, Melenhorst JJ, Rezvani K, Sconocchia G, Solomon S, Hensel N, Barrett AJ. Source: Blood. 2003 November 15; 102(10): 3786-92. Epub 2003 July 31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12893759
•
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Author(s): Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Source: Cancer. 2003 February 15; 97(4): 1033-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12569603
•
Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. Author(s): Myojo T, Hino N. Source: Intern Med. 2004 February; 43(2): 126-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15005255
•
Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Author(s): Kubota Y, Tanaka T, Ohnishi H, Kitanaka A, Okutani Y, Taminato T, Ishida T, Kamano H. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004 June; 18(6): 1127-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15085152
•
Contribution to the study of periodic chronic myelogenous leukemia. Author(s): Pujo-Menjouet L, Mackey MC. Source: Comptes Rendus Biologies. 2004 March; 327(3): 235-44. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15127894
•
Cutaneous sclerosing extramedullary hematopoietic tumor in chronic myelogenous leukemia. Author(s): Lane JE, Walker AN, Kulharya A, Marzec T. Source: Journal of Cutaneous Pathology. 2002 November; 29(10): 608-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12453299
72
Chronic Myelogenous Leukemia
•
Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Author(s): Nakayama H, Ishimaru F, Avitahl N, Sezaki N, Fujii N, Nakase K, Ninomiya Y, Harashima A, Minowada J, Tsuchiyama J, Imajoh K, Tsubota T, Fukuda S, Sezaki T, Kojima K, Hara M, Takimoto H, Yorimitsu S, Takahashi I, Miyata A, Taniguchi S, Tokunaga Y, Gondo H, Niho Y, Harada M, et al. Source: Cancer Research. 1999 August 15; 59(16): 3931-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10463586
•
Deletion of BCR region 3' in chronic myelogenous leukemia. Author(s): Gonzalez FA, Anguita E, Mora A, Asenjo S, Lopez I, Polo M, Villegas A. Source: Cancer Genetics and Cytogenetics. 2001 October 1; 130(1): 68-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11672777
•
Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Author(s): Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Source: Leukemia Research. 1999 September; 23(9): 817-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10475621
•
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Author(s): O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 March; 17(3): 481-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12646934
•
Dendritic cell vaccination for patients with chronic myelogenous leukemia. Author(s): Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H. Source: Leukemia Research. 2003 September; 27(9): 795-802. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12804637
•
Detection and quantification of residual disease in chronic myelogenous leukemia. Author(s): Hochhaus A, Weisser A, La Rosee P, Emig M, Muller MC, Saussele S, Reiter A, Kuhn C, Berger U, Hehlmann R, Cross NC. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2000 June; 14(6): 998-1005. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10865964
Studies
73
•
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. Author(s): Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, Alyea EP, Soiffer RJ, Dranoff G, Ritz J. Source: The Journal of Clinical Investigation. 2000 September; 106(5): 705-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10974024
•
Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia. Author(s): Min CK, Yang IH, Kim DW, Lee JW, Han CW, Min WS, Kim CC. Source: Acta Haematologica. 2000; 104(2-3): 135-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11154991
•
Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood. Author(s): Lee YK, Lee DW, Kim YL, Lee S, Min CK, Kim YJ, Oh IH, Kim TG, Kim CC, Kim DW. Source: International Journal of Hematology. 2002 August; 76(2): 180-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12215018
•
Development of hyperthyroidism during long term interferon therapy in a patient with chronic myelogenous leukemia: case report. Author(s): Ozet A, Ozet G, Caliskaner Z, Komurcu S, Ozturk B. Source: Endocrine Journal. 1997 October; 44(5): 715-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9466328
•
Development of interferon-alpha resistant subline from human chronic myelogenous leukemia cell line KT-1. Author(s): Yamauchi H, Sakai I, Narumi H, Takeuchi K, Soga S, Fujita S. Source: Intern Med. 2001 July; 40(7): 607-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11506301
•
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Author(s): Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J, Kontoyiannis D, Giles FJ, Raad I, Verstovsek S, Ferrajoli A, Kantarjian HM. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2003 March; 9(3): 976-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12631595
74
Chronic Myelogenous Leukemia
•
Differentiation in chronic myelogenous leukemia cell K562 by spongean sesterterpene. Author(s): Aoki S, Higuchi K, Isozumi N, Matsui K, Miyamoto Y, Itoh N, Tanaka K, Kobayashi M. Source: Biochemical and Biophysical Research Communications. 2001 March 30; 282(2): 426-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11401476
•
Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. Author(s): Ren R. Source: Leukemia & Lymphoma. 2002 August; 43(8): 1549-61. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12400597
•
Disseminated granuloma annulare associated with chronic myelogenous leukemia. Author(s): Jee MS, Kim ES, Chang SE, Lee MW, Koh JK. Source: The Journal of Dermatology. 2003 August; 30(8): 631-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12928535
•
Disseminated Mycobacterium kansasii infection with pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Author(s): Goldschmidt N, Nusair S, Gural A, Amir G, Izhar U, Laxer U. Source: American Journal of Hematology. 2003 November; 74(3): 221-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14587059
•
Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Author(s): Leda M, Ladon D, Pieczonka A, Boruczkowski D, Jolkowska J, Witt M, Wachowiak J. Source: Leukemia Research. 2001 April; 25(4): 353-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11248334
•
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Author(s): Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Gomez M, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D. Source: Blood. 2002 July 15; 100(2): 397-405. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12091328
Studies
75
•
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Author(s): Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J. Source: Blood. 2003 January 15; 101(2): 473-5. Epub 2002 September 12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12393385
•
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Author(s): Muller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG, Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, Konig H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003 December; 17(12): 2392-400. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14523462
•
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. Author(s): Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 March; 16(3): 882-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9508169
•
Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Author(s): Wilhelm M, Bueso-Ramos C, O'Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1998 January; 12(1): 65-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9436922
•
Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Author(s): Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM. Source: Blood. 2000 January 15; 95(2): 410-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10627443
76
Chronic Myelogenous Leukemia
•
Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group. Author(s): Sao H, Kato C, Kitaori K, Adachi T, Yano K, Kobayashi M, Kojima H, Tanimoto M, Hirabayashi N, Minami S, Yamada H, Morishita GY, Morishima Y, Kodera Y. Source: International Journal of Hematology. 2000 August; 72(2): 237-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11039675
•
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Author(s): Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, GarciaManero G, Ferrajoli A, Wierda W, Kantarjian H. Source: Cancer. 2003 September 15; 98(6): 1105-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12973833
•
Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features. Author(s): Thiele J, Kvasnicka HM, Schmitt-Graeff A, Bundschuh S, Biermann T, Roessler G, Wasmus M, Diehl V, Zankovich R, Schaefer HE. Source: American Journal of Clinical Pathology. 2000 July; 114(1): 57-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10884800
•
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Author(s): Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, Kaufmann SH. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2000 January; 6(1): 237-49. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10656455
•
Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Author(s): Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Source: Clinical Rheumatology. 2003 October; 22(4-5): 329-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14576993
•
Engineering dendritic cell grafts for clinical trials in cellular immunotherapy of cancer: example of chronic myelogenous leukemia. Author(s): Dietz AB, Litzow MR, Gastineau DA, Vuk-Pavlovic S. Source: Croatian Medical Journal. 2001 August; 42(4): 428-35. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11471194
Studies
77
•
Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Author(s): Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, Weisdorf DJ. Source: The American Journal of Medicine. 2001 April 1; 110(5): 339-46. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11286947
•
Establishment and characterization of a novel cell line, TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormonerelated protein. Author(s): Watanabe T, Kataoka T, Mizuta S, Kobayashi M, Uchida T, Imai K, Wada H, Kinoshita T, Murate T, Mizutani S, et al. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1995 November; 9(11): 1926-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7475285
•
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Author(s): Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Source: Nature Medicine. 2000 September; 6(9): 1018-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10973322
•
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Author(s): Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RB. Source: Cancer Research. 2001 January 1; 61(1): 138-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11196151
•
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Author(s): Ravandi F, Kantarjian HM, Talpaz M, O'Brien S, Faderl S, Giles FJ, Thomas D, Cortes J, Andreeff M, Estrov Z, Rios MB, Albitar M. Source: Cancer. 2001 June 1; 91(11): 1964-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11391574
•
Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Author(s): Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H. Source: Blood. 2001 March 1; 97(5): 1172-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11222358
78
Chronic Myelogenous Leukemia
•
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Author(s): Hao SX, Ren R. Source: Molecular and Cellular Biology. 2000 February; 20(4): 1149-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10648600
•
Expression of the TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t(3;12)(q26;p13). Author(s): Nakamura Y, Nakazato H, Sato Y, Furusawa S, Mitani K. Source: American Journal of Hematology. 2002 January; 69(1): 80-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11835339
•
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy. Author(s): Kaban K, Kantarjian H, Talpaz M, O'Brien S, Cortes J, Giles FJ, Pierce S, Albitar M. Source: Cancer. 2000 February 1; 88(3): 570-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10649249
•
Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha therapy. Author(s): Beedassy A, Topolsky D, Styler M, Crilley P. Source: Leukemia Research. 2000 August; 24(8): 733-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10936425
•
Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Author(s): Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, Salvatore F, Rotoli B. Source: Blood. 1998 August 1; 92(3): 981-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9680367
•
Fatal bone marrow aplasia during interferon-a treatment in chronic myelogenous leukemia. Author(s): Chiusolo P, Sica S, Laurenti L, Piccirillo N, Giordano G, Leone G. Source: Haematologica. 2000 February; 85(2): 212. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10681733
Studies
79
•
Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Author(s): Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ. Source: Cancer Chemotherapy and Pharmacology. 1999; 44(5): 433-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10501919
•
Female predominance in megakaryoblastic transformation of chronic myelogenous leukemia. Author(s): Linares M, Miguel-Garcia A, Miguel-Sosa A, Garcia S, Navarro M. Source: European Journal of Haematology. 1988 April; 40(4): 375. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3163303
•
Fine needle aspiration cytology of extramedullary chronic myelogenous leukemia. Author(s): Mourad WA, Sneige N, Huh YO, Katz RL, Caraway NP, Corck A, Wojcik E. Source: Acta Cytol. 1995 July-August; 39(4): 706-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7631544
•
First case in Tunisia of PH1 positive chronic myelogenous leukemia in a 3 year old child. Author(s): Toumi NH, Ben Abid H, Meddeb B, Ben Othman T, Trabelsi C, Boukef K, Hafsia A. Source: Nouv Rev Fr Hematol. 1991; 33(3): 275-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1956767
•
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Author(s): Li L, Keating MJ, Plunkett W, Yang LY. Source: Molecular Pharmacology. 1997 November; 52(5): 798-806. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9351970
•
Fluorescence in situ hybridization analysis of complex translocations in two newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia patients. Author(s): Rajcan-Separovic E, Bence-Bruckler I, Wells P, Wang H. Source: Cancer Genetics and Cytogenetics. 1999 October 1; 114(1): 71-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10526539
80
Chronic Myelogenous Leukemia
•
Fluorescence in situ hybridization for the detection and monitoring of the Ph-positive clone in chronic myelogenous leukemia: comparison with metaphase banding analysis. Author(s): Cuneo A, Bigoni R, Emmanuel B, Smit E, Rigolin GM, Roberti MG, Bardi A, Piva N, Scapoli G, Castoldi G, Van Den Berghe H, Hagemeijer A. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1998 November; 12(11): 1718-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9823946
•
Fractionation of chronic myelogenous leukemia marrow cells by stroma adherence: implications for marrow purging. Author(s): Rizzoli V, Mangoni L, Piovani G, Garau D, Caramatti C, Almici C, CarloStella C. Source: Leukemia & Lymphoma. 1993; 11 Suppl 1: 109-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8251884
•
Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridization. Author(s): al-Amin A, Lennartz K, Runde V, Seeber S, Opalka B, Kloke O. Source: Cancer Genetics and Cytogenetics. 1998 July 1; 104(1): 45-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9648557
•
Frequency of molecular elimination of Ph1 clone in chronic myelogenous leukemia (CML) with interferon alpha. Author(s): Henic N, Preudhomme C, Noel M, Lai J, Wetterwald M, Simon M, Fenaux P. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1996 January; 10(1): 185-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8558928
•
Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Author(s): Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Source: Cancer Research. 1992 December 1; 52(23): 6588-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=1423304
•
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Author(s): Rezvani K, Grube M, Brenchley JM, Sconocchia G, Fujiwara H, Price DA, Gostick E, Yamada K, Melenhorst J, Childs R, Hensel N, Douek DC, Barrett AJ. Source: Blood. 2003 October 15; 102(8): 2892-900. Epub 2003 June 26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12829610
Studies
81
•
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia. Author(s): Szabo P, Macera MJ, Verma RS. Source: Mol Biol Med. 1988 December; 5(3): 139-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=3072467
•
Gamma-IFN induced cell adhesion in chronic myelogenous leukemia cells. Author(s): Grander D, Xu B, Wang P, Einhorn S. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1994 February; 8(2): 299-304. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7905942
•
Gancyclovir-induced megakaryocyte loss in chronic myelogenous leukemia post bone-marrow transplant. Author(s): Gardner L, Grosso LE. Source: American Journal of Hematology. 1996 November; 53(3): 204-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8895696
•
Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy. Author(s): Leo E, Kramer A, Hochhaus A, Krasniqi F, Hehlmann R, Ho AD. Source: Annals of Hematology. 2002 August; 81(8): 467-9. Epub 2002 August 15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12224005
•
Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Author(s): Zhao RC, McIvor RS, Griffin JD, Verfaillie CM. Source: Blood. 1997 December 15; 90(12): 4687-98. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9389683
•
Gene therapy for chronic myelogenous leukemia. Author(s): Verfaillie CM, McIvor RS, Zhao RC. Source: Molecular Medicine Today. 1999 August; 5(8): 359-66. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10431169
•
Generation of chronic myelogenous leukemia-specific T cells in cytokine-modified autologous mixed lymphocyte/tumor cell cultures. Author(s): Muller L, Provenzani C, Pawelec G. Source: Journal of Immunotherapy (Hagerstown, Md. : 1997). 2001 NovemberDecember; 24(6): 482-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11759071
82
Chronic Myelogenous Leukemia
•
Generation of dendritic cells from patients with chronic myelogenous leukemia. Author(s): Heinzinger M, Waller CF, von den Berg A, Rosenstiel A, Lange W. Source: Annals of Hematology. 1999 April; 78(4): 181-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10348149
•
Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Author(s): Neubauer A, He M, Schmidt CA, Huhn D, Liu ET. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1993 April; 7(4): 593-600. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8464238
•
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Author(s): Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al. Source: Blood. 1994 May 15; 83(10): 3068-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7514051
•
Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Author(s): Wada C, Shionoya S, Fujino Y, Tokuhiro H, Akahoshi T, Uchida T, Ohtani H. Source: Blood. 1994 June 15; 83(12): 3449-56. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8204873
•
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Author(s): Cohen MH, Moses ML, Pazdur R. Source: The Oncologist. 2002; 7(5): 390-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12401900
•
Glutathione depletion restores the susceptibility of cisplatin-resistant chronic myelogenous leukemia cell lines to Natural Killer cell-mediated cell death via necrosis rather than apoptosis. Author(s): Dedoussis GV, Andrikopoulos NK. Source: European Journal of Cell Biology. 2001 September; 80(9): 608-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11675936
Studies
83
•
GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Author(s): Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1998 June; 12(6): 860-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9639411
•
Good predictive value of combined cytogenetic and molecular follow up in chronic myelogenous leukemia after non T-cell depleted allogeneic bone marrow transplantation: a report on 38 consecutive cases. Author(s): Preudhomme C, Wattel E, Lai JL, Henic N, Meyer L, Noel MP, Cosson A, Jouet JP, Fenaux P. Source: Leukemia & Lymphoma. 1995 July; 18(3-4): 265-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8535192
•
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Author(s): Slavin S, Nagler A, Varadi G, Or R. Source: Experimental Hematology. 2000 July; 28(7): 853-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10907647
•
Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia. Author(s): Kolb HJ, Mittermuller J, Holler E, Thalmeier K, Bartram CR. Source: Bone Marrow Transplantation. 1996 March; 17(3): 449-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8704705
•
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Author(s): Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J. Source: Cancer. 2004 June 15; 100(12): 2592-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15197801
•
Granulocyte-macrophage colony stimulating factor and interleukin-6 enhanced white blood cell synthesis of leukotrienes in chronic myelogenous leukemia. Author(s): el-Ahmady O, Mansour M, Kamel H, Baker A. Source: Anticancer Res. 1997 July-August; 17(4B): 3179-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9329631
84
Chronic Myelogenous Leukemia
•
Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity. Author(s): Schwartz GN, Liu YQ, Tisdale J, Walshe K, Fowler D, Gress R, Bergan RC. Source: Antisense & Nucleic Acid Drug Development. 1998 August; 8(4): 329-39. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9743470
•
Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Author(s): Issaad C, Vainchenker W. Source: Blood. 1994 November 15; 84(10): 3447-56. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7524739
•
Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. Author(s): Usman M, Kakepoto GN, Adil SN, Sajid R, Arain S, Khurshid M. Source: J Pak Med Assoc. 2004 January; 54(1): 17-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15058636
•
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. Author(s): Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, GambacortiPasserini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E; International STI571 CML Study Group. Source: The New England Journal of Medicine. 2002 February 28; 346(9): 645-52. Erratum In: N Engl J Med 2002 June 13; 346(24): 1923. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11870241
•
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Author(s): Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ, Sawyers CL, Paquette RL, O'Dwyer ME. Source: Blood. 2002 July 15; 100(2): 435-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12091333
•
Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Author(s): Schlaifer D, Dumazer P, Spenatto N, Mignon-Conte M, Brousset P, Lumbroso C, Cooper M, Muller C, Huguet F, Attal M, et al. Source: American Journal of Hematology. 1994 November; 47(3): 254-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7942805
Studies
85
•
Hemoperitoneum due to splenic rupture in a CAPD patient with chronic myelogenous leukemia. Author(s): Wang JY, Lin YF, Lin SH, Tsao TY. Source: Perit Dial Int. 1998 May-June; 18(3): 334-7. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9663901
•
Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. Author(s): Katoh M, Takeuchi K, Murashima N, Nakajima M, Yamaguchi H, Endo Y, Hara M. Source: Japanese Journal of Clinical Oncology. 1994 April; 24(2): 111-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8158858
•
High expression of UDP-N-acetylglucosamine: beta-D mannoside beta-1,4-Nacetylglucosaminyltransferase III (GnT-III) in chronic myelogenous leukemia in blast crisis. Author(s): Yoshimura M, Nishikawa A, Ihara Y, Nishiura T, Nakao H, Kanayama Y, Matuzawa Y, Taniguchi N. Source: International Journal of Cancer. Journal International Du Cancer. 1995 February 8; 60(4): 443-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=7829256
•
High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. Author(s): Dann EJ, Anastasi J, Larson RA. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1998 April; 16(4): 1498-504. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=9552058
•
Histamine excess symptoms in basophilic crisis of chronic myelogenous leukemia. Author(s): Ishii N, Murakami H, Matsushima T, Tamura J, Sawamura M, Morita K, Karasawa M, Naruse T, Kubota K, Tsuchiya J, et al. Source: J Med. 1995; 26(5-6): 235-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8721900
•
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylatesensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Author(s): Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K. Source: Cancer Research. 2003 August 15; 63(16): 5126-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12941844
86
Chronic Myelogenous Leukemia
•
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Author(s): Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, Hirai H, Fujita S. Source: Blood. 2001 September 1; 98(5): 1498-505. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11520800
•
How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells? Author(s): Bergan R, Neckers L. Source: Blood. 1996 May 1; 87(9): 4019-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=8611740
•
Hydroxyurea-induced fever in a patient with chronic myelogenous leukemia. Author(s): Tsurumi H, Goto H, Hara T, Moriwaki H. Source: International Journal of Hematology. 2000 October; 72(3): 386-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11186000
•
Hydroxyurea-induced gangrene of the toes in a patient with chronic myelogenous leukemia. Author(s): Yasuda N, Ohmori S, Usui T. Source: American Journal of Hematology. 2000 February; 63(2): 103-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10629580
•
Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. Author(s): Kato N, Kimura K, Yasukawa K, Yoshida K. Source: The Journal of Dermatology. 1999 January; 26(1): 56-62. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=10063214
•
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Author(s): Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. Source: Mini Reviews in Medicinal Chemistry. 2004 March; 4(3): 285-99. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15032675
•
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Author(s): Hochhaus A. Source: Annals of Hematology. 2004; 83 Suppl 1: S65-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15124676
Studies
87
•
Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML). Author(s): Chrobak L, Voglova J. Source: Acta Medica (Hradec Kralove). 2003; 46(3): 85-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14677715
•
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Author(s): Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS. Source: Molecular Cancer Research : Mcr. 2002 December; 1(2): 89-95. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12496355
•
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Author(s): Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA, DiazMediavilla J, Sierra J. Source: Haematologica. 2003 November; 88(11): 1213-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14607749
•
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Author(s): Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Source: Cancer Research. 2004 January 15; 64(2): 672-7. Erratum In: Cancer Res. 2004 March 15; 64(6): 2306. Shishodin, Shishir [corrected to Shishodia, Shishir]. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14744784
•
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Author(s): Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz M. Source: Blood. 2002 September 1; 100(5): 1590-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12176876
•
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Author(s): Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Source: Cancer. 2003 December 15; 98(12): 2636-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14669283
88
Chronic Myelogenous Leukemia
•
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Author(s): Kantarjian HM, Cortes JE, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Jeha S, Rios MB, Letvak L, Bochinski K, Arlinghaus R, Talpaz M. Source: Blood. 2003 January 1; 101(1): 97-100. Epub 2002 August 29. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12393600
•
Immunophenotypic and genotypic characteristics of chronic myelogenous leukemia in blast crisis. Author(s): Yen CC, Liu JH, Wang WS, Fan FS, Chiou TJ, Tai CJ, Yang MH, Chao TC, Hsiao LT, Chen PM. Source: Zhonghua Yi Xue Za Zhi (Taipei). 2000 November; 63(11): 785-91. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11155753
•
Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia. Author(s): Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Niederle N, Schaefer HE. Source: Acta Haematologica. 2003; 109(1): 53-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12486326
•
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Author(s): La Rosee P, Johnson K, O'Dwyer ME, Druker BJ. Source: Experimental Hematology. 2002 July; 30(7): 729-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12135670
•
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Author(s): Xiao Z, Hao Y, Liu B, Qian L. Source: Leukemia & Lymphoma. 2002 September; 43(9): 1763-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12685829
•
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Author(s): Vigneri P, Wang JY. Source: Nature Medicine. 2001 February; 7(2): 228-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11175855
Studies
89
•
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Author(s): La Rosee P, O'Dwyer ME, Druker BJ. Source: Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2002 July; 16(7): 1213-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12094245
•
Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. Author(s): Bremer CT, Lastrapes A, Alper AB Jr, Mudad R. Source: American Journal of Clinical Oncology : the Official Publication of the American Radium Society. 2003 June; 26(3): 262-4. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12796597
•
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Author(s): Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Source: Leukemia Research. 2004 June; 28(6): 613-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15120938
•
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Author(s): Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. Source: Blood Cells, Molecules & Diseases. 2003 July-August; 31(1): 11-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12850478
•
Is another bcr-abl inhibitor needed for chronic myelogenous leukemia? Author(s): Sausville EA. Source: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2003 April; 9(4): 1233-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12684388